var title_f37_19_38192="Anterior drawer test";
var content_f37_19_38192=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F73257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F73257&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Anterior drawer test",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 349px; height: 292px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEkAV0DASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD2AfWnKM8n9KaAKcMelcSGSL09aeO3SmKKeKpCHj9acO1MHNPUYpgPxUgGKjHTjA+pp4/WmgHD8KeuO1IKcM8U0AtOH6UgHHagfSqEPH4Uo5po/wA4p35UxDu1KM/hSUvQ00IcOp4/+tSH2/WjH+c0HI+lMBAadTRR+lADulJkdj+dA+vNGTn/ABoAUHjn9KQCm8A89PWnHgDFAhc5+lGSCD6HIopDiqA53UfBui6jqE17dW7G6lADsD1/Wqb/AA78OsTm1bJ9z/jXW8e1IxPTIqrsRx5+G/hvn/RnH1J/xqF/hl4cb/l2P/fR/wAa7YHApACP/rU1JoVjgm+Ffhs9IWHOeGP+NdF4Y8P2HhjTG0/SldbcuXIb1NbROaYfwx9aTdwsV7nAQ57V554tYeTqX/XpIf8AyG1eh3GdhPH4V5p4/fytM1WTPS2I/NWqokvc8k8TLv8ABXwv/wB9P6VW+Mn7z4uXC9jMg/8AQKu6+MeCvho64+WVf6VV+LA3/GmRCM5uEGPwWuqkrL/t1/mZS1LvxHHnfHa0iH/PeFf/ACEK5/4rYn+JOor1MkkUfH+4RXR+Kx537RVsnpdwjH/bIVz/AImX7Z8XnT727UIk/mK2p6O/aJM9Uy58bn3eMhFxiDToYx7Ew/8A1qb8Z28u28KWatt+z6asn4vHn+lRfFUm6+Is0a5zI9vF+SlcVW+PUxHi62iX7sGn28WPQhWFXBWlTT6RuG7kX9fZ7D4N6FCzAveXc7knuAM1Bor/AGD4MeILth899dtAPoMGpvikRbeGPBlgvHl2ZuCP99P/AK1QeLlNh8HvDNmDg3l40zD1BTFRCzhTv1bf5glr8iOY/wBk/A49pNU1AjnuNtbmm61H4O8GeGo3IV721M53f75FYXxQVrXwt4J0JB+8Fqtyyj+8x21P8adJv7/XbCx0u1kmt9MtUtwUHGT83H51nCUbxc9tX9+iLir2SPqFemM1IOtRr09KeD+NeGdo9aePeo161IKpCHing+1RjrT1NUBIP0p4/EUwHing+tMB45NOH6U0fSnCmgHijn1pBThVCFFKOe9NXnIJ59Kdn3oAeKX8KZnHOKeCe/NMkD9KXPNID1FHtTAXPtSEmjse1IDnvQIUn86M03OelAP+etAAcEg9Kdkn6U0deKX8KYC59qTOO2PxpM+uRQTTAMntk/QUh9unrRn8PpSHrQAvfn0/OkJ96TPfJozTJEJ4prH/ADigGkJFAyC4OFxXnnjW2F5a6jbk4D2sjZ/3Y2NehXPK/SuK1oBr6RWGQ8EiH6FCD/Ori7akPc8U11w3w7+HTgdZlwaZ8TF3fHLaO90n/oK1pfESwGleFPA9pGP3Ud4Ngz0XC1S+IQ3fH2JR3uk/9BFdMG+V/wCF/mzJos6gvn/tIQ+13Gfyirn7UfavjVGOv/E0QkfRmrpLUeb+0a567ZlP/kOuf8CL9q+MaPnO28dz+EjVq9FP/CiX+pB4hze/GOOLBKnUIh+TmqfxYb7f8TLm3GWzcRQAegDkf1q34YU3/wAZEfJIW/kbH+7Iarcaj8Zp0OWLamCOOyy5NXJ2lJ9oh0bLfxnmDeMbWwU5S1sLeAD35H9asfFKIm/8F6EnCxWcDsD2JbB/SsXxvI2pfGG5jUbla+SJeOyutdZ47MS/EDULsRtcXMI+zW8arkJgggn86yqz9nGMe0fz0LjC8nY0/GekWt94hfWC5kMEaw2UWOEUYIY/rxWDLeXKSN5jSMx6kMeat2+qXsAgivrPO9RkBulXltopxvUhQexHSvLlNy+I64xS2Pexmng0wfWng1ghkiinCmLgjg5p4wO9UgHjqKcOBmmKcj/CnEjpTAlU9+1OU5GccVGWAfGeMdqR5lhVR1JHA9KYFhWBNO3YPJ/KsSbVYLSMGaQBzwoJHze1VJfEdpHINjhx3ORn6ZqXUit2NRb2OpBAx05oXJyvft7153feOIYruVII3lQAZGRxWdd+L9UuCPsUQiRl4d8Er+VYyxtOPU1jh6ktkemPdrFO0bMMqMkmq93rVhbxqXuFB6N7V5a1xq11HiS4OW6qO/1oGmXU0mZZdxJ5VsnaK55Zgvso3jgZvc9Cl8X2PzpZuLiTsQMAfnUh8U24Xk/Jxgjk15qmgXsN2ZrfdLC55jGQR9K6Wz06Rtm9UhcjBJHI+tZvHz6ItYJdWdB/wlluGKx5Y+u3GKntfESzSMCUyo6hdorKGmIUXDKDg8HPPvQunpHywGTxknINJY+oDwUejOgXVo5CCCMVoxTxsq4YE1w8toySbVBVuxHQ0wzXdsdwPmKPQVrTzB395GU8G1segdhjkUfSuKs/EJDKGyOxrobDVYrhcE4J9xXbSxVOpomcs6Uo7mp/nijPNNVwyhlIweeKXOa6UZC596Q9aSg0wA/5NGaTJ7fhSA/lTAUn6U0mimFuKBCk89/zpCfc03vQT+tAiOb7hzXFax/x/k/7Df8AoJrtJz8tchq1uZLveCykIwA7HKkCqWxL3PLPjKNugeC2Pa7UfotYvjv5v2ibVM9bpP8A0AVtfF6zuP8AhGfC0ZV5Jbe+Ak2gnbwtZXjJGf8AaLspAjGL7So3gEjOwd63Uvdf+F/mRaxP4cJl/aH1Fs/cOf8AxysH4SES/Eu9nJyIUuZT+Eh/xrb8Hc/HXxHOTxFEzc/7orn/AISMY9Y8S3RBBktLqKHIwGlZvlFaykkp37JfkJrt3D4SL5/xJuLg5xGbqU/99Zqn8PpEk+Jt1qc2/wAmOe4kL7CVBzlRnpya6bwnoc3h+6kuGkIu5o3SRecAOOa2IolsrYx2UapHhnWNeAz9fzJrnxGMi5SjT1vbU1hRbV5aHO2ehQW+uXWs3az3F9JcPcRbJMBN3OCPUVu2dzbSK90n/HxIxLno273NUNHurycy3t5bLA6sUMSDG3HGfxp0wNtdCcYMcp2vgdD61xylKq7yepuklsjQhQSKzXDgyE4OeaWWKOCQxSghl96ZJbkW8rqpAjGXPYf41TW7JG25jeQrwrDuPeqVPzE5WPfVJ/Gnr7Go1+lKzbeR16VzlEwPIFOJI+6M59KgLbSq8lzyAPSqmp6rb6dHm4dVfGQhPJobUVdglfYuyv5Q3BiCeAP8aa1zGqqXdN+eVB5JrkZ/FLTxAw2UzZP8YwvtzWddT6lNExeUx7iSFHoa5KmOpx2dzohhKkt1Y6bVvE2nadKwmuV83GBHCfmPt0xisObxVd3CEadA8Yf+M1kC2VIA1tAkhPeQnJq9Fb3EpVRDhiM7cdK4Z46pLbQ7IYKC+LUzJ1vb9pTdztJJ6Z+VfpSppsnlpiXd2AJP410HkLHy8Y6YI/iB9aSKOAhhOWTd0IHSudylL4mdUacY7IzI9HW4VQCSVP8Ay06GrP2WG2AaQIOdpwOtanloF2qiHsWBOT/9erMlriABABEeSH65/wD10KNyrpFKytA06wxRIqd3Tofb61uWltGIjuVVKnDDFQWti9vDncdxJZtvOM9hWtp4XYwibzRnkN94VpGHchyIY4lDEFBherAdfrT/ALMNxYrkerdQKl8vcwXBDqNoJqeFVaIYxsHG6tOQm5WaFGQfqD6U0wxxuGjiAIH8NW3j2oV254JB/wAadGrMoGFKgfep8o0zPliLbcAYPOe4P/16a0YdPnUbxxmr5TDFUBB6n2qo4YMwH4HvmpcBmNeWCyPujQK+MgjqazmknsZRksq/3uxPpXUtsZBvAAx196y763+STABHOQf4vcUnDqtzOUFIsaVr2xQkre3JrpbO8juI8o4z9a8vuAbYx8sFZ8DNammanJaypliVz6110MbKm1GpscFXD9j0RW3E+1OJrN069WdS24cmr+a9mElJXRwtWYufWg85pKQn9KskCfWmk0vtTSaBCZ9KQn2oJOaYSOcUAMlI2GsS5CtJhgGHpW1J905wB+lc9rWoWenoZLmZF4yFzya1pSS1ZE03sQXdurRuqKmxhny2Hyk1io0Fqk11qNq1jPJKXIbbmY4xu7/Ss++8XXNwrJp9qUUjAlfII9xWJfJdmdLu8mMqMNrAn7o9a5a2OoRfLDV+Wx0wwVZx5pKyKaWMEHiG/wBVsyyT3amNyf4lPrT0hRU8tVCoudoAwRnripJSEcBzhW6E+tSdQS3DD9RWUnKesmNJR2I53ed49y/MBhj6jtmpVRZIfIwN65ZD6etYOueIbLSbhLe481pWIyVHEYPc+3Fa0REzILcefvUMrJzkev0pqCQXGEbVHyjB6kdxUEdvBcl7e+nWGJeUJ/i9l96v4iiJE22acD5Yx91frVC4EjRJ5O1XU7xnqfatEhCtdNcI8BASCI4RB0Pufeq/mKCQqquOuR1prSq6lwCu7t3Bo3K5J3hf607CPcndUG6Vgg9WOKoXetW0Hyg+fIvIVBkfnWAIpZyWkZyD2LEgVMtsucqMBepC14M8wk9IKx6UMEvtsdcatfTKxQi3Vu+cnHpzVWKzkmU7juY/eLHd/OtAQlgHIBTsTxVqG38lG3ZKkZ4PJrllOdT42dUacKfwozxbqhVQOB3IwKm+xlyNxwGOdpq99nYbQFBLDjLdPwqzHELcb5c/N7ZxSUC+YqQ2MXBCqABx7VJZwLvdU++GwR6fStBQB8wXII5AGcfWoZbZ/NEsAMcud3sfatFATZE9u0gfGBz+IFR/YkZMZDIOpwP0qYC9STcAFUnnvV62KORG6bO645HvmtFDuLmsZltpZScMi7RjIOc/pWzFCzpiXO/02jBqeBHGWJwmcfd71YjciTIQDtye9axgiJSbI4YBKNrJnb2bippLOIH5kDRtwMHBz+FP2A5dWAYHnmp0O7eTkYPA7E/WtFEjmMiYGIKRzIDz64qxDEhQqgKZGQW4APr9K0pFj3+YVGdmOf8APNVggWIZfhRkp3xmnyDUyJrdV3DG4bSCc/e460eSFiA3ZIGBnjFX44pJbSNuEYc49R6VCUwjEjOR0pcoKRQkg/dYckuB19aqzxE26pyC3f0rVVfNi3vnAONtRSKDw3y7ecnpj0qXHqVzGaEZAynDDsTWfNA08ZI4QDB9vp61syqCdoHJ569BVKeQBMqpPf0zU2FzdjhPFSXEkFtY2Vq7XbNkTfwIM9S3r7VWjkMLJHKx3hcH0Jx29a7LUFLxzgBkwNynt9K5m/tvPhjYoC6tkEfWsqkdLBbmNTRdS+zy+Wzf/WrtbW6SSEMDXlUDnzSynk8Yx6V1Gh3+QYXIyT6104LEuD9nLY4K9Lqjt1YMoOaCeahhYeWKk69M5r207nE0KT700ntWfqOsWlgSJXV3HVVOcVzeoeMZRFItnab3x8rliOfpWc61On8TLhRnP4UddcTRQrmVwvpmsHV/FNnZDYpWSbrhScVw+parfXpQz7ti9lPIPvVO0t4r2f8AfIFx0O7k/hXDUzFbU19530sue9RmxqPiTUNTXZAwgXuUYnmucvLC9L+bceZMSeGY9fwzW+thHbsxjJBXtVhGJQYk5I6EdB61xznUq/GzthSp0tYIxrW1cASSD5VGAMYwa0UVWjYSBWR+qnvSuqyJtQkjOSc9TTowsUaEKT2GfWpUEi3K5zk1t5UzwcNjJXnPGahKsOj5YdTXQatZmS18yNcSx9h3HpXMSvcfu2tIo585375Nm0+3rXrUJ80TyMRT5JabFXULO1vLmCa9gWV4QyqMDnPr61dSQeXsTEWBgBe1VYL1pLu4t3thHNEAWKvvHIyKtSWsKKklw26QjKwq3H4t2roa7mA1QGUPHyynDY5zT5FAbevzb6ieSZpPM+VQAF2Ko6dh/wDXpy79pHlyEEcnYRTSEU7pDHMX2gxyfeA/hb1qtGrBcBc4/GrgDyBlZR5JHzEnFct4g07Ubi4jFre+UiKR0+9z1rSMeZkt2Pedny5X1xj1qaCDEZDEgdeKnZFxtQHPUnOcVYjjwAucjGcV8lGB79yERyMEyEx2XsatJAd2Gx9PT2ojIGGmA2HOMDpVlDFIp2Esw7YrVQJbIxARuPDEcgdx+NOUh1XeAB6dcj1/+tU4j7jJI7dqkZQMCNV3kZArTkI5tSJojjKdCMnBxmnQg5IViWzkZPQelSuwQBNm4P8Ad9qdBDhmYLy3r0B9hVKI76DXRwR0bHBxTxbpuKqpJI6dKmUJvCxHpwQBjBqRYS3zOzhuc4bgitYwJuLFEcbCcP6E9Keg2HbKFDevXNRQKwm2sQ3o2KtLCHyFG7HJzWqgQ3YhuFUIJsfdOdo6fjVtmWWJtjA4HAxj9KjUqY8AAE8Edm/CpbZGSby2jUgklWA+YD6+taRpmbkBK+Sskhyh6Db3qZ4kkRHCAlTljnBI9KiIkj3QSfMmflI/kKnR1SX5iNoHX1/CtVDuQ5EO4hfLc4IOC3sajYblKk8HjgYqa6UM6qMhj82D2FMlcgAqM8YyPSs5QsVGVysUKDZuG0e2SahcK6tkcZ+6asNkFWXkkcZ71WxuiYgYZmO7PUGsXE1UinJiQvg7W6A47VVMEjyK0oHqQOABWhMuFDY4I596rTMAjgfgazcSmyhqMJlhb+EKMqfX61mXNuGjGF2uOeO9bu3CMkhBIXNZssbCMMCGbOBjjFS1caZyOp2zQ3PmqMIQNwFNgl8tw6HJFdHcQLJwyk8ZYCsG605opJDbuxUjcNxzXJUg73iU48x12javD9lZ7h9oXrxk/Sq2rapPfx+Va7reA8Fgfmb6HtXP6EokDyS5BU4AP862VlTb8oz7DrXU8ZUcFFf8Eyp4WCleSuYs+nmIM6/M3UlzuJ/GnW1mbhASfLOeCO1XppY5FkVW4HBB6iobGTMbsDwpyw9q5vi1R2uSS0E+zCOTypcBiMZA6/40640czxie3jPmx8MEU8j14pL2XMTRMR8hGCfQ81UvtKl8UaK8Ntq+oaTewqSk9rP5UeP+mnHzCtIRvKzM5TcUPlt7pQN1rcnHU+S3Q9O1MubacsirDKp7koRx+VfOnjrVPE/hbV/sA8cT6pIUDO9pduyrxwCc4/AVH4FHi/x1r8dhBrep+SgVri4NxJiGPIGSRnnnA/8A112rBytzc2hz/W1flcdT6LUMWG1MY7elOVt+xjwf7vvVu0sIbOzgt7SWeSKCMRpJO++VwO7nueetQTJtbhvmA4zxzWUYPqdDlEV3IOVbjGee9czd2wtL19ozHIdwHofStied1BK4GOCKoasA8fHbHXtXXQVnY5K8eaJjabD9mik81x5sjku+OWAPA/CpHCyH5AAAep70vyzrn+JcBgD09KjaMFsA59u1diR5xIoEMgkVhvHGWGRSzX12vCyIT67KjtiY5mS5Ae3kG08fdPbHpzWdqCzW0jQk7pFO3I/nVJPuS2F/eHaXYc9SqjA/Ks2a4WQgy7c9qSaOQbpJZDuxk844rn5NUcOVtbZZgvDM+DzW0Y9iGz6bhXyzhE25GWJ6fSrcKBvmTC55/wDr1CgYggqRg4OehHtVmJgCNuNrdPrXzEYnuuRIgL9sN0I/vUOP3qx7wuR839KRVV3xMo46ehq08KHGFAyOorVRuRcIl2jaGBQcYHUfWpYQoJ2qQx5z2JpsaAAE53Ac1PHlowEG4kc56GtFElsYkaGZCBhlP3R/Spm+bcVbPt/jUfyhxgjcDyrdTU6FmKoAuwDPuK0USWyKOJ+kjEp1DelWvKGQQmCBjJ70nCqMYCg4+n1qY8YCDLEcBe9aKAnMjliIi4DoD2otSyR8Y2jI96nMhTHmRkA8c9AaBgvlFAccEH0rWMSOZkLxyOQUIWQD+MZDVdsSywKZA3mHqo7f/Wpsb5GGRAew9akt2MLYyxXrxjj2+laKJnJ6WJWRUVRksoGVx0FUyF86VowPkYFW75xVsyqy5RhgcgnvVIrvVzlsvztPRfpVMmI4yl3J6gD8qinkKkEj5SR+FIh+QDoOaikDBG2hSME/U1k0aLcjYM7uU69R6VGGRoWdh+8HBPv71JZnMa8nccklqjkUiKZSAMNuB7nNZNXNL9Csu9owsmRyahCliGwcDqKnciMj5QMjH0pjM0cIIHDDGfQVi42KuVrlVeBnQ5dTx71lTXIb5gu5QwUD+961r3mxYiQmR6DpWQ0a5htYlwd2S345rKaLiSKMxMdoLDpjoPY1j6hIsWC6H5j29a6BYSCWyM9Dnpx0rmfEUwERR90MyNuUgfK31rKSLhLUyL+7aCRGUkxucEgcj0FdTotrNDAJDaysvVunNVPCNqNUuZLy9tVC2wGwgfeOcEfhXYOYQRBbSLF1ZsMB26tmppLV2Oj2lo2W5554wJgt5r62PzwrnHftwayfB+pfbtAlvQyqk7eSm9gOfXJwMcVkfGv4i6BY2Nzp2m36anrTq0Mj2pzHFgjhyRgtwfumvKLCDxZ4i0i10y4u30zQoh8sGSikElt23Pzde5rrp4Vyk5S0TMJYlONkrs9J8XfE7QdKuJY4Wk1K5xtWO1cBVccfMSCMcHgVz2mWHj3x5YyyXd+nh7QZI5Dsw0X2hF+8oCj5jyByQDTdG8OaTprw2uk2n2i/kOz7VMMvz1OMlQPpXpdqyB4oIWHkwMsJZeAzNw+Pxro5FT+FfM55OU/ifyR5p448A6Xpmk+H/DvhfT2vdd1qRpDdznMkSR8noTtGCCcDopr1fwj4f07wJoS6TZyRyyOP9LuV4M7j+IZP3eBgVLAllZ6heX2xDqAURmRhysa8DHpxXKahrgutRMiuWtVUBjnjI607ykkmEYxi2zrTrEJZobKFp5ycfLjA+tUL0zH5r2VE74XjFc7/AMJOqQbbG0kizzwOCfWsO71G+u2LzXTBM/czwKpUilM6q41q0twyb9/0I5rDvPEUUqlUyST6j8qwpTGoyZcu3JHOfrUMiXUh26fplzcOx4kC8CrtGO7IctC+mteTeIzoxjPDgY4Hc10U08e1ChBDDKkHtXO2PhDxFeIPNiEKt94EHJH50/VrO/8ACax2urMzwTAtbznO0/3l79MVtT992Rx1nFO6NO61BUjOTtI7Z6iud1jxJEqR7WyVXYDkdBWBqep6peKw0u1mniVSXnKnYAB615/Lq1xKG82RpDk4B+7W8eROzZh7zV0dbq3iVrncobEQ6gEc+5rnJ9cdioR5UAGMRkAfyqla2rT28szM2BVFuCabk0tASTZ9/JJhgQuGI79Ksxu4B+TPGcn+GoYAfusBgDHuDUh29Xbofvdh/jXz8YnrtlmJTncwBx0x+tShNrthlMfXGaqxfO2IiwUHJJ7/AEqzJwh3oQc87RmtIxIvqOC87BwW5FWYJAVIlILDqTVOG3j4ZSQwOV571NbOGdg6lQp5JHGfrWiiS2Tq4eQMFO0HgHvUzMBhjGQ3vxSAhcggAHuOaa4OBtzz39K0SsIWES7yXAPcZ6VLDLljlV3cgkHgU0HA+Yk/SmZG98EDkbeetaJEt3LSXGXZHypAHQZBFOkwqHLHb2FQtIqY3gkn0HSkLbAx4JPvmrSJuTq+IwQQM8gjn8KVZA+xiWG709aqoeyYH1NDE7SWU7T1A9aaBlx23JtkUjt7YqFPkUEFhgc1G5ZolAJz/SnblUAbiOcYI60CGxMwiUk5kGevfmm+ejAKy9eCPensEI6jcRxzVcOC3bORyetS0UtSKJGXLrk7SQQPSlc+ayqh+QqODTpv3QLkEoT0HQZpYVwhcnjGMe3as2uhV+pTvgTKhAB7mMH71NL5tlck8NyPwp8rjzd52qyjC5NU3lDpc4I2sNw5rKS6lIS+kYW7iNSzdCT2qBt0JWSbJG0c4qdQRD8/zenuar3rn7KZmH7lWALMDtH1IFZSj1NE+hYhcGVcDgjJ9Paq9/bec0rEgxquXfaCEGDya868VfGHw74fkktdGVtf1x9qrDaEtbg+m8EEn2APNctN4e+InxKiik8X6gNB0JizJYghZOPWMnfzk/ePbp0pqk7XloiedXtHU6q5+L3hTwdpkun6Qsuv6tLK7R29sCYyzDjc2AeuOFya4+80v4h/Ei4WfxPdt4c0BzlbOMkNsxjCxlgW4z94/hXrPgXwT4W8F6Ksmk6dDLfuBuvblRLK3+7uX5R04GK25l8yJ5Jd+MZGef8A9VQpxgrUl82aRpuTbqfceHeOPAfhfw98O7/+xraRtQt4g73VwoMj/MoJ746npXF+GtTa50iFIgcRjaxHXNe2eMNOTUdH1CzbJjuIWQ/3sZB/pXg3w1sRPqNxYX7kKuWVV7kZFdFCo38W5pKmrWhsdvos628jBJFNzKNryD+Bcchfc11+mo1xcQGIbLO36nu7HvUmk6LYWkYIiAT1PP8ASp9Z1W3t7cRwFUA6ADGTVVZO1hQpq9zN8VTNBdS3kYJRU2yAdwQefwrhophNbwqmSkkrNtHVhxj8KveKtdCRLaRtm4lAD9cKG6VwY8VXmiXT6egSQABWYjkY7e1JSmovkV2Y1ZRjbmZ6jpWgX+rSeVBhFHaH5iB75rq7H4VQZSTUFlZhg4IAz+teN23j21iGfLuI5e7Ru4/ka0bb4mmEgQ6neRem5Wf+ZqqcKm9ZXfk9DjnUb+B2PcrXwVotmVMVqisowCQD/OtWLTLOI/u4Yzj0Uf4V4Qnxj1C3UldaMiL/AAtbAE/rXpnwk8X3/jXQb7UNQjWMQzrFEQPvArkkj611wcE9I2OaXNbVnZbFHAVQPpVHV9KsNYt0t9TtY7mFGDqrjoc+taJPao2roTMjiviubbT/AIcaq8cEUQiQLEqIo25yDyBnvXxxX118eSf+FY6jjpvTP/fRr5FomvdRtT2N7T50j0edT1YelYR607zG2bcnFMonPmil2CMbNs/QS3QPJxuRgOCR2+lSMvmYL4AX8jUMUZWRmd2DEcHP6VIHkEXIXb6EcNXiJHpkirsKMvI6bc4x71OfnQ53A+m7n2qoolDKGAbHI9qsJIgDF23A/wAQGCtaJEsdCzZZTjPdulSxOgfIbJUBSp6Gq6zoGV85A+UnH5cVM8ir1Qbc84HP1q0gJnJWTYpzEeh9KFk/fquCPlyDnrVbcWnjHcc+35VKc7io/WtEiS0ZcPjI6cGoJZSrjABHrjv61EpViFzkg5HapA/UPg+mOMfhVC2FWV9zK4GR1+bqKeSPlIcKR0NQYV/m/iH61KjAIC6r6EbelNA2WAysmVHbOc04SgjJbgcZzVAsdp2DI6detORwTscAsRxgcUx8uhcR8IwOeDjjv70xJHJ5A3AYqISMgxjBHfNOV9pDMeOn1oJaJ1kyNpAA74qC4Ql12gE565xgU5SQ+SmEHK4PWlBHmEsMBu9JgrojclxJG4IU8jBzRC+3C7gVqWZwykKME+9Uh8rZOMd+Kkpa7hPghhgFT39Kx0w0N4F/1qyYX3GOuPStLJYkMRhmIAFQyW/yu4OT0BHHHpWUlctaHGfEjxx/whem6fcRaXNqd1dSiOCBCyqW9CV5z1wACTXnf/CKePPije/a/Geopomjk8WsKjcV6hdi+xxls4xyK9xuMwyxSoPkU5Lc5Q+o9DTpxubzwzMVIILEkn86nn5VpuLl5tzG8E+B/Dfg0g6Hpq+cMj7Vc4llJPo20EfhW9qDLL9p89mdgnVySRnPc1Y+7HHKnKk4K56E1n6hMvlTHgMcoQRzxWcryepa93Ygs9zabCuATjAJ9KuzXUKQbDzgYxnNZq7zbwxRjhVAJoS1yBuySeuOK42m9jrspasw/EsqQ2k06ZUBCTn/AD714bpludP1z7WR+7kkLKR2GTx+te9a7poktZo1O5HQhlY15A9sFiura4JSWNijL6HPBHpWE5yptdjanodbHfie34k4I6YrHvIEgRpj88n8G49T24rLsJ4rCVodScxsgyp7OK0rNHvbhbqVSsXKwRnrz3rreJtDne5FW0UcD4isXi8Tadb7i166PPOR0xtyox7Vwt7ua+uZHO6QucnFep3ZCePdbvJ+lrp6IPYtGRXkyuXAYnJYAn8q9PDxaoqUt2eHVnzTZPZ2NzeLM1rA8ywrukKrnYucZNVJY8D5gPTpWpouoT6XcPJbyS+XKuyWNH2+YvUA+2aqardteXck0iKjOd2xBgL7AVulpcyu7mVMoA7flX1z8B7QWfwysm6G5YyH9K+RpuSor7d8EWP9meC9GtCuGSBWI/3lU0LWS+ZM3obJPJprGnE1Gx471uZnNfEbSjrfgbWbCP8A1rReYn/AAzH+VfFlfee8KefukFW9wRg/oa+SPjD4Rk8LeKpmii26beHzrdgDtAPJXPqM1cleHoVTfQ4OiiisTY/QJW3N0GegQ1O5D4RmPXv2qmcrLgnvx6gVYkkHlndhtvOf8a8xI7yzjJUZ5XoRSqscgbd97uwqD+JfmwpGMelMWQ5Ksee47+xq0SP2yRsSdrL6qMH8aljlyu4YJ9RwRTVdWONxzgc0yRcOJDhWx94d/rWluwl5iq+HJUn5hwRUwmdlIdo8r6L0qqytkFcEd/cUsYbkK2PY9fpTQMssC7b+6+negsNwbBIHcnmo1O0qpXB/nSTN8gDfn6VQWLKFcZyQe3NNJJBLN8w7etRmRHwxHzqO9RGXcdxGT0OaBpEwyvHBx0qbnbgfK/p2NQIMqSCasRlTxxjNMbBsAru781OANuARnHQVW/5abxnpzThOBJzjPpQJrsTSh/LyhG5en+FMciVAxJDYPOf0pytvXOQfX0qKWMMCDja3Q+hpMSEeY5AZSvGNwPenOhEGX25zj8P8aQQk7FkBUjo46GpVtwYz8/Gc57/jUMojW3G2NSdp+9nvmogMTPE4wV5wOjCrsYLlWzjPTd1p5jAILDbj5ef4TUsZmXEJETGLLFuVB/ven0p4RJbZdg+UDP4jsanIUXaRkKqbshu1G3yrp/ly7fM3qcdCKxluUkZqyiJNmQFY8Z/pWfqkit+7/jBzken9a1dQijO4YBA5Hv6/jWFIJHmjWQEMgyM9QD0rO7TKspFm3Kxwkuec81ajlG0ghcEZ3CqLsgjw5GM/lRG5YDqAOgFFktjpirodeYVwDzu7HmvPfH2kIrpqtqrc/JOgBO7J64r0O6XK7wOvOD1FUBF5pZSQA3BVuhrlrLmVi1pqeSNaQ6hHElwA7QkPEc8sOuDWpYzI8sbYwI3XKnsAelLr+gXWkaikoAe2kJKGMH922eAazr2X7NvvIf3g2NvT0I71wpO/LLdGdWN1dHn2q6wbg+J7tioeeRIU24HCsR/WuIjTC/QVJdSsLaYEEGW4Zzn6imRsGXpnIIr6lS91I8RqzZftNKvbiyN5bwtJAvdeayZ8u5YdD3rrPC/iCDQ9DvLOWK4luXJNsYyuwEgg7sjPQ9q5SQt90nPU/rW0+RRTi9epnFyu+Yk0KwbUfEFhZAEmeVUH4mvuXasccMa8COGNPyRR/SvkT4LWBv8A4l6TwCsEvmt34ANfXcjZZvTOKmGsm/QU9xhIJ71G7evSiaSONd0sioPUmsqfWIS/l2iNPITgMPu5rVyUVdkpN7F6U+n61xXxV0aDX/Bl3ayQ+feRnzLJVb5hIePX0rV1K8naTyo5WUqMSFem7uKpJZkSbzncB949TSWIS+FXKVJp3Z43onwgYwrNrt/5Zz81vbj58c9yMeleh6R4L0KyhaO302IrkfNICWPHc5roIUX7KoiUu/3zirQibccOF9u34Vz8rluanbzKH5PBBwKoySMfMjfhT8uc9M1bZw8LKGB7H6VTu12QgdugI5yK5rHcnYutnYgB6YBH8jTZlcwsy5Dr3ojwbZG9sZoMhZc8lACG/DpVpCuLDIUjjkO70bNWt67NyDPf6VRchgBgnegP5DNPgYGONgSyNwc9jVIW5bRQYwQAAeCP8ajdSOSSz5qOaQjJGTzhh6055WKgcLIOme9UJEyzbgATx0x6Gml98Zxzz071WeUCZVdcb+h9DUok24G0g0wJN2eoJHrS7iuCnX+dMbhhkfMRUioBwe/OaReg5W+QYbLeppyvjAH51CAFbK5wTjPpUiYWQDIJzx70BcmVn2/N1PHNV47RjfCZpG2AcJ2qcsoznBx+lOikB+U43D+KgSm1sSliBhQQe/t9alBBGNvUc1UkuRyvHmL1pIp9x3J909QfWi4kXkwE28fL0IqaJiRhQOTk/SqsdwB+7k4Y9MiprdgzqGfOTnjtUMaHyxjcu1lEYbBJPT3qw0alQy8oOGA9KY5G5woJJHJxyKnjIkhUthSV6ipsO5SngxexoDwo3AenNVrzMcqTqrME4Ydx7/Sr9tk3MokUcjAOe3tVG7cCSQhisaDDt2x7VnJaFRu3ZFPUnif97GwZTgtjoD2x9axGGHdmxvYZJPYVZnuGnb918sI+6v8AWqMjDfgHIHU1zuV2dEVbQiaUSkhAMD0qSLcF3mTAHf8ApVUbnuGRVxjkjpmrAXZIF3ZbH3RzgVOrdzZPoWGbzEJ37gOw7VWlnKEFV3kdM1MkqqWYAZHHy881WMBkLecx24wCPT0omtLhcfNHFqdq8VyFw42+/wBRXmut6Q+l3UlvdLvt3BCk/wAS967CaF7KT9zucryvNYGrz3WrW8sU6gPGRtbPr61xV4cyv1WxUYtPyPAfHOm/Yb9UjXFu/wA0bDoeOlc5E5JCrnk4A969g1rR7nULWSB4wzxn5SmGx61kWPwzu79gxVox3zgGvRw2Mj7NRqbnn18I3JuBwl7b3NrKsV5C8Em3IVxgketVjBKTgKxP0r2aH4apKY/tEjRqnViQ2fxNdDpfgfSrW5CpB5u0fMxA/L61csbFfCrkRwUn8Rw/7PsH2DxJe6jeRlFSBhGHGDuIPSvc5tflnJFiDubJUt2561z0ljHbkWdhCi4GSQoAx9RWtagpa5VVVuhArXD4idVtJWM8RhoUrO97kKxy3PlzXk7TO245Y9MGprUrC/mBdxGSM9j2P4VPbQs9qvlRlvvdOcc1DBdWguPsyTxyT45RTyv1rr9m3qct0LGu4GRlLySMWLnual2Akh9oHfHc1M0ilSAm4gZIFL9tkEUb20SwgMQ2OT096tQFzDjaSeUCyLDCw4eXgEf7OKrxIrIDkD601mZ3Z5HLP94nPH5dKYJFXhVJqrWJvc6aJX80EYDbcgUsWJogr4CE5A9KAwIyp2v057Ukw8thIoGQeR0rhR6I6xbbG1vIOVOQAaWA7hOhH3ewPY1WLGSQMPlJyQf6UrbuXDfOOMj/AA71SFYsyMDCuQQF4B9u2aarZIAP+sH0BPrSeb5kO8dQMEY60yJfMjA3A91x/KqAkE5ZUyPmB2keh9afHIcMkpPmIOuOtZ1zuhQvkkA5BHHFXFmWcKyDJ25z2NNPWwNaaDm+Y5xnBxn09qsoygHdkcZFRSEJsxjB4Jz+tM80GIFl5U+vUUxIuiT5hnBI/lSGQhjnoelV9/CHleO/f0prTDoRnPqcYoCxZWYb9uMN0qSOZOoB3KfSqJYFge3Q0/cBncfl/iNAMvJL5mTjHOMetJJKQuFPy+4xVIzoGUowZe7A1Fd3C4IRuBTsS9yS6lUKWaQKccetVY7l4o8QBie5YYrOvLlDxlcr3Nc/qfiuzsZjHJdoCMAR7hk/rWbSuaK/Q7u2u4y4IOePmYnpVyK5Y3MLI2McYx/D2Neb2viS1lP+sVn7CLDY9M4NdJodzfXsim2gIGP9Y3YfTvUSko7s0UG9T0KKRDGHcgjHPOKjivIooCqP8itwFG44rLiEcJ/0iQyv3CjaCfpUU1yXJWKMIo7AY/Wsp11sgjSb3Ll1eoHE7sVjAxtHVvw7VlzzzX7AEeXbjO2P/GomjMsm5+SORT1YhSFHP51m+aWrNklHRCuVRGRVxxzVFn8vBUEsw6Y6VbOI13P1zzVeaVCsjnOAOvSosWZ0zPuIiOJX5LDsKmgg3xnyyVYnv1xUcWSqlMEtyfp2qwXTynC8ygbQAev40rXKRVvZYkkQA/PjhQf1qWByYG3OWDDnj9BVMW5aVpNnPQE0/bIgCkhkT7rdM/hTtcqxYaIkEoR5fQI3DVmyWazTMzgxp0HGMn0rTiAZlyxLA5Pr9Kkj2zMVbPXgH/PaolTuykzFj02KIkqnOCeB0py2kkyqquVz1AHWtPdvLbThRnP+1jrUVgWI858gOfkGccfWkqaBuww6bHCo3t5sjdPm6UyR4bNhHGACV3Y65q5eSj7VHsGW2cLjBzWCR9v1maWQr5NuPKAB75z171pGCXQzZLbxGS2cFcTz8sxOML61LGm+OMpxlSAx7846VE0shmSMLxIMc8FB6H1p1oY/s21GYtbyBDnvnmu3CKzaOHGrRM53xbo2tXemPNaamxhtwTLbKgjJHqrDk/Sj4e6PHZ6NNcGNzcXbD53OSAMY+ldOJWjfK9T3J6ioUk2uwTlW52jgCvRu2rHmFgkBOSe+4Ac1Bb5bduyFz8ufWnOj7huIiBGRnk4qCNwfMUEncNwJ+tCWgmySM75ACOoxiohOkJKtG7nPUDipJmBywbOPmB6ZFPiaMbgzFeeOM09BXN2dvLlAJAyuRnuc0+4kBRN4I5H41WvCGgspTg4kCk1buAHQFuhxj6+teWj1XoQygMEYkAj8jTnf90QQAynOR3qO12yW4BHzKSTUpILv6FRjFWiWSAqFEkZznhlotohtkiVduWLqR2J61Ft2Y2HO4DIqRCQQ27BHBqkHQdcDcPLlAVyMe1QWm5YHjI2yRHbgdKleTdGRgP7n1p4GAdnccg84NMm9iOdR5QjJywYH8O9TRlDGCMbunNV5htGTncVKnnimpKfK+bClSBx1qkJscZSTtkPPNMm+6MMDj261WuCS/wB7bg54qKa5AUgnr0GaqwcxMtycFiSrqenrSXF15g2YO1xgn0rHN1tBJcuB1wcYqOTU4xgbucY5pWBvsaFigsbUW6yNJjncxzUFxerGS+4A45B6ZrFudaRHMaOxc/wg1j3MtzeOdxIU/wAP8WPrWFWvTorVlKLk7sm1nVJLmR4rfA7F8evpXHHRotW8UP5iKYwigtjkEDnn3rsUsXFpNcSIEgt4mmZmHOBWVoIt5rS3v7V96ys+WBBJ5GOfxrjoyq15ubVkbRcVod7o2nabp1ukVpZwjkln2/Mfqa6IXi20CrEx3vwMHoK461vCEPbANXNHne7kQuSVU84rWdO2ptB8zsdbaSEkFs7j0zU7FyWYjA6VBbukbKSBgDvVlrkEMXwv9BRGk0tDRtJ2sMjbBfB2gD5Se9QyPkqIjkk8npmnOwdWx061GzDcQAu89CBV8jIclfQIkd3kV2AX0PNRXqk/u+gx0qWJ0il+Z/vcAGq8xZ1dwckEgA+gqJQHF66kcKFCI8YLcE56Cp9saHzThUX2qoVJUTSuY+N2F7jtUis8sbADnqA3XNRYpMLkNJGpZtsScnH8qhnX96jEfu1HAz/L0q35YCtGuGB5Y+9RyIrw5zn5wAp/kKdtCkV4mKTtKxyhUsPfFSWVwrK7t98ttBPoammjjJjh+6zKR9B3xWPJARIBvYFG6579quwXRqXiJBDKyEHdgA+//wBeq8RL7Qh2lBlg3IBpbyRZbZF3ZK8t6E1EsuUUIoWQ8ZPelYHLQZ5nkJc3Dg+ft2pznH+QaowKlnpzCNA6pz1GWPr+tS6tOILCRkZBt539h2qkhUafBkAyP8rH9eadiTV02JbdHlunDySHzAW5wOmKoRsIpHQggyqxH1zxUsUo8iRio8w8Env7Cq17OEtUuYwWEcgDsSOf/rVtRlySRz14c8Gh5ZpDkDO3hsnpSlZGUFMYGenApiFQ7ASKcgMCOBzz+lM+0KhZXKkjqG6fhXp2fQ8U0pds9pbzB8spMZz22jvVVTjEiJlfXHT2zUSXCGPCgsO4z8v4ipLS4Z2uLTICzrlUXhQc5yPwosxXHuVGQcEAYGe9QsxAUZyQOT61BI/nQl8Yx83vUDSOp2uwwvAz3FWkFzq3HmWrJHztXeoNXMh449pIVxgg9c1mwOUmCZ+Urg/7PtWgi5yo5K859DXjo9eRBDvWdtnCyfdA9RxSpI2VjbgqTz9aLFvMAncfMGKj25qvqD+RI8h+ZMH6ZqltcVtbFx2CLt6kt8o/GrjshGeuOMe9ZTfPBAxySRn3zVolY9rEjaeprRESVh0gSSDBCkquM9z9ahSY+TtGeTyfQU8sNu4cgfrVISFI9pPMh59vaqS7CuXbpg8eFBYY496zJLht3yEZ7n19qVrg4I3EL3IqjLOpmfLA4FVYi9iW7u9o4P4d6yNQuyUOSQvZh60l7cqqli3AIya5W91WW8neDTwW5wX7CoqVY01eTKim3oaN1rC4EauWk7AHnNVo/tVyzGRsI3YdajsbARsSw8yVuS3c112i6MZj5kgIB5xgV5bxFXES5aWiNHy01dmVpmjtIi4U7TzyK6nTtCWMAsoz3yK17O2SGMKF5HtVx/lQ7RyB0rto4KEfelqzlnWctjzT446rD4a8AT29uwS/1I+RGOh8o8OR+Vcj8ONFvdL+HVtql0x+yyTtiJuqbyu0j645rP8Aj3dP4i+LFn4ZtzuhsCsGVOQS+HY+nANeteJLGLTvDek6dEo8iD+Htkd/0rpkve5Vstf8v1FTbVvM5aHU4vLKglHHZq0fCurx29xJFNjDMSCfrTMW8yBQEJ6471R1G2SJVmhXa69StZyimehB8nQ9HgvIZnTDgnrtq68sbEkuMnqK880m+cgbidwrchvCcYfI70+UtyudGzKoyD160zcXlUAgAc/WsRtQmCqBhkA5psV+WLKrZB496hrUE9DaLqzSM4ye2Paqb3CFMSMwQHhR6mqMd6vnAKc464/rUrTBmccevPepcRpl4OEG4tu2/Lk1MrNIgZQMjlQemazoZoyiMfuN296me48qAqmMDk5pctijVmVIF2FicDJJqgHH2gMp+XPf19abcXJXdGSJCflOeo96qrcDbISfnA+Uep9KHG+gJtGixJuN5HtzWbqBIkCD5drjcv1NRretIrNwcg59j61Tubh5dku4hwQDj9KLWGmaFzOmzAxkZX+lVVdhAQpGQu33z3NUgJHZt8m5S2frT2YRRM6kKFLA5+nemlqLpYr7UvklQAmFRj6Ec0hnLhyF+dBuK/4U+wKxQcAguS/I+8p7VRacQG6RwFCZ2MO9Sl1GWYbx2SMFiIkGd/aqcoknhK4YRSNlVPXFJpGdnlXAXCn5AemPWr4Adi5IBzgD0ojqrsHpsRtsjVQxYNEACO5B6CpSlvIVLEEcY9VNU7i6wWlfiNTsY+me9V1cQtzJlGwUz6etepQnzw0PExEOSZosyQSN5oDL6n+dRXF2Y40ktBuljOQR2qEjz+d3A/M+lNWNoZD94kjOV5zW6RhcW41RDPI8YO6T5ip/hPpUUNxFKp+2SOjrwNh7fjVe9UDDqyKjD5j/AHfeq8N5EFzIhbPQ02B37B4nRzjan3h6rV+3uVXIVvvcj29qiVQ8JU91xuPesyUlFy3Dh8g9Mj1rxT2Xrob0GEGDwrHPFUb9BhlzuV+3pij7QFCYOeNxz60kpEoIwfmxk4q0rmd7aj7WQ7AGyQAMH2qSSTAYDlSeKpROx3hjg52j8KJJR86/3TjINaJEN6lh5yy4yAAeRVeduFIbBB6etZGoXksEbm3jWWXHCk4qBb5zArXACvjkDsasGtLmhcXHG4EBh+Vc/dajHbGSRWPJAx1Bqlq2qmNW3NsGcc9c1zG+bUZcRn5S3yn271z1q8aauEY3Ll1cXOpzMAxWI8EZ61t6XYCOFEiXAPfuaTT7BfkijQ4HJOevrXaaNpwG1mXgV5cYTxU7y2LnNU1ZDdH0kCZSwGMZ7V08UaxphRUMCBCSBjtU+eK9mjRjTjZHFKTk7sdjPNK10lkj3cuPLt181vcAj/Gmk89a4r4zayNF+GurSZPmXv8AoCY65bDZ/JTW6MzyH4MW8niP4nX+sTMZAhklyxznOcDn2xX0LrdgmrWMlsW2MXDxv6EE4H0NeX/s46SLPwnPqTDD3cjDJ9F4r1jPFZ01fml3f5aFTbTSXQ8mvbXUNKvnN1EwVerj7v1FWY7sXUGM5z0I716j8spVJlWRGIBDDPGea8zvtOzq2pNZny4452RExwMY4qXBx2OyliHPSSLfh+JZrgqOhPFdA2mh8t9044xXL6VObS7KyDazHIPbNdbDqERUbnOCuRlcYNQ00dsEmtCtJAUG3HJGDVeNfKmPA3Y6Grz3qE4C7h61Snl354APXPcUBy9yR4I1zKvcc1CswI+9z04qJ5vNjAZ9jL1IHBrPmBLs8RIP044pCVjTdnWBijfdPPtT4roupR+vY+lZtteb8iRTu7jpmo3ugjkqDlufpQ0CbNZ7w7Mse23nrTHuY1TfvwSMg1kyt5qPtPJ7E4qQhJI1bPyHjp0oskO5civI0Z03AZGeaaZYUhLWshPOW3Dp/wDWqmkSEKhXkHv3XvUCiMLIp3J83Ax1/wAaTSBM1IrlGAb5voBwfXFQ3cy3KvFFu2qQRn696gtAEJM4ACqcYPTj+tWbNrYBWDDcRnAPPNTZlN9SKW4AkDHcg3n5ccgY61VcObe5kOD/AAIPbrz6VamQyElASAduSOn1p8kXlWe5CDIj49e3Uihq7EmZ6Sh7hRFgxRLiTJxk9cU97o2lrlSXmbJz2AqrpKEQksSZHfPTgtzyfwp853253YBORkenepiuoPexl6lJcXSW8GCqOx3EfxDPNXgwhVYRhwvygseuKJru3SOOVnWMKDjcegHXH1rnNZ8Q6elzAwk3qMlChztJ65/wrWnU9nLmMa1L2kbM6NdQmi3ApyOhqWLUvOVVUBXHrnkVjaTrtvqu9YZFM0YyYyACw9QO/wBKnMkcjHa8ZkxyoIz/APWr1YyUldHjyi4uzMbxf4nudLmFvDaRxbh8tw7nDdOMdKj0LU11Kz+0KCJGPzoein0B7itqe2jvRFFfW4ZYm3Rl+ADjrz1qzbyNaqVhjiVTz8sQwattPRIhux6JA/lkwSn5QcD/ABzTrsxtbFpAPk5PtVK5lMboWGedxxUt04KIjgDdgsPUV4qXQ9Zu5VjaRFbf0CHafWrkk+LWMbtpOMmsu+uCkezPDHaCOtOeUR23zsCQAPU1aE2Wp58GMj7vPNVGn+ZiTwetVpbg7VdvlI4ANZF7dM4J3+Xbg/Mw6t7VV0iNy9PdKjM4I6cn+grA1bU1jikkmbEY6DpzVHVtWit4GdnVRyQPauD1bV3vp8sx8sHhT0+v1rKVS4PTVnQT6hFezrJcS7VJ4B/h/wDr10WmXenIAPtCA47DH9a8yiLSsCQSPer8Sqq9Bn37VzSwrrSu2c8sYoaJHuOhT6YAGN9DnB4LAf1rqra7s/LUR3lseP8Ansv+NfNA25HA/KnBsHhiD+FdtKn7ONkjmliVJ3aPqBJIiPluLcj2lX/GpBz0ZD9GBr5fS5mTmO4mXHowH9Knj1TUU/1ep3yf7suP6VqpPsL28T6aKOBwjH6A14T+1BqD+boWjICCVa4dSOd24qOPpWEniDWox8mt6kOP+e//ANaqGq3EurXaXWqSNeXUYASaY7mUZzjP1Oabk+iBVoXufQXgfS20fwbpNn5bhkiDNwe4U1tnd/dP5V8+w+OPEkAVU1AMoGFEg3YA4FWk+JXiWMfM1m4HrFRC0YqI5Vott3PeFJVg2DwQa4/W0bT9SuN/Nvcfvlc8fM3VfwxXn8fxW1yPHmWlq/0RRT5vixdXEJhv9Gt54z7Lx7iqlqVSrxg73N8yxzNgtkE4Bz0ojvJbdwsq71HbpxXFy+NLCRgyadcQHPJ81TXQW9zNPCshUNGy7hn7wFYyfRnpUq0amtM6aC+jlUbcr7dMU+a6DELGuTjnPeuct72MSFWVl2sF+b+KteO4Vofl2nnii5sncCdoDHt/Cf8AGlN2k0TFTtIP3QOn407yzIg8wde3ahLVEIDHb6ik0PYgf7285x0yO1NklWJlD/MDx9afclEHyviInn2qpdSxuNh+9jgjg/nQ0CZKssaIqry/86I7jmVEb5Y+MevespmaN5UbJIPysP4arrcuwaSMZDHcQOMgcVN7aD8zeN24VpAoLKMEVE+pN8khjU7BkdO9YrakI0z/AHjyKpTXiBw5k2AZLBuh9KTYI3bzUzcsZEwu8KCuOmOp/Gm28kfmCRX+XdnOOTXJzazBLOBbFmZf7o4Oa1INP1G5eMKPLjbkY65781hUxEIO0jWKZ2El/wCRZzOPmRgM4PPXrUM+rQRQOrTRkzjO8YG0enWs0eH7l7cs96ywvxnnipR4Sijh/esztnAySQfrWUsUkrqLBJPS5kt4mggt2jtkeVs4yOATWBquv6kY1/drbxueAQGNd82h2yQBo40TjkAVj67oyXNg+1PujKkdQa5ni6t0rWRo4RadnqebXBmnbM07MT69BWlp3h9rmMbQAAc8D9azpFdSyuORxmvRvAbw3NkVbG9OCPyrpor2s1Fs86vNwjcz7Hwv5Mkc8TFJ0OQ6jBrek0mO5CGdTFIP+WkQwT+VdSLePAwAaeY1A6CvZo0lS+E8ydRz3PNUtb2fXJbeG6ZbC1GJTKNxkb+6PTjvWw26ABFnTGOPlzXVTWdtISTEoJ+9gfe+tQmxt8DMEZ+gxXVzXZnc0yDIRg8LwwNQSXYQl342MDye1MkuQI0RRjIySe9Ys7rNOQAGbrz0A9/evGvY9jc01f7TMLhm2xoCFz3zUAlHzSR4yCfnbtVVyWiBlcKuex5NZ17qsagLGSVB69s0+ZR3Js3sTXlyXcAnCDrz1rD1vVI4YGZ2UbeijvWTquuLEz7mwSecHk1yN3dy38vG7ZmsuZyFOSgtSXUb6e8maRjzn5V/xqG3tWIQPyW5NTw2u35mOWPJq2q4z0zW8KPc82tinLYaiYwAMYqQDil245o9M10JJHG5XEPtR9adSgUWE2Nz2peR0paXGaLD5rjec5owaeQTQQe9FhcxGQR/jTSvqTUpB6fjTSOvFOwrkDKOajZBVkrnqaaVAHemFysU6cV1XhvW3+0W1pcADcRGrjv9feud2mgKVIIJyOQR2qZR5kbUK8qM+aJ6ZeWvnn7MRlSMn3FT2trJFEWiY4Xjaa5bRPEcjXMEN7jecIsvr7H8q7EXIVWI6Vjblep7cK0asbxZc06dZkBxgg8irczJkjcvTj1rnkvY7e6EquArfeHatSW7tZsMrhQR97tRfU1TM6+I+0qHI8tkAwfUd6o3F5Alq7OVV1bgd/pTNXv40lBhBmkI24Xq1Uo/DV9qML3eoSeUpOViHUfWpctbLVlOaSuySe+tyiN52HY5bHQ/Wqkup2qmNlYBFUjGOhzWzZ+H7DPlzRrIqnaxPrRFpNnZyyXENuqIr7AAPvChRlYy9suxy0+pvctJHYWrzTDqwHyj86fD4dvbl4zq0pWNlLeWnA47V16osMSZVRNcnHA6dqSUtJcLFGP4SrY7AcH86iVNtasaqvojCsNKhtpJRBECUUnkdiK6jRQklpEOgXv6jtVC0dVmZAwJIKL6jtzVzTf3KG3XI24Ofx6VyyppO6NFJvc27T5oZonj3Jk8e1JaTs6xwSYLxnyye7e9FvIyxu68sfmA9SetU5ZhbX8UwBMcozk/+gn3qJKyuXHUvTFApVceW54PpWeiBI5EkA54GavThcsDkBhnP94e9VZGZsDByo2keorCUTW+h5z4i0OR7pWtI8uxOUHfnjFZ+gajNpGo7JlMeW2urDGOa9D16ywYjHyy/NGR69xWR8QdEuNRaxvLCAy3KRBblUAz0O2nRlKLb7GFdRe/U7DT7yG6jxG4J64Bq3n1ryHRb7UNE1KEXqSxxsduHr1SK/tpgDHKvPTmvew2JjWieRVpODLDH8qYTTiaac5611XMTE8+RkOVwzHlj3qpJexQnZGplcc7V5zVO+v1yBGr7ieXOR+lUHuyodkQs5HpwPxrxuax7DQ++vbh2JkDMB/CvauZ1fWZFRlhjZmGPujgVanlub13t7fIfaWZgf0rqPC/h028eZFQs6gvuwc8CpipTempE5qCPJUSS6dmmcjJ5BNalvCiKAgzxXuMllbSxCOS0hZAOgjVT+grLuvCejXG4m3aIn+62ea7oQ5Oh5VRTm73PKNpJ707HGMHNeiyeAbGRR5F1LEw6/IDn86j/wCFeRkZTVZB9YlrX5HO6c+x5/j8KXHtxXbS/Dy8/wCXe9ik/wCuhVKpv4F1tSQv2JgPS4HNF0TySXQ5UY4wKXt710Ung3W4xnyIW/3Jc1Vfw5rCAlrGQgd1GafMieWS3RkY5pQDg1qR6Dqrj5bGY49VqT/hHNX/AOfCXr6UXQrPsZGMnmjGeP1rYHh3V+f9Am/75NMbQtTQDNhPj/dougszKx14pNvFaEmnXsf37Kcf8Aqs8EqZ3wyqPdcU00Ir7Mf0pCv51KOTgfzFIQccq1GgXI9nc0FfrTzjnnJ+opSpxwp5piuQlOPTPf0rsfDepi9txbXRBuY+D/tr6/hXKBCeSrAUwO8MqSwvskU5U5AqJRudFCs6cr9D1CO2tQQpgU8+uc1Z+ywNv3RjaewPTFc/o2uw6kgRyI7tAcqT1z3HrW5DNhAXJyRjp0xXNonZnrxkpK6EWCFZtsUYGR6Z6VaglaO1mR14YlgfamR4yhODxnPpUF06yW2TkSZ2j0qloVuNeVEtkkA6Pxj0pyf6Q4iA/dhgxPq1NkjVNvmN+7V84/CrSokVnIxJUfe3elNdiXYztSMZeFl4dTnPsD1pkMchaVy4QuD8p43elQKTJDvkBVowRj/ZJ5rSjCyQwMSCeOfQUt2VeyKV1biN4uCGOCDj7p74p8UmJMqSCWP596S+cjYWOTuIWljgxPGzttAzkLzk1jOOuiNYvQ3bVgLeORxxjDDv/nmq95arCzRL/qh8yj0qKGbYYXkBCk4ceox/OleXPnKzZIbHPb2rJxNIssqxa1cunKjk9wf8Kdp4ZrlHbBXoM96gt5mZSxAJc4OPX6U6FmgjCjkbtxA5zWEo6aGqa6lq6tzLOQPlVGEh/wBkDkimQbd7u7Nhz8r44AzxTC7SFreNiXfDSn+6B0H5VOWVRsVSOOmP5VUaVkcdSrzMxfF9lHeaLNG8e6RTuiZAM5ry+DUb+zcBmkR0PzI3BHPSvWHY3d8sMfzQQ/O5JxknoPwrifiTGg1K3lRQpZAr7QMA4pSTjrHoEGnozs/DmpLqWmRSsw34GR+dan4GvJfC2qS2WpQoH/cuwB/WvWic4K4PA/lXqYWv7WGu6OKtT5JaHDyQIlm0oyXPXJ4rBv5HSWOJWISQ4bmiivNfwnoy6nWeGbKBbYyhPnYYJJrp41ChQOmKKK9HDr3EedUd2XEAeN2PVcYpE53Z7Ciiuh7mT2F6GMjqxwakYbdoHaiik+gICOM+tKgGRj0oooGPyQfvN+dKXfA+d/8Avo0UUg6DQ7grh2GR2Y1MWbON74/3jRRTQCCRx0d/++jQ0r7R8zfnRRTQhjyFSOFPHcZpsiROBuhhOeuUFFFFgGCztRki1t8j/pmKRre2bANrb4/65iiilZAkiCSytA+BaW/P/TMUvkW+MfZoMD/pmKKKhIqyGiGADAtoP+/YpslpavtDWtvyf+eYooprYVkV7ywtEVXS2hR1yAyoAaxl+S4dB933oorOqkkjWhvYs2zk5B6Co5lDQSMepP8AhRRWXQ6uo61PnW6yycsT+FLK7FJVJyo7GiirRLKdyo8yP/aYKfcGrOpHyZI1iwoaM5A9ulFFSuo3ujItGNzeNHMcrEAVrZuj5XlMnVzzRRUrqadSS6ANkyH7qqMfnWZuK3UiZ+WSP5vzoorGp0NYdTW0ZjvuG4zvH8qmjP8ApF1J/Enyj0HFFFKPQmtsFpGsUIZc7nyWJOScVJcO32RpM/Oikg/hRRTkcqKVgPL09bhOJJCGb0JPWmiON76ZJIo5FkOw71DYHtmiis6mzHHoee+KbGDS9bdLMFFDZAJzjpW3pGsXjW3zSA9O3tRRUYZtVHY0qq8Vc//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The anterior drawer test is used to assess the integrity of the anterior cruciate ligament. With the knee flexed to 90&ordm;, the foot is stabilized by sitting on it. The proximal tibia is grasped firmly with both hands, and the tibia is forcibly pulled anteriorly, noting any pain, laxity, or abnormal movement compared with the opposite side.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Bruce C Anderson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38192=[""].join("\n");
var outline_f37_19_38192=null;
var title_f37_19_38193="Patient information: Vesicoureteral reflux in children (The Basics)";
var content_f37_19_38193=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17231\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/27/14769\">",
"         Anatomy of the urinary tract in children",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/45/3794\">",
"         Patient information: Prenatal hydronephrosis (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?10/38/10850\">",
"         Patient information: Urinary tract infections in children (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?37/58/38818\">",
"         Patient information: Urinary tract infections in children (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Vesicoureteral reflux in children (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/vesicoureteral-reflux-in-children-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H28150375\">",
"      <span class=\"h1\">",
"       What is vesicoureteral reflux?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Vesicoureteral reflux is a condition that causes some urine to flow in the wrong direction inside the body. Normally, urine that the kidneys make flows to the bladder through tubes called &ldquo;ureters.&rdquo; It then flows from the bladder out of the body. In",
"      <strong>",
"      </strong>",
"      children with vesicoureteral reflux, some of the urine flows backward from the bladder through the ureters to the kidneys (",
"      <a class=\"graphic graphic_figure graphicRef65630 \" href=\"mobipreview.htm?14/27/14769\">",
"       figure 1",
"      </a>",
"      ). This can happen in 1 or both of the ureters.",
"     </p>",
"     <p>",
"      This problem is most common in babies and young children. It often gets better or goes away as the child gets older. But it can also happen in older children and in adults.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28150392\">",
"      <span class=\"h1\">",
"       What are the symptoms of vesicoureteral reflux?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There are no symptoms.",
"     </p>",
"     <p>",
"      Why would a doctor think my child has vesicoureteral reflux?",
"     </p>",
"     <p>",
"      Doctors sometimes think a child might have vesicoureteral reflux if the child has 1 of the following conditions:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Hydronephrosis &ndash; This condition causes part of the kidney to swell because it has too much urine inside. It can be seen on a routine imaging test (ultrasound) to check on the baby during pregnancy. If an ultrasound done on a baby after delivery shows hydronephrosis, the baby might have vesicoureteral reflux.",
"       </li>",
"       <li>",
"        Urinary tract infection (or &ldquo;UTI&rdquo;) &ndash; These infections are usually caused by bacteria in the bladder or kidneys. If a child has had several UTIs, the doctor might want test him or her for vesicoureteral reflux. If both conditions occur together, infected urine could flow backwards to the kidney and cause damage.&nbsp;",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28150407\">",
"      <span class=\"h1\">",
"       Is there a test for vesicoureteral reflux?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes, there is a test called a &ldquo;voiding cystourethrogram&rdquo; or &ldquo;VCUG.&rdquo; For this test, the doctor puts a small, flexible tube inside the child&rsquo;s bladder. Next the doctor fills the child&rsquo;s bladder with a special fluid that shows up on X-rays. Then the child urinates on the X-ray table. X-rays taken during this test show if the urine is flowing the wrong way.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28150422\">",
"      <span class=\"h1\">",
"       How is vesicoureteral reflux treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Treatments include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Antibiotics &ndash; These medicines help prevent urinary tract infections. Children being treated with antibiotics take them every day but at a lower dose than they would if they had an infection.",
"       </li>",
"       <li>",
"        Surgery - Different kinds of surgery can stop the backflow of urine from the bladder to the kidney.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H28150437\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/45/3794?source=see_link\">",
"       Patient information: Prenatal hydronephrosis (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/38/10850?source=see_link\">",
"       Patient information: Urinary tract infections in children (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/58/38818?source=see_link\">",
"       Patient information: Urinary tract infections in children (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/19/38193?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17231 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-203.80.222.8-8F853297CB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38193=[""].join("\n");
var outline_f37_19_38193=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28150375\">",
"      What is vesicoureteral reflux?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28150392\">",
"      What are the symptoms of vesicoureteral reflux?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28150407\">",
"      Is there a test for vesicoureteral reflux?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28150422\">",
"      How is vesicoureteral reflux treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H28150437\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17231\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?14/27/14769\">",
"      Anatomy of the urinary tract in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/45/3794?source=related_link\">",
"      Patient information: Prenatal hydronephrosis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?37/58/38818?source=related_link\">",
"      Patient information: Urinary tract infections in children (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?10/38/10850?source=related_link\">",
"      Patient information: Urinary tract infections in children (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_19_38194="Patient information: Deciding to breastfeed (The Basics)";
var content_f37_19_38194=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/15825\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/30/8674\">",
"         The breast",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?35/22/36194\">",
"         Patient information: Breast pumps (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?16/43/17075\">",
"         Patient information: Breastfeeding (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?3/26/3491\">",
"         Patient information: Common breastfeeding problems (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?7/13/7379\">",
"         Patient information: Health and nutrition for women who breastfeed (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?4/27/4531\">",
"         Patient information: Weaning from breastfeeding (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"mobipreview.htm?1/19/1333\">",
"         Patient information: Breastfeeding guide (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"mobipreview.htm?33/63/34805\">",
"         Patient information: Deciding to breastfeed (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Deciding to breastfeed (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/deciding-to-breastfeed-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H9660565\">",
"      <span class=\"h1\">",
"       Do doctors recommend breastfeeding?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors recommend that women breastfeed their babies for at least 1 year (12 months) when possible. For the first 6 months, breast milk is the only food a baby needs. After 6 months, doctors recommend that women still breastfeed. But babies can start eating and drinking other foods, too.",
"     </p>",
"     <p>",
"      Some women choose not to breastfeed. They might think that it is easier to feed a baby formula. Or they might be embarrassed to breastfeed.",
"     </p>",
"     <p>",
"      But breastfeeding has many benefits for both the mother and baby, even if a woman breastfeeds for only a short time. Also, these benefits can last even after the breastfeeding has stopped.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9660572\">",
"      <span class=\"h1\">",
"       What are the benefits for babies?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Breastfeeding can keep babies from getting stomach infections that can cause vomiting or diarrhea. It can also keep babies from getting ear or lung infections.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9660579\">",
"      <span class=\"h1\">",
"       What are the benefits for women?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Breastfeeding can benefit women in many ways. Compared with women who feed their babies formula, women who breastfeed usually:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Have less bleeding from the uterus after giving birth",
"       </li>",
"       <li>",
"        Have less stress",
"       </li>",
"       <li>",
"        Lose more weight after pregnancy (if they breastfeed at least 6 months)",
"       </li>",
"       <li>",
"        Have a lower chance of getting breast cancer",
"       </li>",
"       <li>",
"        Don&rsquo;t spend as much money to feed their baby",
"       </li>",
"       <li>",
"        Don&rsquo;t spend as much money on healthcare or miss as much work, because their babies get sick less often",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9660586\">",
"      <span class=\"h1\">",
"       How do the breasts make milk?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Breast milk is made by the &ldquo;milk glands&rdquo; in the breasts (",
"      <a class=\"graphic graphic_figure graphicRef72583 \" href=\"mobipreview.htm?8/30/8674\">",
"       figure 1",
"      </a>",
"      ). During pregnancy, these glands get ready to make breast milk.",
"     </p>",
"     <p>",
"      After a woman gives birth, substances in her body called &ldquo;hormones&rdquo; cause the breasts to fill with milk. For the first few days after birth, women make only a small amount of yellowish milk called &ldquo;colostrum.&rdquo; Colostrum has all of the nutrition a newborn needs. Women start making more breast milk a few days later, usually 2 to 3 days after giving birth.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9660593\">",
"      <span class=\"h1\">",
"       Will I make enough milk?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most healthy women can make enough breast milk. Each time a baby feeds and empties the breasts, the body makes more milk. After 2 to 4 weeks of breastfeeding, most healthy women make about 3 cups of milk a day.",
"     </p>",
"     <p>",
"      Sometimes, women can have trouble making enough milk. This can happen if they:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Are tired or sick",
"       </li>",
"       <li>",
"        Have a lot of stress",
"       </li>",
"       <li>",
"        Take certain medicines",
"       </li>",
"       <li>",
"        Do not eat enough",
"       </li>",
"       <li>",
"        Smoke cigarettes",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      If you have trouble making enough milk, talk with your doctor or nurse. Some women also find it helpful to work with a breastfeeding expert called a &ldquo;lactation consultant.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9660600\">",
"      <span class=\"h1\">",
"       When can I start breastfeeding?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most women can start breastfeeding in the delivery room. Women should start breastfeeding within the first few hours of giving birth. During this time, most babies are awake and want to breastfeed.",
"     </p>",
"     <p>",
"      If you can&rsquo;t be with your baby right after birth, there are things you can do so that you can still breastfeed. You can use a device called a breast pump to collect breast milk that your baby can drink later. Using a breast pump also helps the breasts continue to make milk.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9660607\">",
"      <span class=\"h1\">",
"       Can I breastfeed if I had breast surgery?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you had breast surgery, you can try to breastfeed and see if you make enough milk. Many women who had surgery to make their breasts smaller or bigger can make enough milk, but some can&rsquo;t.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9660614\">",
"      <span class=\"h1\">",
"       When is breastfeeding not recommended?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors do not recommend breastfeeding if a woman:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Is infected with something, such as the HIV virus, that the baby can catch by breastfeeding",
"       </li>",
"       <li>",
"        Is getting treated for cancer",
"       </li>",
"       <li>",
"        Uses too many drugs or drinks too much alcohol",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Also, doctors do not recommend breastfeeding for babies who are born with a medical condition called &ldquo;classic galactosemia.&rdquo;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9660621\">",
"      <span class=\"h1\">",
"       Do I need to do anything or buy anything to get ready?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most women do not need to do anything or buy anything to get ready for breastfeeding. But some women buy or rent a breast pump later on. A woman can use a breast pump for times when she is at work or away from her baby.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9660628\">",
"      <span class=\"h1\">",
"       What if I have questions about breastfeeding?",
"      </span>",
"      &nbsp;&mdash;&nbsp;If you have questions about breastfeeding, ask your doctor or nurse, or talk to a lactation consultant.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H9660785\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/43/17075?source=see_link\">",
"       Patient information: Breastfeeding (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/26/3491?source=see_link\">",
"       Patient information: Common breastfeeding problems (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/13/7379?source=see_link\">",
"       Patient information: Health and nutrition for women who breastfeed (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/22/36194?source=see_link\">",
"       Patient information: Breast pumps (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/27/4531?source=see_link\">",
"       Patient information: Weaning from breastfeeding (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/19/1333?source=see_link\">",
"       Patient information: Breastfeeding guide (Beyond the Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/63/34805?source=see_link\">",
"       Patient information: Deciding to breastfeed (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"mobipreview.htm?37/19/38194?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 15825 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-2332FC6495-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38194=[""].join("\n");
var outline_f37_19_38194=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9660565\">",
"      Do doctors recommend breastfeeding?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9660572\">",
"      What are the benefits for babies?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9660579\">",
"      What are the benefits for women?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9660586\">",
"      How do the breasts make milk?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9660593\">",
"      Will I make enough milk?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9660600\">",
"      When can I start breastfeeding?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9660607\">",
"      Can I breastfeed if I had breast surgery?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9660614\">",
"      When is breastfeeding not recommended?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9660621\">",
"      Do I need to do anything or buy anything to get ready?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9660628\">",
"      What if I have questions about breastfeeding?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9660785\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/15825\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/30/8674\">",
"      The breast",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?35/22/36194?source=related_link\">",
"      Patient information: Breast pumps (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?16/43/17075?source=related_link\">",
"      Patient information: Breastfeeding (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?1/19/1333?source=related_link\">",
"      Patient information: Breastfeeding guide (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?3/26/3491?source=related_link\">",
"      Patient information: Common breastfeeding problems (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?33/63/34805?source=related_link\">",
"      Patient information: Deciding to breastfeed (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?7/13/7379?source=related_link\">",
"      Patient information: Health and nutrition for women who breastfeed (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?4/27/4531?source=related_link\">",
"      Patient information: Weaning from breastfeeding (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_19_38195="Corticorelin: Drug information";
var content_f37_19_38195=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Corticorelin: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/0/11267?source=see_link\">",
"    see \"Corticorelin: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F3281687\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Acthrel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F3281690\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Diagnostic Agent",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F3284295\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Testing pituitary corticotrophin function: I.V.: 1 mcg/kg; dosages &gt;1 mcg/kg or &gt;100 mcg have been associated with an increase in adverse effects and are not recommended.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Venous blood samples should be drawn 15 minutes before and immediately prior to corticorelin administration to determine baseline ACTH and cortisol (baseline ACTH value is the average of the 2 samples). At 15-, 30-, and 60 minutes after administration, venous blood samples should be drawn again to determine response.",
"     <b>",
"      Basal and peak responses differ depending on AM or PM administration; therefore, any repeat evaluations on the same patient are recommended to be done at the same time of day as the initial testing.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F15795903\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F15795904\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No dosage adjustment provided in manufacturer&rsquo;s labeling.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F3284298\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, powder for reconstitution, as trifluoroacetate [ovine derived]:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Acthrel&reg;: 100 mcg [contains lactose 10 mg]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F3281689\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F3284296\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer I.V. over 30-60 seconds. Concurrent heparin (even to maintain I.V. patency) is not recommended.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F3281691\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnostic test used in adrenocorticotropic hormone (ACTH)-dependent Cushing&rsquo;s syndrome to differentiate between pituitary and ectopic production of ACTH",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3281685\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Acthrel&reg; may be confused with Acthar",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Corticorelin may be confused with corticotropin, cosyntropin, or Cortrosyn&reg;",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F3284279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Cardiovascular: Flushing (face, neck and upper chest, 16%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%: Respiratory: Dyspnea (urge to inspire, 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Asystole, dizziness, dyspnea, hypotension (severe), loss of consciousness, metallic taste, nausea, palpitations, seizure, tachycardia (severe), vomiting, xerostomia",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F3284274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no contraindications listed in the manufacturer's labeling.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F3284275\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concurrent drug therapy issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Heparin: Concurrent use of heparin (even to maintain I.V. patency) and corticorelin is not recommended; heparin use during the corticorelin test may result in severe hypotension and loss of sinus rhythm.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sheep derived: Use with caution in patients with previous reactions to sheep products (lanolin).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Dose-dependent adverse effects: High doses  (&gt;1 mcg/kg or &gt;100 mcg) have been associated with hypotension, transient tachycardia, dyspnea, chest tightness, loss of consciousness, and asystole; doses &gt;1 mcg/kg are not recommended. In addition, administering recommended doses as an infusion over 30 seconds instead of a bolus dose may reduce the potential for these effects.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; False negative responses: May occur in 5% to 10% of Cushing&rsquo;s disease patients, which may lead to an incorrect diagnosis of ectopic production of ACTH.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F3284285\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Corticosteroids: May diminish the therapeutic effect of Corticorelin. Specifically, the plasma ACTH response to corticorelin may be blunted by recent or current corticosteroid therapy.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Beclomethasone (Nasal); Budesonide (Nasal); Ciclesonide (Nasal); Desonide; Dexamethasone (Ophthalmic); Difluprednate; Flunisolide (Nasal); Fluocinolone (Ophthalmic); Fluticasone (Nasal); Loteprednol; Mometasone (Nasal); PrednisoLONE (Ophthalmic); Triamcinolone (Nasal); Triamcinolone (Ophthalmic).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Heparin: May enhance the adverse/toxic effect of Corticorelin. Significant hypotension and bradycardia have been previously attributed to this combination.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F3284271\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F3284272\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F3284273\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322950\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution (reconstituted)",
"     </b>",
"     (Acthrel Intravenous)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mcg (1): $658.98",
"    </p>",
"   </div>",
"   <div class=\"block rer drugH1Div\" id=\"F3284289\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reference Range",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     High basal plasma ACTH and cortisol (20-40 mcg/dL) resulting in",
"     <b>",
"      increased",
"     </b>",
"     plasma ACTH and cortisol after administration of test indicates",
"     <b>",
"      ACTH-dependent disease of pituitary origin.",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     High basal plasma ACTH (may be very high) and cortisol (20-40 mcg/dL) resulting in",
"     <b>",
"      little to no change",
"     </b>",
"     in plasma ACTH and cortisol after administration of test indicates",
"     <b>",
"      ACTH-dependent syndrome of ectopic origin.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F12992804\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      CRH (AT, DE, NL);",
"     </li>",
"     <li>",
"      CRH-Ferring (KP);",
"     </li>",
"     <li>",
"      Stimu-ACTH (FR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F3284287\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Corticorelin ovine, a peptide of ovine corticotropin-releasing hormone (oCRH) and an analogue of human CRH (hCRH), stimulates adrenocorticotropic hormone (ACTH) release from the anterior pituitary. ACTH stimulates the adrenal cortex to produce cortisol. Depending on the plasma ACTH and cortisol response following the corticorelin stimulation test, the results aid the clinician in the differentiation between the source of ACTH-dependent hypercortisolism (pituitary vs ectopic).",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F3284290\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action: I.V.: Plasma ACTH level increases 2 minutes after injection; plasma cortisol level increases within 10 minutes after injection",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: I.V.: Plasma ACTH and cortisol levels remain elevated for up to 2 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak, plasma: ACTH: 15-60 minutes; Cortisol: 30-120 minutes; both levels show a dose-dependent, biphasic response with a second lower peak 2-3 hours after injection; basal and peak response levels vary depending on AM or PM administration (baseline ACTH and cortisol levels are generally higher in the AM)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Corticorelin: ACTH RF, Corticoliberin, Corticotropin-Releasing Hormone, Corticotropin-Releasing Factor, Human Corticotropin-Releasing Hormone, Ovine Corticotrophin-Releasing Factor, Xerecept,&rdquo;",
"      <i>",
"       Drugs R D",
"      </i>",
"      , 2004, 5(4):218-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/19/38195/abstract-text/15230628/pubmed\" id=\"15230628\" target=\"_blank\">",
"        15230628",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Newell-Price J, Bertagna X, Grossman AB, et al, &ldquo;Cushing&rsquo;s Syndrome,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 2006, 367(9522):1605-17.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/19/38195/abstract-text/16698415/pubmed\" id=\"16698415\" target=\"_blank\">",
"        16698415",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Nieman LK, Oldfield EH, Wesley R, et al, &ldquo;A Simplified Morning Ovine Corticotropin-Releasing Hormone Stimulation Test for the Differential Diagnosis of Adrenocorticotropin-Dependent Cushing&rsquo;s Syndrome,&rdquo;",
"      <i>",
"       J Clin Endocrinol Metab",
"      </i>",
"      , 1993, 77(5):1308-12.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/19/38195/abstract-text/8077325/pubmed\" id=\"8077325\" target=\"_blank\">",
"        8077325",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8866 Version 33.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-178.219.2.221-D2DE38DEA4-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38195=[""].join("\n");
var outline_f37_19_38195=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281687\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281690\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3284295\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795903\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15795904\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3284298\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281689\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3284296\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281691\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3281685\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3284279\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3284274\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3284275\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299094\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3284285\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3284271\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3284272\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3284273\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322950\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3284289\">",
"      Reference Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F12992804\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3284287\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3284290\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8866\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8866|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?11/0/11267?source=related_link\">",
"      Corticorelin: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_19_38196="Cefditoren: Drug information";
var content_f37_19_38196=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cefditoren: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/21/42323?source=see_link\">",
"    see \"Cefditoren: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F147246\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Spectracef&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F147267\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Antibiotic, Cephalosporin (Third Generation)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F147249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Acute bacterial exacerbation of chronic bronchitis:",
"     </b>",
"     Oral: 400 mg twice daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Community-acquired pneumonia:",
"     </b>",
"     Oral: 400 mg twice daily for 14 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      Dental infections (unlabeled use):",
"     </b>",
"     Oral: 400 mg twice daily for 10 days",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Pharyngitis, tonsillitis, uncomplicated skin and skin structure infections:",
"     </b>",
"     Oral: 200 mg twice daily for 10 days",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F147261\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Children &ge;12 years: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F147250\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block dor drugH1Div\" id=\"F147251\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Renal Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     30-49 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Maximum dose: 200 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cl",
"     <sub>",
"      cr",
"     </sub>",
"     &lt;30 mL/minute/1.73 m",
"     <sup>",
"      2",
"     </sup>",
"     : Maximum dose: 200 mg once daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     End-stage renal disease: Appropriate dosing not established",
"    </p>",
"   </div>",
"   <div class=\"block doh drugH1Div\" id=\"F147252\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Hepatic Impairment",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Mild-to-moderate impairment: Adjustment not required",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Severe impairment (Child-Pugh class C): Specific guidelines not available",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F147224\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral: 200 mg, 400 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Spectracef&reg;: 200 mg, 400 mg [contains sodium caseinate]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F147209\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F147226\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Administer with meals.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F147225\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute bacterial exacerbation of chronic bronchitis or community-acquired pneumonia (due to susceptible organisms including",
"     <i>",
"      Haemophilus influenzae",
"     </i>",
"     ,",
"     <i>",
"      Haemophilus parainfluenzae",
"     </i>",
"     ,",
"     <i>",
"      Streptococcus pneumoniae",
"     </i>",
"     -penicillin susceptible only,",
"     <i>",
"      Moraxella catarrhalis",
"     </i>",
"     ); pharyngitis or tonsillitis (",
"     <i>",
"      Streptococcus pyogenes",
"     </i>",
"     ); and uncomplicated skin and skin-structure infections (",
"     <i>",
"      Staphylococcus aureus",
"     </i>",
"     - not MRSA,",
"     <i>",
"      Streptococcus pyogenes",
"     </i>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F3264118\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Spectracef [U.S., Great Britain, Mexico, Portugal, Spain] may be confused with Spectrocef brand name for cefotaxime [Italy]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F147265\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &gt;10%: Gastrointestinal: Diarrhea (11% to 15%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     1% to 10%:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Central nervous system: Headache (2% to 3%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Glucose increased (1% to 2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Gastrointestinal: Nausea (4% to 6%), abdominal pain (2%), dyspepsia (1% to 2%), vomiting (1%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Genitourinary: Vaginal moniliasis (3% to 6%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Hematologic: Hematocrit decreased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Renal: Hematuria (3%), urinary white blood cells increased (2%)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     &lt;1% (Limited to important or life-threatening): Acute renal failure, albumin decreased, allergic reaction, arthralgia, asthma, BUN increased, calcium decreased, eosinophilic pneumonia, coagulation time increased, erythema multiforme,  fungal infection, hyperglycemia, interstitial pneumonia, leukopenia, leukorrhea, positive direct Coombs' test, potassium increased, pseudomembranous colitis, rash, sodium decreased, Stevens-Johnson syndrome, thrombocythemia, thrombocytopenia, toxic epidermal necrolysis, white blood cells increased/decreased",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Reactions reported with other cephalosporins: Anaphylaxis, aplastic anemia, cholestasis, hemorrhage, hemolytic anemia, renal dysfunction, reversible hyperactivity, serum sickness-like reaction, toxic nephropathy",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F147229\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to cefditoren, any component of the formulation, other cephalosporins, or milk protein; carnitine deficiency",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F147213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elevated INR: May be associated with increased INR, especially in nutritionally-deficient patients, prolonged treatment, hepatic or renal disease.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Penicillin allergy: Use with caution in patients with a history of penicillin allergy, especially IgE-mediated reactions (eg, anaphylaxis, angioedema, urticaria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including",
"     <i>",
"      C. difficile",
"     </i>",
"     -associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Carnitine deficiency: Do not use in patients with carnitine deficiency; causes renal excretion of carnitine.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Hepatic impairment: Use with caution in patients with hepatic impairment",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Renal impairment: Use with caution in patients with renal impairment; modify dosage in moderate-to-severe impairment.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Seizure disorders: Use with caution in patients with a history of seizure disorder; high levels, particularly in the presence of renal impairment, may increase risk of seizures.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sodium caseinate: Tablets contain sodium caseinate, which may cause hypersensitivity reactions in patients with milk protein hypersensitivity; this does not affect patients with lactose intolerance.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Duration of therapy: Not for long-term therapy due to the possible development of carnitine deficiency over time.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13298987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F147217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the serum concentration of Cefditoren. Management: Concomitant use of cefditoren with antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy. If antacid therapy can not be avoided, separate dosing by several hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the serum concentration of Cefditoren. Management: Concomitant use of cefditoren with H2-antagonists and antacids is not recommended. Consider alternative methods to control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of H2-antagonists can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Probenecid: May increase the serum concentration of Cephalosporins.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the serum concentration of Cefditoren. Management: If possible, avoid use of cefditoren with proton pump inhibitors (PPIs). Consider alternative methods to minimize/control acid reflux (eg, diet modification) or alternative antimicrobial therapy if use of PPIs can not be avoided.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vitamin K Antagonists (eg, warfarin): Cephalosporins may enhance the anticoagulant effect of Vitamin K Antagonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F147242\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Food: Moderate- to high-fat meals increase bioavailability and maximum plasma concentration. Management: Take with meals. Maintain adequate hydration, unless instructed to restrict fluid intake.",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F147220\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     B (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F147231\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have not been observed in animal reproduction studies. An increase in most types of birth defects was not found following first trimester exposure to cephalosporins.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F147256\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F6298495\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is not known whether cefditoren is excreted in human milk. The manufacturer recommends caution when using cefditoren during breast-feeding. If cefditoren reaches the breast milk, the limited oral absorption may minimize the effect on the nursing infant. Nondose-related effects could include modification of bowel flora.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F147232\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Cefditoren should be taken with meals. Plasma carnitine levels are decreased during therapy (39% with 200 mg dosing, 63% with 400 mg dosing); normal concentrations return within 7-10 days after treatment is discontinued.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F6884405\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Cefditoren Pivoxil Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (20): $294.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (20): $294.81",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablets",
"     </b>",
"     (Spectracef Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     200 mg (20): $357.08",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     400 mg (20): $357.08",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F147222\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Monitor renal function. Observe for signs and symptoms of anaphylaxis during first dose.",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F5539827\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Giasion (IT);",
"     </li>",
"     <li>",
"      Meiact (CL, ES, JP, TH);",
"     </li>",
"     <li>",
"      Spectracef (GR, PT);",
"     </li>",
"     <li>",
"      Spektracef (TR)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F147212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Inhibits bacterial cell wall synthesis by binding to one or more of the penicillin-binding proteins (PBPs) which in turn inhibits the final transpeptidation step of peptidoglycan synthesis in bacterial cell walls, thus inhibiting cell wall biosynthesis. Bacteria eventually lyse due to ongoing activity of cell wall autolytic enzymes (autolysins and murein hydrolases) while cell wall assembly is arrested.",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F147228\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: 9.3 &plusmn; 1.6 L",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 88% (",
"     <i>",
"      in vitro",
"     </i>",
"     ), primarily to albumin",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Cefditoren pivoxil is hydrolyzed to cefditoren (active) and pivalate",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Bioavailability: ~14% to 16%, increased by moderate- to high-fat meal",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 1.6 &plusmn; 0.4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak: 1.5-3 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Urine (as cefditoren and pivaloylcarnitine)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      Darkes MJ and Plosker GL, &ldquo;Cefditoren Pivoxil,&rdquo;",
"      <i>",
"       Drugs",
"      </i>",
"      , 2002, 62(2):319-36.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?37/19/38196/abstract-text/11817976/pubmed\" id=\"11817976\" target=\"_blank\">",
"        11817976",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8599 Version 38.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-199.231.185.123-BC6E475435-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38196=[""].join("\n");
var outline_f37_19_38196=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147246\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147267\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147249\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147261\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147250\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147251\">",
"      Dosing: Renal Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147252\">",
"      Dosing: Hepatic Impairment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147224\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147209\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147226\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147225\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F3264118\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147265\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147229\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147213\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13298987\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147217\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147242\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147220\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147231\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147256\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6298495\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147232\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F6884405\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147222\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F5539827\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147212\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F147228\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8599\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8599|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?41/21/42323?source=related_link\">",
"      Cefditoren: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_19_38197="Arcades and vasa recta of the small intestines";
var content_f37_19_38197=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F85571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F85571&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 547px\">",
"   <div class=\"ttl\">",
"    Arcades and vasa recta of the small intestines",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 527px; height: 600px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The superior mesenteric artery gives rise to the arcuate system that supplies the vasa recta of the small intestine. The arcades are simple and primary in the upper jejunum but increase in complexity in the more distal portions of the intestine. The vasa recta arise from the most peripheral arcades, and do not intercommunicate.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38197=[""].join("\n");
var outline_f37_19_38197=null;
var title_f37_19_38198="Chapter 1A: Introduction to renal function";
var content_f37_19_38198=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 1A: Introduction to renal function",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/19/38198/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38198/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38198/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/19/38198/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38198/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/19/38198/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38198/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/19/38198/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 26, 2000.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidney normally performs a number of essential functions:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It participates in the maintenance of the constant extracellular environment that is required for adequate functioning of the cells. This is achieved by excretion of some of the waste products of metabolism (such as urea, creatinine, and uric acid) and by specifically adjusting the urinary excretion of water and electrolytes to match net intake and endogenous production. As will be seen, the kidney is able to regulate individually the excretion of water and solutes such as sodium, potassium, and hydrogen, largely by changes in tubular reabsorption or secretion.",
"     </li>",
"     <li>",
"      It secretes hormones that participate in the regulation of systemic and renal hemodynamics (renin, angiotensin II, prostaglandins, nitric oxide, endothelin, and bradykinin), red blood cell production (erythropoietin), and calcium, phosphorus, and bone metabolism (1,25-dihydroxyvitamin D3 or calcitriol).",
"     </li>",
"     <li>",
"      It performs such miscellaneous functions as catabolism of peptide hormones [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/1,2\">",
"       1,2",
"      </a>",
"      ] and synthesis of glucose (gluconeogenesis) in fasting condition [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This chapter will review briefly the morphology of the kidney and the basic processes of reabsorption and secretion. The regulation of renal hemodynamics, the specific functions of the different nephron segments, and the relationships between hormones and the kidney will then be discussed in the ensuing chapters.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RENAL MORPHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic unit of the kidney is the nephron, with each kidney in humans containing approximately 1.0 to 1.3 million nephrons. Each nephron consists of a glomerulus, which is a tuft of capillaries interposed between two arterioles (the afferent and efferent arterioles), and a series of tubules lined by a continuous layer of epithelial cells (",
"    <a class=\"graphic graphic_figure graphicRef60157 \" href=\"mobipreview.htm?8/37/8785\">",
"     figure 1",
"    </a>",
"    ). The glomeruli are located in the outer part of the kidney, called the cortex, whereas the tubules are present in both the cortex and the inner part of the kidney, the medulla (",
"    <a class=\"graphic graphic_figure graphicRef60157 \" href=\"mobipreview.htm?8/37/8785\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef72356 \" href=\"mobipreview.htm?17/53/18271\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The initial step in the excretory function of the nephron is the formation of an ultrafiltrate of plasma across the glomerulus. This fluid then passes through the tubules and is modified in two ways: by reabsorption and by secretion. Reabsorption refers to the removal of a substance from the filtrate, whereas secretion refers to the addition of a substance to the filtrate. As will be seen, the different tubular segments make varying contributions to these processes.",
"   </p>",
"   <p>",
"    Fluid filtered across the glomerulus enters Bowman's space and then the proximal tubule (",
"    <a class=\"graphic graphic_figure graphicRef60157 \" href=\"mobipreview.htm?8/37/8785\">",
"     figure 1",
"    </a>",
"    ). The proximal tubule is composed anatomically of an initial convoluted segment and a later straight segment, the pars recta, which enters the outer medulla. The loop of Henle begins abruptly at the end of the pars recta. It generally includes a thin descending limb and thin and thick segments of the ascending limb. The hairpin configuration of the loop of Henle plays a major role in the excretion of a hyperosmotic urine. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29384?source=see_link\">",
"     \"Chapter 4B: Countercurrent mechanism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It is important to note that the length of the loops of Henle is not uniform (",
"    <a class=\"graphic graphic_figure graphicRef76121 \" href=\"mobipreview.htm?16/29/16851\">",
"     figure 3",
"    </a>",
"    ). Approximately 40 percent of nephrons have short loops which penetrate only the outer medulla or may even turn around in the cortex; these short loops lack a thin ascending limb [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/5\">",
"     5",
"    </a>",
"    ]. The remaining 60 percent have long loops that course through the medulla and may extend down to the papilla (the innermost portion of the medulla). The length of the loops is largely determined by the cortical location of the glomerulus: glomeruli in the outer cortex (about 30 percent) have only short loops; those in the juxtamedullary region (about 10 percent) have only long loops; and those in the midcortex may have either short or long loops (",
"    <a class=\"graphic graphic_figure graphicRef76121 \" href=\"mobipreview.htm?16/29/16851\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The thick ascending limb also has a cortical segment which returns to the region of the parent glomerulus. It is in this area, where the tubule approaches the afferent glomerular arteriole, that the specialized tubular cells of the macula densa are located (",
"    <a class=\"graphic graphic_figure graphicRef69949 \" href=\"mobipreview.htm?31/9/31889\">",
"     figure 4",
"    </a>",
"    ). The juxtaglomerular cells of the afferent arteriole and the macula densa compose the juxtaglomerular apparatus, which plays a central role in renin secretion (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/25/13720?source=see_link\">",
"     \"Chapter 2B: Renin-angiotensin system\"",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    After the macula densa, there are three cortical segments (",
"    <a class=\"graphic graphic_figure graphicRef76121 \" href=\"mobipreview.htm?16/29/16851\">",
"     figure 3",
"    </a>",
"    ): the distal convoluted tubule, the connecting segment (previously considered part of the late distal tubule), and the cortical collecting tubule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. The connecting segments of many nephrons drain into a single collecting tubule. Fluid leaving the cortical collecting tubule flows into the medullary collecting tubule and then drains sequentially into the calyces, the renal pelvis, the ureters, and the bladder (",
"    <a class=\"graphic graphic_figure graphicRef72356 \" href=\"mobipreview.htm?17/53/18271\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The segmental subdivision of the nephron is based upon different permeability and transport characteristics that translate into important differences in function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/5\">",
"     5",
"    </a>",
"    ]. In general, the proximal tubule and loop of Henle reabsorb the bulk of the filtered solutes and water, while the collecting tubules make the final small changes in urinary composition that permit solute and water excretion to vary appropriately with alterations in dietary intake. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33352?source=see_link\">",
"     \"Chapter 5B: Collecting tubules\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    There may also be significant heterogeneity within a given tubular segment, particularly in the proximal tubule and cortical collecting tubule. In the latter segment, for example, there are two cell types with very different functions: the principal cells reabsorb sodium and chloride and secrete potassium, in part under the influence of aldosterone; and the intercalated cells secrete hydrogen or bicarbonate and reabsorb potassium, but play no role in sodium balance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33352?source=see_link\">",
"     \"Chapter 5B: Collecting tubules\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     REABSORPTION AND SECRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of glomerular filtration averages 135 to 180",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    in a normal adult. Since this represents a volume that is more than 10 times that of the extracellular fluid and approximately 60 times that of the plasma, it is evident that almost all of this fluid must be returned to the systemic circulation. This process is called tubular reabsorption and can occur either across the cell or via the paracellular route between the cells. With transcellular reabsorption, the substance to be reabsorbed is first transported from the tubular lumen into the cell, usually across the luminal aspect of the cell membrane; it then moves across the basolateral (or peritubular) aspect of the cell membrane into the interstitium and then the capillaries that surround the tubules (",
"    <a class=\"graphic graphic_figure graphicRef64169 \" href=\"mobipreview.htm?39/58/40878\">",
"     figure 5",
"    </a>",
"    ). With paracellular reabsorption, the substance to be reabsorbed moves from the tubular lumen across the tight junction at the luminal surface of adjacent cells (see below) into the interstitium and then into the peritubular capillaries (",
"    <a class=\"graphic graphic_figure graphicRef64169 \" href=\"mobipreview.htm?39/58/40878\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Most reabsorbed solutes are returned to the systemic circulation intact. However, some are metabolized within the cell, particularly low-molecular-weight proteins in the proximal tubule.",
"   </p>",
"   <p>",
"    Solutes can also move in the opposite direction, from the peritubular capillary through the cell and into the urine. This process is called tubular secretion (Fig. 1-5).",
"   </p>",
"   <p>",
"    Filtered solutes and water may be transported by one or both of these mechanisms. For example, Na+, Cl-, and H2O are reabsorbed; hydrogen ions are secreted; K+ and uric acid are both reabsorbed and secreted; and filtered creatinine is excreted virtually unchanged, since it is not reabsorbed and only a small amount is normally added to the urine by secretion.",
"   </p>",
"   <p>",
"    The transcellular reabsorption or secretion of almost all solutes is facilitated by protein carriers or ion-specific channels; these transport processes are essential since free diffusion of ions is limited by the lipid bilayer of the cell membrane. The spatial orientation of the cells is also important because the luminal and basolateral aspects of the cell membrane, which are separated by the tight junction, have different functional characteristics.",
"   </p>",
"   <p>",
"    As an example, filtered sodium enters the cell passively down a favorable electrochemical gradient, since the active Na+-K+-ATPase pump in the basolateral membrane maintains the cell Na+ concentration at a low level and makes the cell interior electronegative. Sodium entry occurs by a variety of mechanisms at different nephron sites, such as Na+-H+ exchange and Na+-glucose cotransport in the proximal tubule, a Na+-K+-2Cl- carrier protein in the thick ascending limb of the loop of Henle, and through a Na+ channel in the cortical collecting tubule and papillary collecting duct (",
"    <a class=\"graphic graphic_figure graphicRef62197 \" href=\"mobipreview.htm?42/6/43117\">",
"     figure 6",
"    </a>",
"    ). The sodium that enters the cells is then returned to the systemic circulation by the Na+-K+-ATPase pump in the basolateral membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/8\">",
"     8",
"    </a>",
"    ]. Removal of this Na+ from the cell maintains the cell Na+ concentration at a low level, thereby promoting further diffusion of luminal Na+ into the cell and continued Na+ reabsorption.",
"   </p>",
"   <p>",
"    This simple summary of the mechanism of Na+ transport illustrates that reabsorption can involve both active and passive mechanisms. This is also true for tubular secretion. Potassium, for example, is secreted from the cortical collecting tubule cell into the lumen. The Na+-K+-ATPase pump in the basolateral membrane actively transports K+ from the peritubular capillary into the cell; the ensuing rise in the cell K+ concentration then promotes secretion into the lumen via K+ channels in the luminal membrane.",
"   </p>",
"   <p>",
"    The tubular cells perform these functions in an extremely efficient manner, reabsorbing almost all the filtrate to maintain the balance between intake and excretion. In an individual on a normal diet, more than 98 to 99 percent of the filtered H2O, Na+, Cl-, and HCO3- is reabsorbed (",
"    <a class=\"graphic graphic_table graphicRef62415 \" href=\"mobipreview.htm?8/58/9135\">",
"     table 1",
"    </a>",
"    ). Although this process of filtration and almost complete reabsorption may seem inefficient, a high rate of filtration is required for the excretion of those waste products of metabolism (such as urea and creatinine) that enter the urine primarily by glomerular filtration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Role of the tight junction",
"    </span>",
"    &nbsp;&mdash;&nbsp;The tight junction is composed primarily of the zona occludens, which is a strand-like structure on the luminal membrane that brings adjacent cells into apposition at their luminal surface [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/9,10\">",
"     9,10",
"    </a>",
"    ]. Within the kidney, the tight junction has two important effects on segmental function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/9,11,12\">",
"     9,11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      It serves as a relative barrier or gate to the passive diffusion of solutes and water between the cells.",
"     </li>",
"     <li>",
"      It serves as a boundary or fence between the luminal (or apical) and basolateral membranes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It has been proposed that these two functions &mdash; paracellular gate and fence for polarity &mdash; are mediated by different kinds of molecular contacts between the tight junction strands: the gate function may be due to contact between strands on apposing cells, while the fence function may be due to contact between the particles forming the strands within a single cell [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The \"leakiness\" of the tight junction barrier to passive diffusion varies with the nephron segment. The barrier is relatively leaky in the proximal tubule, with as much as one-third of proximal Na+ reabsorption occurring via this paracellular route. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24617?source=see_link\">",
"     \"Chapter 3A: Cell model for proximal transport\"",
"    </a>",
"    .) This leakiness is important, because it allows the proximal tubule to efficiently reabsorb 55 to 60 percent of the filtrate (or over 90",
"    <span class=\"nowrap\">",
"     L/day).",
"    </span>",
"   </p>",
"   <p>",
"    In comparison, the collecting tubule is a relatively \"tight\" epithelium with a thicker tight junction than the proximal tubule [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/9\">",
"     9",
"    </a>",
"    ]. As a result, diffusion across the tight junction is limited. This relative impermeability to passive paracellular transport allows this segment to create and sustain very large transepithelial concentration gradients. As an example, the medullary collecting tubule is able to lower the urine pH to 4.5, which represents a H+ concentration that is almost 1000 times greater than that in the plasma (where the pH is about 7.40). The proximal tubule, on the other hand, can only reduce the tubular fluid pH to about 6.8, which represents a H+ concentration only four times higher than the plasma. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12762?source=see_link\">",
"     \"Chapter 11A: Renal hydrogen excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The boundary function of the tight junction is thought to play an important role in the maintenance of the polarity of the two membranes preventing lateral movement of transporters or channels from one membrane to the other [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/9,11,12\">",
"     9,11,12",
"    </a>",
"    ]. Membrane polarity is an essential component of reabsorption or secretion in the renal tubular cells, as each component of the cell membrane plays an important role [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Luminal membrane &mdash; The luminal (or apical) membrane contains the channels or carriers that allows filtered solutes to enter the cells or some cellular solutes to be secreted into the lumen (",
"      <a class=\"graphic graphic_figure graphicRef62197 \" href=\"mobipreview.htm?42/6/43117\">",
"       figure 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Basolateral membrane &mdash; The basolateral membrane performs two major functions. That part of the membrane adjacent to the luminal membrane (also called the lateral membrane) contains the components of the tight junction and the cell adhesion molecules that participate in cell-cell contact and communication. The more distal part of this membrane (also called the basolateral or basal-lateral membrane) plays an essential role in ion transport and hormone responsiveness, as it contains the Na+-K+-ATPase pumps, hormone receptors, and solute carriers and channels.",
"     </li>",
"     <li>",
"      Basal membrane &mdash; The basal membrane contains the basement membrane receptors that allow the cell to be anchored to the basement membrane.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example of transcellular transport, filtered Na+ enters the cells across the luminal membrane via specific transporters or channels; it is then returned to the systemic circulation by the Na+-K+-ATPase pump to the basolateral membrane. Disruption of this normal polarity, as with opening of the tight junctions due to ischemia, is associated with an impairment in Na+ reabsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/11\">",
"     11",
"    </a>",
"    ]. This may be mediated in part by the translocation of functioning Na+-K+-ATPase pumps onto the luminal membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The signals that govern the initial insertion of a protein into the luminal or basolateral membrane are incompletely understood. One signal appears to be the presence of cassettes of unique amino acids (located within the sequences of the proteins themselves) that relay localization information to cellular sorting machinery. One such amino acid motif, contiguous leucines located in the cytoplasmic tail, helps direct the vasopressin V2 receptor to the basolateral membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another mechanism may involve the type of membrane anchor: studies in kidney cells suggest that the presence of glycosylphosphatidylinositol (GPI) at the C-terminal end of the protein leads to specific insertion on the luminal membrane, perhaps because this membrane is rich in glycosphingolipids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. On the other hand, the localization of the Na+-K+-ATPase pump to the basolateral membrane may be mediated by specific attachment to basolateral cytoskeletal proteins, such as actin microfilaments and ankyrin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/11,18\">",
"     11,18",
"    </a>",
"    ]. Disruption of the actin microfilaments following ischemia impairs this tethering function, allowing Na+-K+-ATPase pumps to diffuse onto the luminal membrane through the now open tight junctions, thereby impairing net Na+ reabsorption [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The attachment to actin and fodrin also may promote the basolateral localization of Na+-K+-ATPase pumps by preventing their endocytic removal. Pumps that do get inserted into the luminal membrane are removed at a rate 40 times faster than those inserted into the basolateral membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aberrant localization of membrane proteins may contribute to the development of multiple disorders, such as autosomal dominant polycystic kidney disease (ADPKD). ADPKD is in most cases caused by mutations in a membrane protein termed polycystin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/20\">",
"     20",
"    </a>",
"    ], which appears to be involved in cell adhesion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/21\">",
"     21",
"    </a>",
"    ]. Abnormal apical polarity of the Na+-K+-ATPase pumps in these patients may cause sodium secretion into and fluid accumulation in epithelial cysts [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/22\">",
"     22",
"    </a>",
"    ]. In addition, abnormal epithelial proliferation within the cysts may be due to apical mislocation of epidermal growth factor receptors. The correlation between polycystin mutations and abnormal polarity is unclear, but may result from the dampened expression of fetal genes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Membrane recycling",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to proper polarity, normal functioning of transporting epithelia requires the delivery of newly synthesized and recycled membrane components to precise locations in the cell membrane [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/23\">",
"     23",
"    </a>",
"    ]. As an example, antidiuretic hormone combines with its receptor on the basolateral membrane of collecting tubular cells. This initiates a sequence of events in which preformed water channels (called aquaporin-2) in cytoplasmic vesicles are specifically inserted into the luminal membrane, thereby allowing the reabsorption of luminal water. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16552?source=see_link\">",
"     \"Chapter 6B: Antidiuretic hormone and water balance\"",
"    </a>",
"    .) The hormone-receptor complex is internalized by endocytosis in clathrin-coated pits and then enters acidic endosomes where the hormone and receptor are split (",
"    <a class=\"graphic graphic_figure graphicRef52911 \" href=\"mobipreview.htm?25/49/26396\">",
"     figure 7",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/23\">",
"     23",
"    </a>",
"    ]. The former is metabolized within the cell, while the receptor is returned to the basolateral membrane. Attenuation of the ADH effect is associated with endocytosis of only those areas of the luminal membrane that contain water channels, thereby restoring the relative water impermeability of the luminal membrane.",
"   </p>",
"   <p>",
"    The signaling events that control membrane recycling are incompletely understood but activation of adenylyl cyclase appears to be involved [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/24\">",
"     24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19988?source=see_link\">",
"     \"Chapter 6A: Mechanisms of hormone action\"",
"    </a>",
"    .) In addition, the structure of aquaporin-2 helps dictate cellular distribution and recycling. Mutations of the aquaporin-2 gene can cause resistance to antidiuretic hormone (called nephrogenic diabetes insipidus). In the families reported thus far, the defect appears to involve misrouting rather than loss of function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Composition of urine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The composition of the urine differs from that of the relatively constant extracellular fluid in two important ways. First, the quantity of solutes and water in the urine is highly variable, being dependent upon the intake of these substances. A normal subject, for example, appropriately excretes more Na+ on a high-salt diet than on a low-salt diet. In both instances, the steady-state and therefore the extracellular volume are maintained as output equals intake. Similarly, the urine volume is greater after a water load than after water restriction, resulting in a stable plasma Na+ concentration&dagger;. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7893?source=see_link\">",
"     \"Chapter 8A: Effective circulating volume and the steady state\"",
"    </a>",
"    .)This relation to intake means that there are",
"    <strong>",
"     no",
"    </strong>",
"    absolute \"normal\" values for urinary solute or water excretion. We can only describe a normal range which merely reflects the range of dietary intake, eg, 100 to 250",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    for Na+.",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;&dagger; These changes in Na+ and water excretion are relatively precise, so that increasing Na+ intake from 100 to 200",
"    <span class=\"nowrap\">",
"     meq/day,",
"    </span>",
"    for example, results in a parallel rise in Na+ excretion. If, as depicted in Table 1, 26,000 meq of Na+ is filtered per day, then a 100 meq increase in excretion represents a change involving less than 0.5 percent of the filtered load. This illustrates the high degree of efficiency required to maintain salt and water balance.",
"   </p>",
"   <p>",
"    Second, ions compose 95 percent of the extracellular fluid solutes; in comparison, the urine has high concentrations of uncharged molecules, particularly urea. This allows urea and other metabolic end-products to be excreted, rather than accumulating in the body.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Summary of nephron function",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following chapters in Part Two will describe the roles of the different nephron segments in the regulation of solute and water homeostasis. These functions are summarized in Table 2 (",
"    <a class=\"graphic graphic_table graphicRef57561 \" href=\"mobipreview.htm?21/28/21964\">",
"     table 2",
"    </a>",
"    ). As can be seen, there are marked differences in segmental function, a finding consistent with the differences in segmental histology (",
"    <a class=\"graphic graphic_figure graphicRef60157 \" href=\"mobipreview.htm?8/37/8785\">",
"     figure 1",
"    </a>",
"    ) and permeability and transport characteristics [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38198/abstract/5\">",
"     5",
"    </a>",
"    ]. In addition, multiple sites participate in the regulation of the rates of excretion of the different substances in the filtrate. This diversity provides the flexibility that allows the kidney to maintain solute and water balance, even in the presence of major changes in dietary intake.",
"   </p>",
"   <p>",
"    (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30771?source=see_link\">",
"     \"Chapter 1B: Units of solute measurement\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW, Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/1\">",
"      Carone FA, Peterson DR. Hydrolysis and transport of small peptides by the proximal tubule. Am J Physiol 1980; 238:F151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/2\">",
"      Madsen KM, Park CH. Lysosome distribution and cathepsin B and L activity along the rabbit proximal tubule. Am J Physiol 1987; 253:F1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/3\">",
"      Owen OE, Felig P, Morgan AP, et al. Liver and kidney metabolism during prolonged starvation. J Clin Invest 1969; 48:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/4\">",
"      Burch HB, Narins RG, Chu C, et al. Distribution along the rat nephron of three enzymes of gluconeogenesis in acidosis and starvation. Am J Physiol 1978; 235:F246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/5\">",
"      Jacobson HR. Functional segmentation of the mammalian nephron. Am J Physiol 1981; 241:F203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/6\">",
"      Madsen KM, Tisher CC. Structural-functional relationship along the distal nephron. Am J Physiol 1986; 250:F1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/7\">",
"      Imai M. The connecting tubule: a functional subdivision of the rabbit distal nephron segments. Kidney Int 1979; 15:346.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/8\">",
"      Doucet A. Function and control of Na-K-ATPase in single nephron segments of the mammalian kidney. Kidney Int 1988; 34:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/9\">",
"      Gumbiner B. Structure, biochemistry, and assembly of epithelial tight junctions. Am J Physiol 1987; 253:C749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/10\">",
"      Madara JL. Loosening tight junctions. Lessons from the intestine. J Clin Invest 1989; 83:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/11\">",
"      Molitoris BA. Ischemia-induced loss of epithelial polarity: potential role of the actin cytoskeleton. Am J Physiol 1991; 260:F769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/12\">",
"      Mandel LJ, Bacallao R, Zampighi G. Uncoupling of the molecular 'fence' and paracellular 'gate' functions in epithelial tight junctions. Nature 1993; 361:552.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/13\">",
"      Rodriguez-Boulan E, Nelson WJ. Morphogenesis of the polarized epithelial cell phenotype. Science 1989; 245:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/14\">",
"      Molitoris BA. Na(+)-K(+)-ATPase that redistributes to apical membrane during ATP depletion remains functional. Am J Physiol 1993; 265:F693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/15\">",
"      Brown D, Breton S. Sorting proteins to their target membranes. Kidney Int 2000; 57:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/16\">",
"      Brown DA, Crise B, Rose JK. Mechanism of membrane anchoring affects polarized expression of two proteins in MDCK cells. Science 1989; 245:1499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/17\">",
"      Brown D, Waneck GL. Glycosyl-phosphatidylinositol-anchored membrane proteins. J Am Soc Nephrol 1992; 3:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/18\">",
"      Nelson WJ, Hammerton RW. A membrane-cytoskeletal complex containing Na+,K+-ATPase, ankyrin, and fodrin in Madin-Darby canine kidney (MDCK) cells: implications for the biogenesis of epithelial cell polarity. J Cell Biol 1989; 108:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/19\">",
"      Hammerton RW, Krzeminski KA, Mays RW, et al. Mechanism for regulating cell surface distribution of Na+,K(+)-ATPase in polarized epithelial cells. Science 1991; 254:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/20\">",
"      Geng L, Segal Y, Peissel B, et al. Identification and localization of polycystin, the PKD1 gene product. J Clin Invest 1996; 98:2674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/21\">",
"      Huan Y, van Adelsberg J. Polycystin-1, the PKD1 gene product, is in a complex containing E-cadherin and the catenins. J Clin Invest 1999; 104:1459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/22\">",
"      Wilson PD. Epithelial cell polarity and disease. Am J Physiol 1997; 272:F434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/23\">",
"      Brown D. Membrane recycling and epithelial cell function. Am J Physiol 1989; 256:F1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/24\">",
"      Bichet DG, Oksche A, Rosenthal W. Congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 1997; 8:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38198/abstract/25\">",
"      Mulders SM, Knoers NV, Van Lieburg AF, et al. New mutations in the AQP2 gene in nephrogenic diabetes insipidus resulting in functional but misrouted water channels. J Am Soc Nephrol 1997; 8:242.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7274 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-197.136.42.3-6DBE490E2D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38198=[""].join("\n");
var outline_f37_19_38198=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RENAL MORPHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      REABSORPTION AND SECRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Role of the tight junction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Membrane recycling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Composition of urine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Summary of nephron function",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7274\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7274|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?8/37/8785\" title=\"figure 1\">",
"      Nephron anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?17/53/18271\" title=\"figure 2\">",
"      Anatomy of the kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?16/29/16851\" title=\"figure 3\">",
"      Loop of Henle anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?31/9/31889\" title=\"figure 4\">",
"      Macula densa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/58/40878\" title=\"figure 5\">",
"      Reabsorption secretion nephron",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?42/6/43117\" title=\"figure 6\">",
"      Tubular sodium entry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?25/49/26396\" title=\"figure 7\">",
"      Endocytosis of water channels",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7274|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?8/58/9135\" title=\"table 1\">",
"      Solute reabsorption by kidney",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?21/28/21964\" title=\"table 2\">",
"      Major functions of nephron segments",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/29/12762?source=related_link\">",
"      Chapter 11A: Renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/3/30771?source=related_link\">",
"      Chapter 1B: Units of solute measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/25/13720?source=related_link\">",
"      Chapter 2B: Renin-angiotensin system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/2/24617?source=related_link\">",
"      Chapter 3A: Cell model for proximal transport",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/44/29384?source=related_link\">",
"      Chapter 4B: Countercurrent mechanism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/36/33352?source=related_link\">",
"      Chapter 5B: Collecting tubules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/33/19988?source=related_link\">",
"      Chapter 6A: Mechanisms of hormone action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/10/16552?source=related_link\">",
"      Chapter 6B: Antidiuretic hormone and water balance",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/45/7893?source=related_link\">",
"      Chapter 8A: Effective circulating volume and the steady state",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_19_38199="Clinical manifestations and diagnosis of Legionella infection";
var content_f37_19_38199=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical manifestations and diagnosis of Legionella infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/19/38199/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38199/contributors\">",
"     M Luisa Pedro-Botet, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38199/contributors\">",
"     Janet E Stout, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38199/contributors\">",
"     Victor L Yu, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/19/38199/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38199/contributors\">",
"     Stephen B Calderwood, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/19/38199/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38199/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/19/38199/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 21, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the organism was first recognized in 1976 during an outbreak at an American Legion Convention in Philadelphia, Legionella has been identified as a relatively common cause of both community-acquired and hospital-acquired pneumonia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32680?source=see_link\">",
"     \"Epidemiology and pathogenesis of Legionella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Legionellosis refers to the two clinical syndromes caused by bacteria of the genus Legionella:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Legionnaires' disease is the more common syndrome of pneumonia caused by Legionella species",
"     </li>",
"     <li>",
"      Pontiac fever is an acute, febrile, self-limited illness that has been linked to Legionella species",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical manifestations and diagnosis of Legionella infection will be reviewed here. The treatment of this entity is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33015?source=see_link\">",
"     \"Treatment and prevention of Legionella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pneumonia is the predominant clinical manifestation of Legionella infection. In epidemiologic studies, Legionella is consistently reported among the top three or four most commonly identified pathogens in community-acquired pneumonia in immunocompetent patients and is also a common cause of hospital-acquired pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In a retrospective review of six clinical trials among 1551 evaluable patients with community-acquired pneumonia, 71 (4.6 percent) were documented to have Legionella infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/3\">",
"     3",
"    </a>",
"    ]. Extrapulmonary presentations are rare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Legionnaires' disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first clinical descriptions of Legionnaires' disease were of toxic patients with high fever and gastrointestinal symptoms accompanying pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/4-6\">",
"     4-6",
"    </a>",
"    ]. As specialized laboratory diagnostic tests became more widely available, it became clear that the clinical presentation was more varied and nonspecific.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incubation period for Legionnaires' disease ranges from 2 to 10 days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/4\">",
"     4",
"    </a>",
"    ]. Respiratory symptoms are not prominent initially; the cough at first is mild and only slightly productive. The sputum may be blood-streaked, but gross hemoptysis is rare. Chest pain can occur in some patients and, if accompanied by hemoptysis, may lead to an erroneous diagnosis of pulmonary embolus. Gastrointestinal symptoms are often prominent with diarrhea, nausea, vomiting, and abdominal pain. Patients are commonly lethargic with headache and occasionally stupor. The frequency of the symptoms of Legionnaires' disease is [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/1,4-8\">",
"     1,4-8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Cough &mdash; 41 to 92 percent",
"     </li>",
"     <li>",
"      Chills &mdash; 42 to 77 percent",
"     </li>",
"     <li>",
"      Fever &gt;38.8&ordm;C &mdash; 88 to 90 percent",
"      <br/>",
"      Fever &gt;40&ordm;C &mdash; 20 to 62 percent",
"     </li>",
"     <li>",
"      Dyspnea &mdash; 25 to 62 percent",
"     </li>",
"     <li>",
"      Headache &mdash; 40 to 48 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Myalgia/arthralgia",
"      </span>",
"      &mdash; 20 to 40 percent",
"     </li>",
"     <li>",
"      Diarrhea &mdash; 21 to 50 percent",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       Nausea/vomiting",
"      </span>",
"      &mdash; 8 to 49 percent",
"     </li>",
"     <li>",
"      Neurologic abnormalities &mdash; 4 to 53 percent",
"     </li>",
"     <li>",
"      Chest pain &mdash; 13 to 35 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21953756\">",
"    <span class=\"h3\">",
"     Physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Physical examination reveals rales with subsequent signs of consolidation. Fever is virtually always present and oral temperature greater than 39&ordm;C should suggest the possibility of Legionnaires' disease. Bradycardia relative to temperature elevation has been found in elderly patients with more severe pneumonia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/5\">",
"     5",
"    </a>",
"    ], but is nonspecific. Miscellaneous findings include disseminated intravascular coagulation, glomerulitis, rhabdomyolysis, various rashes, and neuropathies; these are nonspecific findings that may be related to the severity of infection, underlying disease, or perhaps side effects of drug therapies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory abnormalities are common but nonspecific and include renal and hepatic dysfunction, thrombocytopenia, leukocytosis, and hypophosphatemia. Hyponatremia (serum sodium &lt;130",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    occurs significantly more frequently in Legionnaires' disease than in pneumonias of other etiologies [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/1,5,6,8\">",
"     1,5,6,8",
"    </a>",
"    ]. Hematuria and proteinuria are also common. Serum ferritin levels have also been noted to be elevated in Legionnaires&rsquo; disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/9\">",
"     9",
"    </a>",
"    ]. Elevated procalcitonin levels are a marker for severity of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Chest radiograph",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the rare patient with nosocomial infection, fever may precede visualization of the pulmonary infiltrate, but virtually all patients with Legionnaires' disease have radiographic abnormalities by the third day of illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/12\">",
"     12",
"    </a>",
"    ]. While abnormal, there is no characteristic chest radiograph finding. The most common pattern is a patchy unilobar infiltrate that progresses to consolidation; however, all types of infiltrates have been reported including diffuse, interstitial infiltrates [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/12\">",
"     12",
"    </a>",
"    ]. Pleural effusions are also commonplace.",
"   </p>",
"   <p>",
"    In the immunosuppressed patient, the initial densities may appear as rounded opacities, often pleural based, which can be mistaken for pulmonary infarction. Progression of these nodular infiltrates to cavitation is commonly seen in the immunosuppressed patient receiving corticosteroids.",
"   </p>",
"   <p>",
"    Radiographic abnormalities often progress while receiving active antibiotic therapy; thus, radiographic improvement lags behind clinical response by several days [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Complete resolution of infiltrates on chest radiograph occurs over one to many months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Clinical clues for the diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The following clinical clues in a patient with pneumonia may be especially useful in increasing the index of suspicion for Legionnaires' disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Presence of gastrointestinal symptoms, especially diarrhea",
"     </li>",
"     <li>",
"      Neurologic findings, especially confusion",
"     </li>",
"     <li>",
"      Fever &gt;39&ordm;C",
"     </li>",
"     <li>",
"      The Gram stain of respiratory secretions shows many neutrophils, but few, if any, microorganisms",
"     </li>",
"     <li>",
"      Hyponatremia",
"     </li>",
"     <li>",
"      Hepatic dysfunction",
"     </li>",
"     <li>",
"      Hematuria",
"     </li>",
"     <li>",
"      Failure to respond to beta-lactam",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      aminoglycoside antibiotics",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Suspicion should also be increased in patients at risk for Legionella infection, such as smokers, those with chronic lung disease, and immunosuppressed patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/3\">",
"     3",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32680?source=see_link\">",
"     \"Epidemiology and pathogenesis of Legionella infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pontiac fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the Legionella bacterium was identified from the Philadelphia outbreak, serologic analysis of stored serum from a previous outbreak of a febrile illness at the Pontiac, Michigan Health Department, revealed that Legionella was the cause [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. This mild form of Legionella infection is often referred to as Pontiac fever. The symptoms include fever, malaise, chills, fatigue, and headache, without any respiratory complaints. Chest radiograph is unrevealing. The mean incubation period is 36 hours, much shorter than the 2 to 10 days for Legionnaires' disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/14,16\">",
"     14,16",
"    </a>",
"    ]. The illness is usually self-limited and does not require treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Extrapulmonary disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extrapulmonary disease from Legionella is extremely rare, but cellulitis, sinusitis, septic arthritis, perirectal abscess, pancreatitis, peritonitis, and pyelonephritis have been described in immunosuppressed patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. Bacteremia leads to dissemination of the organism to other sites. The most common extrapulmonary site is the heart; numerous reports of myocarditis, pericarditis, and even prosthetic valve endocarditis have been published [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/17,19,20\">",
"     17,19,20",
"    </a>",
"    ]. Surgical site infections have occurred after contamination of the wound by water containing L. pneumophila [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/17,21\">",
"     17,21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Coinfection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coinfection with other pathogens responsible for community-acquired pneumonia has been a topical issue. However, most studies reporting co-infection have used serologic tests as the basis for diagnosis, and such tests may be nonspecific. On the other hand, one group described five patients with Streptococcus pneumoniae bacteremia who had coinfection with Legionella as defined by urine antigen or antibody seroconversion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     SPECIFIC LABORATORY DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prompt diagnosis of Legionnaires' disease can save lives. Early initiation of appropriate therapy is associated with improved outcome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Because the clinical presentation of Legionnaires' disease is nonspecific, specialized diagnostic laboratory tests are the key feature for diagnosing Legionnaires' disease. Hospitals where Legionella diagnostic tests were available on-site were more likely to identify hospital-acquired Legionnaires' disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/25\">",
"     25",
"    </a>",
"    ]. Among the species in the Legionellaceae family, L. pneumophila is responsible for 90 percent of infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Culture on selective media",
"    </span>",
"    &nbsp;&mdash;&nbsp;The single most important test for Legionnaires' disease is isolation of the organism by culture. When Legionnaires' disease is suspected, both a urinary antigen test and Legionella culture of a respiratory specimen should be ordered. The availability of the clinical isolate from culture can be critical for subsequent epidemiologic investigations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The standard media for Legionella isolation from contaminated clinical specimens is buffered charcoal yeast extract agar (BCYE) supplemented with polymyxin, anisomycin,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/41/42649?source=see_link\">",
"     vancomycin",
"    </a>",
"    , and dyes (",
"    <a class=\"graphic graphic_picture graphicRef61367 \" href=\"mobipreview.htm?13/4/13378\">",
"     picture 1",
"    </a>",
"    ); the antimicrobial agents prevent the overgrowth of Legionella by competing organisms, while the dyes impart a distinctive color to the Legionella organisms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/27\">",
"     27",
"    </a>",
"    ]. The presence of the dyes makes identification of L. micdadei and L. maceachernii easier. Their colonies will appear blue due to uptake of the dye bromothymol blue, whereas L. pneumophila will appear apple-green [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/29\">",
"     29",
"    </a>",
"    ]. Maximal sensitivity is achieved by the simultaneous use of three media: BCYE; BCYE with polymyxin, anisomycin, and cefamandole (PAC); BCYE with polymyxin, anisomycin, vancomycin and dyes (PAV). All three media (BCYE, PAC, and PAV) are commercially available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Urinary antigen testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among reported cases of Legionnaires' disease, there has been a significant increase in the proportion diagnosed by the urinary antigen test [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/30\">",
"     30",
"    </a>",
"    ]. In many hospitals, cases of Legionnaires' disease due to L. pneumophila, serogroup 1 are often diagnosed by urinary antigen rather than by direct fluorescent antibody (DFA) staining or culture (",
"    <a class=\"graphic graphic_table graphicRef69022 \" href=\"mobipreview.htm?16/40/17035\">",
"     table 1",
"    </a>",
"    ). In addition, the introduction of the urinary antigen test into many hospital laboratories has resulted in the detection of unrecognized endemic nosocomial outbreaks of Legionnaires' disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/23,31\">",
"     23,31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The urinary antigen test has several advantages over culture:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For many patients with Legionnaires' disease, obtaining an adequate sputum specimen can be difficult.",
"     </li>",
"     <li>",
"      The fact that test positivity can persist for days even during administration of antibiotic therapy makes it useful in patients who receive empiric anti-Legionella therapy.",
"     </li>",
"     <li>",
"      The results of the urinary antigen test can be available within hours, whereas culture results require three to five days [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The major disadvantage of the urinary antigen test is that it is specific for L. pneumophila serogroup 1 only. However, the vast majority of Legionnaires' disease cases from the community are caused by this species and serogroup [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/33-35\">",
"     33-35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The test format is an enzyme immunoassay (EIA). A high sensitivity and specificity for the assay has been reported by the manufacturers. However, sensitivity may vary with severity of disease. Test performance can be illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a study conducted during a large outbreak (295 cases) of Legionella pneumonia in Spain, the overall sensitivity of the test was only 48 percent (case confirmed by a positive culture for Legionella or fourfold rise in antibody titer) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/36\">",
"       36",
"      </a>",
"      ]. Sensitivity was significantly higher in patients with severe compared with mild pneumonia (86 versus 38 percent). Thus, many patients with mild pneumonia may go undiagnosed if the urinary antigen test is used alone.",
"     </li>",
"     <li>",
"      In a large outbreak in Oklahoma resulting from exposure in an indoor pool and hot tub area, 101 of 107 patients had Pontiac fever, the milder form of L. pneumophila serogroup 1 infection [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pontiac fever'",
"      </a>",
"      above.) The urine antigen test had a sensitivity of 36 percent and specificity of 100 percent, whereas prior small studies had a sensitivity less than 10 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There have been reports of positive urine antigen test results in Legionnaires' disease due to non-serogroup 1 L. pneumophila and other species [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/38\">",
"     38",
"    </a>",
"    ]. However, the sensitivity and specificity of the urine test for detecting other serogroups and species is currently unknown.",
"   </p>",
"   <p>",
"    A rapid urinary antigen test is commercially available that yields a result in less than 15 minutes. This test is the Binax NOW Legionella Urinary Antigen Test. It is an immunochromatographic membrane (ICT) assay that is performed using a swab that has been dipped in urine and inserted into the card-type test device. The reaction is read as the presence or absence of a visually detectable pink-to-purple colored line that results from the antigen-antibody reaction. The ICT assay has been shown to be comparable to the EIA assay, with a sensitivity of 80 percent and specificity of 97 to 100 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/39,40\">",
"     39,40",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     DFA staining",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reported sensitivity of DFA stains on respiratory specimens has ranged from 25 to 75 percent. It is highly specific, and the monoclonal antibody test has eliminated the rare occurrence of cross-reactivity with other gram-negative bacilli. DFA may be performed if the direct culture of the specimen is overgrown by competing microflora. We have found the monoclonal antibody DFA reagent (MONOFLUO, Bio-Rad Laboratories, Redmond, WA) to be superior to polyclonal reagents for detecting L. pneumophila in respiratory specimens because background fluorescence is reduced, and cross-reactivity with non-Legionella bacteria has not occurred in our experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Serology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antibody tests have become less important with the advent of rapid diagnostic tests, such as urinary antigen testing, DFA staining, and polymerase chain reaction (PCR). Because the definitive criterion for serologic diagnosis is a fourfold rise in antibody titer, repeat serology is required 8 to 12 weeks after the onset of infection. Indirect fluorescent antibody (IFA) and enzyme-linked immunosorbent assays (ELISA) are the most commonly used methodologies for L. pneumophila serology.",
"   </p>",
"   <p>",
"    A fourfold rise to &ge;128 in titer between the acute and convalescent titer is required for a definitive serologic diagnosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/41\">",
"     41",
"    </a>",
"    ]. The optimal period for seroconversion is 12 weeks. Use of both IgM and IgG assays maximizes sensitivity since one of the tests may reveal evidence of Legionella infection while the other does not. Effective antibiotics and suboptimal timing of specimen collection are possible reasons for the lower reported sensitivity of this test in some studies. Twenty-five to 40 percent of patients may have elevated titers in the first week of disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/29\">",
"     29",
"    </a>",
"    ]. Some patients never demonstrate a fourfold increase in titer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/42\">",
"     42",
"    </a>",
"    ]. Sensitivity and specificity have been reported to be approximately 75 and 95 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Serology is useful in epidemiologic studies but is less helpful to the clinician in making an immediate diagnosis of Legionnaires' disease for an individual patient. A single elevated titer does not confirm a case of Legionnaires' disease because IFA titers of &ge;1:256 have been found in 1 to 16 percent of healthy adults [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/41\">",
"     41",
"    </a>",
"    ], and the positive predictive value of a convalescent-phase titer is unacceptably low [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/43\">",
"     43",
"    </a>",
"    ]. Nevertheless, in a patient with an acute episode of pneumonia, a single elevated titer of 1:128 or higher may be sufficient to mandate treatment or to classify the infection as &ldquo;presumptive&rdquo; in an epidemiological investigation. Likewise, if the seroprevalence of L. pneumophila antibody titers within the community is known to be low, a single elevated titer (1:256) may indicate the presence of acute disease. False-positive results can rarely occur as a result of cross-reacting antibody to other gram-negative organisms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Polymerase chain reaction",
"    </span>",
"    &nbsp;&mdash;&nbsp;DNA amplification by PCR of Legionella has been reported from patients with pneumonia using throat swab specimens, bronchoalveolar lavage (BAL), urine, and serum [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/19,44-47\">",
"     19,44-47",
"    </a>",
"    ]. To date, clinical experience has not shown PCR to be more sensitive than culture, and therefore the United States Centers for Disease Control and Prevention (CDC) does not recommend the routine use of genetic probes or PCR for the detection of Legionella in clinical samples [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38199/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Approach to diagnosis",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      While a number of prominent clinical manifestations are distinctive for Legionella infection, none of them are pathognomonic or highly specific. Thus, laboratory testing using specialized tests for Legionella should be performed on all patients hospitalized with community-acquired pneumonia.",
"     </li>",
"     <li>",
"      Culturing for Legionella spp is the single most important laboratory test. Given the frequency of Legionella as a pathogen in both community- and hospital-acquired pneumonia, this test should be routinely available in all clinical microbiology laboratories.",
"     </li>",
"     <li>",
"      Urinary antigen testing is rapid, sensitive, specific, and not costly, but is only useful for the diagnosis of L. pneumophila type 1 infection (which accounts for 90 percent of community-acquired Legionella infections in the United States).",
"     </li>",
"     <li>",
"      In patients suspected of having Legionella infection, we recommend that both culture of an appropriate respiratory specimen and urinary antigen testing be obtained.",
"     </li>",
"     <li>",
"      Serologic tests are generally far less useful for the diagnosis of an individual patient.",
"     </li>",
"     <li>",
"      While PCR-based tests exist, to date they do not exceed the sensitivity of culturing the organism.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21952827\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Since the organism was first recognized in 1976 during an outbreak at an American Legion Convention in Philadelphia, Legionella has been identified as a relatively common cause of both community-acquired and hospital-acquired pneumonia. Legionellosis refers to the two clinical syndromes caused by bacteria of the genus Legionella:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Legionnaires' disease is the more common syndrome of pneumonia caused by Legionella species",
"     </li>",
"     <li>",
"      Pontiac fever is an acute, febrile, self-limited illness that has been linked to Legionella species (see",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pneumonia is the predominant clinical manifestation of Legionella infection. In epidemiologic studies, Legionella is consistently reported among the top three or four most commonly identified pathogens in community-acquired pneumonia in immunocompetent patients and is also a common cause of hospital-acquired pneumonia. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Respiratory symptoms are not prominent initially in patients with Legionnaires&rsquo; disease. The cough at first is mild and only slightly productive. The sputum may be blood-streaked, but gross hemoptysis is rare. Chest pain can occur in some patients and if accompanied by hemoptysis may lead to an erroneous diagnosis of pulmonary embolus. Gastrointestinal symptoms are often prominent with diarrhea, nausea, vomiting, and abdominal pain. Patients are commonly lethargic with headache and occasionally stupor. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Symptoms'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Physical examination reveals rales with subsequent signs of consolidation. Fever is virtually always present and oral temperature greater than 39&ordm;C should suggest the possibility of Legionnaires' disease. Miscellaneous findings include disseminated intravascular coagulation, glomerulitis, rhabdomyolysis, various rashes, and neuropathies; these are nonspecific findings that may be related to the severity of infection, underlying disease, or perhaps side effects of drug therapies. (See",
"      <a class=\"local\" href=\"#H21953756\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory abnormalities are common, but nonspecific, including renal and hepatic dysfunction, thrombocytopenia, leukocytosis, and hypophosphatemia. Hyponatremia (serum sodium &lt;130",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      occurs significantly more frequently in Legionnaires' disease than in pneumonias of other etiologies. Hematuria and proteinuria are also common. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Laboratory findings'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Virtually all patients with Legionnaires' disease have radiographic abnormalities by the third day of illness. The most common pattern is a patchy unilobar infiltrate that progresses to consolidation; however, all types of infiltrates have been reported, including diffuse, interstitial infiltrates. Pleural effusions are also commonplace. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Chest radiograph'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pontiac fever is a mild form of Legionella infection that is characterized by fever, malaise, chills, fatigue, and headache, without any respiratory complaints. Chest radiograph is unrevealing. The mean incubation period is 36 hours, much shorter than the 2 to 10 days for Legionnaires' disease. The illness is usually self-limited. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Pontiac fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While a number of prominent clinical manifestations are distinctive for Legionella infection, none of them are pathognomonic or highly specific. Thus, laboratory testing using specialized tests for Legionella should be performed on all patients hospitalized with community-acquired pneumonia. Culturing for Legionella spp is the single most important laboratory test. Urinary antigen testing is rapid, sensitive, specific, and not costly, but is only useful for the diagnosis of L. pneumophila type 1 infection (which accounts for 90 percent of community-acquired Legionella infections in the United States). In patients suspected of having Legionella infection, we recommend that both culture of an appropriate respiratory specimen and urinary antigen testing be obtained. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Approach to diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/1\">",
"      Fang GD, Fine M, Orloff J, et al. New and emerging etiologies for community-acquired pneumonia with implications for therapy. A prospective multicenter study of 359 cases. Medicine (Baltimore) 1990; 69:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/2\">",
"      Stout JE, Yu VL. Legionellosis. N Engl J Med 1997; 337:682.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/3\">",
"      Yu VL, Greenberg RN, Zadeikis N, et al. Levofloxacin efficacy in the treatment of community-acquired legionellosis. Chest 2004; 125:2135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/4\">",
"      Fraser DW, Tsai TR, Orenstein W, et al. Legionnaires' disease: description of an epidemic of pneumonia. N Engl J Med 1977; 297:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/5\">",
"      Kirby BD, Snyder KM, Meyer RD, Finegold SM. Legionnaires' disease: report of sixty-five nosocomially acquired cases of review of the literature. Medicine (Baltimore) 1980; 59:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/6\">",
"      Mulazimoglu L, Yu VL. Can Legionnaires disease be diagnosed by clinical criteria? A critical review. Chest 2001; 120:1049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/7\">",
"      Roig J, Aguilar X, Ruiz J, et al. Comparative study of Legionella pneumophila and other nosocomial-acquired pneumonias. Chest 1991; 99:344.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/8\">",
"      Yu VL, Kroboth FJ, Shonnard J, et al. Legionnaires' disease: new clinical perspective from a prospective pneumonia study. Am J Med 1982; 73:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/9\">",
"      Cunha BA. Highly elevated serum ferritin levels as a diagnostic marker for Legionella pneumonia. Clin Infect Dis 2008; 46:1789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/10\">",
"      Haeuptle J, Zaborsky R, Fiumefreddo R, et al. Prognostic value of procalcitonin in Legionella pneumonia. Eur J Clin Microbiol Infect Dis 2009; 28:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/11\">",
"      de Jager CP, de Wit NC, Weers-Pothoff G, et al. Procalcitonin kinetics in Legionella pneumophila pneumonia. Clin Microbiol Infect 2009; 15:1020.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/12\">",
"      Tan MJ, Tan JS, Hamor RH, et al. The radiologic manifestations of Legionnaire's disease. The Ohio Community-Based Pneumonia Incidence Study Group. Chest 2000; 117:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/13\">",
"      Singh N, Muder RR, Yu VL, Gayowski T. Legionella infection in liver transplant recipients: implications for management. Transplantation 1993; 56:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/14\">",
"      Glick TH, Gregg MB, Berman B, et al. Pontiac fever. An epidemic of unknown etiology in a health department: I. Clinical and epidemiologic aspects. Am J Epidemiol 1978; 107:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/15\">",
"      Kaufmann AF, McDade JE, Patton CM, et al. Pontiac fever: isolation of the etiologic agent (Legionella pneumophilia) and demonstration of its mode of transmission. Am J Epidemiol 1981; 114:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/16\">",
"      Edelstein PH. Urine antigen tests positive for Pontiac fever: implications for diagnosis and pathogenesis. Clin Infect Dis 2007; 44:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/17\">",
"      Lowry PW, Tompkins LS. Nosocomial legionellosis: a review of pulmonary and extrapulmonary syndromes. Am J Infect Control 1993; 21:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/18\">",
"      Bemer P, Leautez S, Ninin E, et al. Legionella pneumophila Arthritis: use of medium specific for Mycobacteria for isolation of L. pneumophila in culture of articular fluid specimens. Clin Infect Dis 2002; 35:E6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/19\">",
"      Tompkins LS, Roessler BJ, Redd SC, et al. Legionella prosthetic-valve endocarditis. N Engl J Med 1988; 318:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/20\">",
"      Antonarakis ES, Wung PK, Durand DJ, et al. An atypical complication of atypical pneumonia. Am J Med 2006; 119:824.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/21\">",
"      Lowry PW, Blankenship RJ, Gridley W, et al. A cluster of legionella sternal-wound infections due to postoperative topical exposure to contaminated tap water. N Engl J Med 1991; 324:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/22\">",
"      Tan MJ, Tan JS, File TM Jr. Legionnaires disease with bacteremic coinfection. Clin Infect Dis 2002; 35:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/23\">",
"      Lepine LA, Jernigan DB, Butler JC, et al. A recurrent outbreak of nosocomial legionnaires' disease detected by urinary antigen testing: evidence for long-term colonization of a hospital plumbing system. Infect Control Hosp Epidemiol 1998; 19:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/24\">",
"      Heath CH, Grove DI, Looke DF. Delay in appropriate therapy of Legionella pneumonia associated with increased mortality. Eur J Clin Microbiol Infect Dis 1996; 15:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/25\">",
"      Fiore AE, Butler JC, Emori TG, Gaynes RP. A survey of methods used to detect nosocomial legionellosis among participants in the National Nosocomial Infections Surveillance System. Infect Control Hosp Epidemiol 1999; 20:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/26\">",
"      Fields BS, Benson RF, Besser RE. Legionella and Legionnaires' disease: 25 years of investigation. Clin Microbiol Rev 2002; 15:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/27\">",
"      Muder RR, Yu VL. Infection due to Legionella species other than L. pneumophila. Clin Infect Dis 2002; 35:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/28\">",
"      Marrie TJ. Diagnosis of legionellaceae as a cause of community-acquired pneumonia- \"... continue to treat first and not bother to ask questions later\"--not a good idea. Am J Med 2001; 110:73.",
"     </a>",
"    </li>",
"    <li>",
"     Stout, JE, Rihs, JD, Yu, VL. Legionella. In: Manual of Clinical Microbiology, Vol 52, Murray, PR, Baron, EJ, Jorgensen, JH, et al (Eds), ASM Press, Washington, DC 2003. p. 809.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/30\">",
"      Benin AL, Benson RF, Besser RE. Trends in legionnaires disease, 1980-1998: declining mortality and new patterns of diagnosis. Clin Infect Dis 2002; 35:1039.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/31\">",
"      Kool JL, Fiore AE, Kioski CM, et al. More than 10 years of unrecognized nosocomial transmission of legionnaires' disease among transplant patients. Infect Control Hosp Epidemiol 1998; 19:898.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/32\">",
"      Kazandjian D, Chiew R, Gilbert GL. Rapid diagnosis of Legionella pneumophila serogroup 1 infection with the Binax enzyme immunoassay urinary antigen test. J Clin Microbiol 1997; 35:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/33\">",
"      Yu VL, Plouffe JF, Pastoris MC, et al. Distribution of Legionella species and serogroups isolated by culture in patients with sporadic community-acquired legionellosis: an international collaborative survey. J Infect Dis 2002; 186:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/34\">",
"      Helbig JH, Uldum SA, Bernander S, et al. Clinical utility of urinary antigen detection for diagnosis of community-acquired, travel-associated, and nosocomial legionnaires' disease. J Clin Microbiol 2003; 41:838.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/35\">",
"      von Baum H, Ewig S, Marre R, et al. Community-acquired Legionella pneumonia: new insights from the German competence network for community acquired pneumonia. Clin Infect Dis 2008; 46:1356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/36\">",
"      Bl&aacute;zquez RM, Espinosa FJ, Mart&iacute;nez-Toldos CM, et al. Sensitivity of urinary antigen test in relation to clinical severity in a large outbreak of Legionella pneumonia in Spain. Eur J Clin Microbiol Infect Dis 2005; 24:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/37\">",
"      Burnsed LJ, Hicks LA, Smithee LM, et al. A large, travel-associated outbreak of legionellosis among hotel guests: utility of the urine antigen assay in confirming Pontiac fever. Clin Infect Dis 2007; 44:222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/38\">",
"      Benson RF, Tang PW, Fields BS. Evaluation of the Binax and Biotest urinary antigen kits for detection of Legionnaires' disease due to multiple serogroups and species of Legionella. J Clin Microbiol 2000; 38:2763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/39\">",
"      Dom&iacute;nguez J, Gal&iacute; N, Matas L, et al. Evaluation of a rapid immunochromatographic assay for the detection of Legionella antigen in urine samples. Eur J Clin Microbiol Infect Dis 1999; 18:896.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/40\">",
"      Stout, JE. Laboratory diagnosis of Legionnaires' disease: the expanding role of the Legionella urinary antigen test. Clin Microbiol Newsletter 2000; 22:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/41\">",
"      Guidelines for prevention of nosocomial pneumonia. Centers for Disease Control and Prevention. MMWR Recomm Rep 1997; 46:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/42\">",
"      McWhinney PH, Ragunathan PL, Rowbottham TJ. Failure to produce detectable antibodies to Legionella pneumophila by an immunocompetent adult. J Infect 2000; 41:91.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/43\">",
"      Plouffe JF, File TM Jr, Breiman RF, et al. Reevaluation of the definition of Legionnaires' disease: use of the urinary antigen assay. Community Based Pneumonia Incidence Study Group. Clin Infect Dis 1995; 20:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/44\">",
"      Ramirez JA, Ahkee S, Tolentino A, et al. Diagnosis of Legionella pneumophila, Mycoplasma pneumoniae, or Chlamydia pneumoniae lower respiratory infection using the polymerase chain reaction on a single throat swab specimen. Diagn Microbiol Infect Dis 1996; 24:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/45\">",
"      Jonas D, Rosenbaum A, Weyrich S, Bhakdi S. Enzyme-linked immunoassay for detection of PCR-amplified DNA of legionellae in bronchoalveolar fluid. J Clin Microbiol 1995; 33:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/46\">",
"      Murdoch DR, Walford EJ, Jennings LC, et al. Use of the polymerase chain reaction to detect Legionella DNA in urine and serum samples from patients with pneumonia. Clin Infect Dis 1996; 23:475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38199/abstract/47\">",
"      Bencini MA, van den Brule AJ, Claas EC, et al. Multicenter comparison of molecular methods for detection of Legionella spp. in sputum samples. J Clin Microbiol 2007; 45:3390.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7035 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-94E968098A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38199=[""].join("\n");
var outline_f37_19_38199=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21952827\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Legionnaires' disease",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Symptoms",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21953756\">",
"      - Physical examination",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Chest radiograph",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Clinical clues for the diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pontiac fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Extrapulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Coinfection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      SPECIFIC LABORATORY DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Culture on selective media",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Urinary antigen testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DFA staining",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Serology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Polymerase chain reaction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Approach to diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21952827\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/7035\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7035|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/4/13378\" title=\"picture 1\">",
"      Legionella on BCYE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/7035|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/40/17035\" title=\"table 1\">",
"      Dx Legionella",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/58/32680?source=related_link\">",
"      Epidemiology and pathogenesis of Legionella infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/15/33015?source=related_link\">",
"      Treatment and prevention of Legionella infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_19_38200="Coronary artery thickening OCT";
var content_f37_19_38200=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F69676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F69676&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 603px\">",
"   <div class=\"ttl\">",
"    Coronary artery with mild, focal intimal thickening as visualized by intracoronary OCT",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 583px; height: 352px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    (A) Cross sectional view of the coronary artery. The coronary lumen is signal-poor and black, whereas the vessel is visualized using sepia false color scale. The artery wall shows three-layer appearance. (IC) OCT imaging catheter in the center of the lumen; asterisk indicates the angioplasty guide wire artefact.",
"    <br>",
"     (B) Magnification (2.8x) showing mild, focal thickening of the intima to 190 micron.",
"     <br>",
"      (C) Magnification (2.8x) showing three layer appearance; the intima (I) appears signal rich, bright yellow; the media (M) appears signal-poor, dark and the adventitia (A) appears signal-rich, bright yellow, peri-adventitial tissue is visible (PAT).",
"      <div class=\"footnotes\">",
"       OCT: St. Jude/Lightlab Imaging C7XR.",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Dr. Evelyn Regar, Thoraxcenter.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38200=[""].join("\n");
var outline_f37_19_38200=null;
var title_f37_19_38201="Unipolar depression in adults: Prognosis and course of illness";
var content_f37_19_38201=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Unipolar depression in adults: Prognosis and course of illness",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/19/38201/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38201/contributors\">",
"     William Coryell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/19/38201/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38201/contributors\">",
"     Peter P Roy-Byrne, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/19/38201/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38201/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/19/38201/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 20, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H15701673\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major depressive disorder (unipolar major depression), dysthymic disorder, and minor depressive disorder represent depressive syndromes that are distinguished by the type and number of symptoms that occur as well as their duration. Depressive symptoms can include depressed mood, loss of interest or pleasure in most or all activities, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, low energy, poor concentration, thoughts of worthlessness or guilt, and recurrent thoughts about death or suicide [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/1\">",
"     1",
"    </a>",
"    ]. The annual economic consequences of depression were estimated at 83 billion dollars in the United States in 2000 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/2\">",
"     2",
"    </a>",
"    ] and 118 billion euro in Europe in 2004 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/3\">",
"     3",
"    </a>",
"    ], due to increased functional disability and mortality as well as the cost of treatment.",
"   </p>",
"   <p>",
"    This topic reviews the prognosis of major depressive disorder. The prognosis of psychotic depression is discussed separately, as is the epidemiology, clinical features, diagnosis, and treatment of depression:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8055?source=see_link&amp;anchor=H4936027#H4936027\">",
"       \"Unipolar major depression with psychotic features: Maintenance treatment and prognosis\", section on 'Prognosis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37481?source=see_link\">",
"       \"Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=see_link\">",
"       \"Initial treatment of depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=see_link\">",
"       \"Treatment of resistant depression in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=see_link\">",
"       \"Diagnosis and management of late-life depression\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25596061\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major depressive disorder (unipolar major depression), dysthymic disorder, and minor depressive disorder are defined in the American Psychiatric Association's Diagnostic and Statistical Manual, Fourth Edition, Text Revision (DSM-IV-TR) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/1\">",
"     1",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Major depressive disorder",
"      </strong>",
"      is diagnosed in patients who have suffered at least one major depressive episode. An episode is a period lasting at least two weeks, with five or more of the following nine symptoms: depressed mood, loss of interest or pleasure in most or all activities, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, low energy, poor concentration, thoughts of worthlessness or guilt, and recurrent thoughts about death or suicide. Episodes persisting for at least two years are deemed chronic.",
"     </li>",
"     <li>",
"      <strong>",
"       Dysthymic disorder",
"      </strong>",
"      is diagnosed in patients with depressed mood for at least two years that is accompanied by at least two of the following symptoms: decreased or increased appetite, insomnia or hypersomnia, low energy, poor self esteem, poor concentration, and hopelessness.",
"     </li>",
"     <li>",
"      <strong>",
"       Minor depressive disorder",
"      </strong>",
"      is diagnosed in patients who have suffered at least one minor depressive episode. An episode is a period lasting at least two weeks, with two to four of the same nine symptoms that can occur during major depression.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The diagnosis and clinical presentation of major depressive disorder, dysthymic disorder, and minor depressive disorder are discussed further. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The term recovery is used to indicate the resolution of a depressive episode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/4\">",
"     4",
"    </a>",
"    ]. Although different definitions of recovery exist, many long-term observational studies require at least two consecutive months with no more than one or two mild symptoms of depression and no impairment of psychosocial functioning. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1384350\">",
"    <span class=\"h2\">",
"     Setting",
"    </span>",
"    &nbsp;&mdash;&nbsp;The setting of a study can affect the observed prognosis for depressed patients. Individuals who are identified in the community (in epidemiologic studies) may have a more benign course of illness than patients at tertiary care facilities; in either case, the individuals or patients may not be receiving treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. In addition, patients seen in routine clinical practice often differ from patients who are followed after they complete randomized trials. Patients who participate in trials are usually recruited through advertisements, are willing to risk assignment to placebo, and meet extensive exclusion criteria that are typically used in industry-sponsored trials; thus, these patients may have less suicidality, psychosis, comorbidity, and functional impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/7-9\">",
"     7-9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H856410\">",
"    <span class=\"h1\">",
"     MAJOR DEPRESSIVE DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for major depressive disorder is often heterogeneous, which may reflect that the disorder represents a number of different illnesses that differ in their pathogenesis, clinical presentation, and treatment response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/10-12\">",
"     10-12",
"    </a>",
"    ]. Patients may experience a single major depressive episode, follow a highly recurrent course with full resolution of symptoms between episodes, or spend much of their lives struggling with persistent, fluctuating symptoms. Depressive episodes can range in intensity from states that produce limited impairment and are little noticed by others, to catatonic or psychotic conditions that render the patient incapable of self-care.",
"   </p>",
"   <p>",
"    Although the large majority of major depressive episodes eventually end [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/5,13-15\">",
"     5,13-15",
"    </a>",
"    ], some patients are ill for much of their lives due to recurrences",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    lengthy episodes. A prospective observational study of 431 patients with major depressive disorder who sought treatment at study intake and were then followed for up to 12 years found that they were depressed for 59 percent (mean average) of the follow-up time [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H98355615\">",
"    <span class=\"h2\">",
"     Diagnostic stability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who are initially and correctly diagnosed with major depressive disorder may eventually change diagnosis.",
"   </p>",
"   <p>",
"    Patients with bipolar disorder may suffer one or more episodes of major depression prior to their first manic or hypomanic syndrome, and initially receive a diagnosis of major depressive disorder. As an example, a prospective observational study assessed 550 patients with major depressive disorder at least annually for up to 31 years, and found that 20 percent eventually changed diagnosis to bipolar disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/16\">",
"     16",
"    </a>",
"    ]. The probability of switching diagnosis was significantly higher in patients with the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Younger age of onset of their first lifetime major depressive episode",
"     </li>",
"     <li>",
"      Family history of bipolar disorder",
"     </li>",
"     <li>",
"      During major depressive episodes:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Psychosis (eg, delusions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hallucinations)",
"     </li>",
"     <li>",
"      Decreased need for sleep",
"     </li>",
"     <li>",
"      Unusually high energy",
"     </li>",
"     <li>",
"      Increased goal directed activity",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Additional information about distinguishing unipolar depression and bipolar depression, which differ in treatment, is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=see_link&amp;anchor=H12#H12\">",
"     \"Bipolar disorder in adults: Epidemiology and diagnosis\", section on 'Distinguishing unipolar and bipolar depression'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At least 5 to 15 percent of patients initially diagnosed with major depressive disorder eventually change diagnosis to a schizophrenia-spectrum disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. In a 10-year follow-up study of 77 patients diagnosed with psychotic major depression at baseline, the diagnosis changed to schizophrenia in 30 percent; predictors included negative symptoms (eg, flat affect, apathy, poverty of speech, and abulia) and psychosocial impairment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/22\">",
"     22",
"    </a>",
"    ]. Repeated diagnostic examinations find that the change from major depressive disorder to schizophrenia occurs more frequently than the reverse [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/18,21,22\">",
"     18,21,22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25944?source=see_link\">",
"     \"Depression in schizophrenia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H856417\">",
"    <span class=\"h2\">",
"     Recovery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The median time to recovery from a major depressive episode in prospective observational studies is approximately 20 weeks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. This finding is consistent in patients at treatment centers with multiple recurrent episodes (up to five), and for individuals in the community who have not sought treatment.",
"   </p>",
"   <p>",
"    Prospective observational studies have found that the probability of recovery from major depression progressively decreases as the duration of the episode increases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/14\">",
"     14",
"    </a>",
"    ]. As an example, a study of 359 patients and 216 nonclinical individuals with major depression found that recovery occurred in approximately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/13\">",
"     13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      40 percent of the episodes within 3 months of onset of the episode",
"     </li>",
"     <li>",
"      60 percent within 6 months of onset &nbsp;",
"     </li>",
"     <li>",
"      80 percent within 12 months of onset",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    This decreasing rate of recovery is graphically illustrated (",
"    <a class=\"graphic graphic_figure graphicRef73080 \" href=\"mobipreview.htm?20/9/20638\">",
"     figure 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53095 \" href=\"mobipreview.htm?18/52/19278\">",
"     figure 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Major depressive episodes may remit quickly. Prospective observational studies have found that episodes (some of which were untreated) often remitted soon after onset (eg, &le; 8 weeks), in a reproducible manner across different patient populations (",
"    <a class=\"graphic graphic_figure graphicRef53095 \" href=\"mobipreview.htm?18/52/19278\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef73080 \" href=\"mobipreview.htm?20/9/20638\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]. In addition, remission of depressive episodes that occurs during treatment that is started soon after onset of the episode often appears to be the result of a placebo effect [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/23,24\">",
"     23,24",
"    </a>",
"    ]. Thus, for mild to moderate depression with recent onset and no suicidality or psychosis, reassurance and watchful waiting for one to two months may be a reasonable alternative to antidepressant treatment.",
"   </p>",
"   <p>",
"    Several risk factors for a longer time to recovery from major depression have been identified in at least two separate prospective observational studies that included at least two years of follow-up and were not confined to a particular age or diagnostic subgroup:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Longer episode duration at baseline [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/25-27\">",
"       25-27",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Greater baseline symptom severity [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/28,29\">",
"       28,29",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Psychotic features (ie, delusions",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hallucinations) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/30-32\">",
"       30-32",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Higher levels of anxiety [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/28,33-35\">",
"       28,33-35",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Pre-existing comorbid disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/27,29\">",
"       27,29",
"      </a>",
"      ], including personality disorders [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/25,28,36,37\">",
"       25,28,36,37",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      High levels of neuroticism [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/38-40\">",
"       38-40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Poorer psychosocial functioning [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/28,41-43\">",
"       28,41-43",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition, a history of childhood maltreatment may be associated with persistence of major depressive episodes. A meta-analysis of nine epidemiologic studies (13,759 depressed individuals) found that prolonged depressive episodes were twice as likely among individuals who were mistreated during childhood (based upon retrospective recall of physical or sexual abuse, neglect, or family conflict or violence) compared with individuals who were not [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/44\">",
"     44",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H858471\">",
"    <span class=\"h3\">",
"     Chronic major depression",
"    </span>",
"    &nbsp;&mdash;&nbsp;An episode of major depression is chronic if full criteria are met continuously for two years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/1\">",
"     1",
"    </a>",
"    ]. Prospective observational studies have found that the probability of recovery from an episode of chronic major depression is less than the rate of recovery from shorter episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/45\">",
"     45",
"    </a>",
"    ]. Nevertheless, recovery from major depression may occur despite a chronic course [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/45,46\">",
"     45,46",
"    </a>",
"    ]. As an example, a prospective observational study of 35 patients with major depression who were continuously ill for five years found that 38 percent recovered during the following five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/47\">",
"     47",
"    </a>",
"    ]. Thus, clinicians should encourage patients to continue treatment and efforts to manage their illness despite persistent symptoms [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/48\">",
"     48",
"    </a>",
"    ]. Clinical factors at baseline that were associated with a shorter time to recovery from chronic major depression in a prospective study (N = 100) included a high level of psychosocial functioning, less severe depressive symptoms, and absence of psychosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H856424\">",
"    <span class=\"h2\">",
"     Recurrence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major depressive disorder is highly recurrent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study of 92 individuals with a first lifetime episode of major depression found that about 50 percent suffered at least one additional episode [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 318 patients who recovered from a major depressive episode and were assessed semi-annually or annually for up to 10 years, 64 percent suffered at least one subsequent episode [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/51\">",
"       51",
"      </a>",
"      ]. The median time to recurrence for the first the recurrent episode was approximately 3 years and for subsequent episodes was 1 to 1.5 years.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risk of recurrence appears to be greatest in the first few months after recovery from a major depressive episode. Thereafter, the probability of recurrence progressively decreases as the duration of recovery (wellness) increases. As an example, a prospective study found that among 318 patients who recovered from a major depressive episode, approximately [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/51\">",
"     51",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      20 percent suffered a recurrence in months 1 through 6 after recovery",
"     </li>",
"     <li>",
"      19 percent in months 7 through 12 after recovery",
"     </li>",
"     <li>",
"      15 percent in months 13 through 18",
"     </li>",
"     <li>",
"      13 percent in months 19 through 24",
"     </li>",
"     <li>",
"      11 percent in months 25 through 30",
"     </li>",
"     <li>",
"      9 percent in months 31 through 36",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinical factors that may be associated with recurrence of major depression include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prior history of recurrence &mdash; This is the most consistently identified risk factor [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/36,51-61\">",
"       36,51-61",
"      </a>",
"      ]. As an example, a prospective study of 318 patients found that each recurrence increased the risk of a subsequent recurrence by 16 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/51\">",
"       51",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Residual depressive symptoms &mdash; This has been found in multiple studies [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/53,56,58,59,62,63\">",
"       53,56,58,59,62,63",
"      </a>",
"      ]. As an example, a prospective study of 237 patients found that the median time to recurrence was significantly shorter for patients with one or two mild symptoms during the recovery period than for patients with no symptoms (23 versus 68 weeks) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/64\">",
"       64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Childhood maltreatment &mdash; A meta-analysis of seven epidemiologic studies (10,191 depressed individuals) found that recurrent depressive episodes were twice as likely among individuals who were mistreated during childhood (physical or sexual abuse, neglect, or family conflict or violence) compared with individuals who were not [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/44\">",
"       44",
"      </a>",
"      ]. A subsequent study of 687 euthymic individuals with a lifetime history of unipolar major depression found that time to recurrence was shorter among individuals with negative youth experiences [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/61\">",
"       61",
"      </a>",
"      ]. &nbsp;",
"     </li>",
"     <li>",
"      Other factors such as:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Greater severity (intensity) of the preceding depressive episode [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/25,53,61,65\">",
"       25,53,61,65",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Younger age at time of assessment [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/53,61,65,66\">",
"       53,61,65,66",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Younger age of onset of major depressive disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/54,67\">",
"       54,67",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Comorbid personality disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/36\">",
"       36",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Feeling that life circumstances are beyond one&rsquo;s control (ie, low mastery) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/60\">",
"       60",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H856431\">",
"    <span class=\"h2\">",
"     Course of illness over time",
"    </span>",
"    &nbsp;&mdash;&nbsp;For any individual patient who suffers more than one episode of major depression, time to recovery and time to recurrence are inconsistent across multiple episodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/14,51,68\">",
"     14,51,68",
"    </a>",
"    ]. However, long-term prospective studies of patients with major depression, receiving various levels of treatment or none at all, have found that course of illness remains the same for the cohort over time, including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/13,14,69,70\">",
"     13,14,69,70",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Mean time to recovery from an episode of major depression",
"     </li>",
"     <li>",
"      Probability of recurrence",
"     </li>",
"     <li>",
"      Amount of time ill with major depression",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As an example, a study prospectively followed 220 patients with major depressive disorder for 20 years, and examined the proportion of weeks ill with major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/71\">",
"     71",
"    </a>",
"    ]. The 20 years of follow-up were grouped into 5-year periods to determine whether the proportion of weeks ill with depression changed over time, and patients were divided into three groups according to their age at study intake (mean age 25, 36, and 55 years). The amount of time ill with depression did not change as patients moved from their third decade of life to their fifth decade, from their fourth to their sixth decade, or their sixth to their eighth decade of life (",
"    <a class=\"graphic graphic_figure graphicRef60472 \" href=\"mobipreview.htm?6/59/7103\">",
"     figure 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Clinicians may conclude that the course of illness is worsening (eg, episodes are progressively becoming longer or more frequent) when in fact it is not, because patients who experience more symptoms are more likely to continue visiting clinicians than patients who remain euthymic for long periods [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/72\">",
"     72",
"    </a>",
"    ]. &nbsp; &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1384471\">",
"    <span class=\"h2\">",
"     Functional outcomes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Psychosocial functioning in major depression is inversely proportionate to symptom severity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/73\">",
"     73",
"    </a>",
"    ], and most episodes are associated with poor psychosocial and physical functioning and poor self-rated health [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/15,74-76\">",
"     15,74-76",
"    </a>",
"    ]. As an example, an epidemiologic study found that psychosocial functioning (work, household duties, relationships, and social roles) was severely or very severely impaired in almost 60 percent of individuals with major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/15\">",
"     15",
"    </a>",
"    ]. Patients with severe depression may become house- or bed-bound and fail to perform basic activities of living including personal hygiene, toileting, and feeding. Unipolar depressive disorders were the fourth leading cause of disability throughout the world in 2002, and are projected to be the second leading cause in the coming decades [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/77\">",
"     77",
"    </a>",
"    ]. Functioning generally improves significantly in patients who recover from a major depressive episode [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H111698911\">",
"    <span class=\"h1\">",
"     DYSTHYMIC DISORDER",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although most episodes of dysthymic disorder resolve, recurrence is common [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/79\">",
"     79",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A prospective study of 82 patients with dysthymic disorder followed for up to 10 years found that approximately 74 percent recovered; the median time from study entry to recovery was approximately four years [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A prospective study of 53 patients who recovered from dysthymic disorder and were followed for a median of eight years found that 55 percent suffered a recurrence [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/80\">",
"       80",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with dysthymic disorder recover more slowly than patients with non-chronic major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/79\">",
"     79",
"    </a>",
"    ]. In an observational study of 49 patients followed prospectively for six months, recovery occurred in significantly fewer patients with dysthymic disorder compared with unipolar major depression (25 versus 63 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/81\">",
"     81",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Most patients with dysthymic disorder have exacerbations that meet criteria for a major depressive episode, a phenomenon labelled &ldquo;double depression&rdquo; [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/82\">",
"     82",
"    </a>",
"    ]. As an example, two studies of dysthymic disorder (190 and 87 patients) found that most patients also met criteria for major depression (62 and 59 percent of patients) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/80,83\">",
"     80,83",
"    </a>",
"    ]. Underlying dysthymia seems to worsen the course of major depression; studies have found that among patients who recover from major depressive episodes superimposed upon dysthymic disorder, time to relapse of another major depressive episode is significantly shorter than that experienced by patients who recover from major depression not superimposed upon dysthymic disorder [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/82,84\">",
"     82,84",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There may be little difference between episodes of dysthymic disorder and chronic major depression. Most patients with dysthymia experience major depression; in addition, comparisons of dysthymia with chronic major depression have found no significant group differences in demographics, symptom patterns, treatment response, or family history [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/85-88\">",
"     85-88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Predictors of poor outcome in dysthymic disorder include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Family history of dysthymic disorder or chronic major depression [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/80,89\">",
"       80,89",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      High neuroticism scores [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/89\">",
"       89",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Comorbid anxiety disorder [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/90,91\">",
"       90,91",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15701729\">",
"    <span class=\"h1\">",
"     MINOR DEPRESSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Little is known about the prognosis for minor depressive disorder.",
"   </p>",
"   <p>",
"    Minor depression may be the initial manifestation of major depression or dysthymia in some patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A community study of 136 individuals with a lifetime history of minor depression found that during 10 years of follow-up, 23 percent developed major depressive disorder, dysthymic disorder, or both [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/92\">",
"       92",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A study of 300 elderly primary care patients followed for one year found that major depression occurred in significantly more patients with either minor depression or subsyndromal depression at baseline, compared with patients who had no depressive symptoms (12 and 7 versus 1 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/93\">",
"       93",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is not clear if the course of illness for minor depressive disorder and major depressive disorder differ; some studies have found minor depression is marked by less psychosocial impairment or treatment seeking compared with major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/92,94\">",
"     92,94",
"    </a>",
"    ], whereas other studies have found impairment or treatment seeking were comparable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1385537\">",
"    <span class=\"h1\">",
"     MORBIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression may adversely affect the overall health of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/96\">",
"     96",
"    </a>",
"    ]. Depression is associated with coronary heart disease, diabetes mellitus, and stroke, and with worse outcomes in comorbid general medical illnesses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/97-102\">",
"     97-102",
"    </a>",
"    ]. In addition, depression in later life may be an independent risk for subsequent cognitive decline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/103-105\">",
"     103-105",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=see_link&amp;anchor=H7#H7\">",
"     \"Secondary prevention of cardiovascular disease\", section on 'Depression'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27161?source=see_link&amp;anchor=H14#H14\">",
"     \"Mild cognitive impairment: Epidemiology, pathology, and clinical assessment\", section on 'Neuropsychiatric symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1385544\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1385552\">",
"    <span class=\"h2\">",
"     All cause",
"    </span>",
"    &nbsp;&mdash;&nbsp;Depression is associated with increased all-cause mortality [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/106\">",
"     106",
"    </a>",
"    ]. As an example, a study of 11,681 patients with depressive disorders found that life expectancy was significantly shorter compared with the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/107\">",
"     107",
"    </a>",
"    ]. For depressed males, life expectancy was 11 years shorter, and for depressed females it was 7 years shorter. In an observational study that followed 186 patients with major depressive disorder for up to 38 years, total mortality was 63 percent greater than the rate in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For some patients with depression plus a general medical disease, it appears that the mortality risk of depression is not fully explained by the comorbid medical illness [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/109,110\">",
"     109,110",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A community survey and mortality database of 61,349 individuals found that depressive disorders were associated with a significantly increased mortality that was only partly explained by somatic symptoms or illnesses (hazard ratio 1.5, 95% CI 1.4-1.7) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/111\">",
"       111",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A meta-analysis of 25 observational studies (9417 patients) showed that mortality rates were 25 percent higher in cancer patients with depressive symptoms compared with nondepressed cancer patients (risk ratio 1.25, 95% CI 1.12-1.40), and 39 percent higher in cancer patients diagnosed with major or minor depression (risk ratio 1.39, 95% CI 1.10-1.89) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/112\">",
"       112",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study of 4873 women, mortality was higher for women with depression plus diabetes mellitus (relative risk 3.1, 95% CI 2.7-3.6) than diabetes alone (relative risk 1.7, 95% CI 1.5-1.9) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/113\">",
"       113",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a prospective study that followed patients with an acute myocardial infarction for a median of five years, the 358 patients with either major or minor depression were at higher risk for all-cause mortality than the 408 nondepressed patients (HR = 1.8, 95% CI 1.2-2.6) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/114\">",
"       114",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1385559\">",
"    <span class=\"h2\">",
"     Suicide",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many depressed patients kill themselves [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/115\">",
"     115",
"    </a>",
"    ]. In a study that followed 186 patients with major depressive disorder for up to 38 years, the incidence of suicide was 27 times greater than in the general population [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/108\">",
"     108",
"    </a>",
"    ]. Younger and middle-aged adults who die by suicide often have comorbid psychiatric disorders such as alcohol dependence [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/116\">",
"     116",
"    </a>",
"    ]. Most elderly persons who die by suicide suffer from inadequately treated major depression [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38201/abstract/117\">",
"     117",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H854807\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Major depressive disorder (unipolar major depression), dysthymic disorder, and minor depressive disorder represent depressive syndromes that are distinguished by the type and number of symptoms that occur as well as their duration. Depressive symptoms can include depressed mood, loss of interest or pleasure in most or all activities, insomnia or hypersomnia, change in appetite or weight, psychomotor retardation or agitation, low energy, poor concentration, thoughts of worthlessness or guilt, and recurrent thoughts about death or suicide. (See",
"      <a class=\"local\" href=\"#H25596061\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=see_link\">",
"       \"Clinical manifestations and diagnosis of depression\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who are initially and correctly diagnosed with major depressive disorder may eventually change diagnosis to bipolar disorder or schizophrenia. (See",
"      <a class=\"local\" href=\"#H98355615\">",
"       'Diagnostic stability'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The median time to recovery from a major depressive episode is approximately 20 weeks. However, episodes may remit quickly. Thus, for mild to moderate depression with recent onset and no suicidality or psychosis, reassurance and watchful waiting for one to two months may be a reasonable alternative to antidepressant treatment. Possible risk factors for a longer time to recovery include: longer episode duration at baseline, greater baseline symptom severity, psychotic features, higher levels of anxiety, pre-existing comorbid disorders, high levels of neuroticism, poorer psychosocial functioning, and a history of childhood maltreatment. (See",
"      <a class=\"local\" href=\"#H856417\">",
"       'Recovery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Among patients with major depressive disorder, recurrent episodes occur in 50 percent or more. The risk of recurrence appears to be greatest in the first few months after recovery from a major depressive episode and thereafter progressively decreases as the duration of recovery (wellness) increases. Factors that may be associated with recurrence include prior history of recurrence, residual depressive symptoms, childhood maltreatment, symptom severity of the preceding depressive episode, younger age at time of assessment, younger age of onset of major depressive disorder, and comorbid personality disorder. (See",
"      <a class=\"local\" href=\"#H856424\">",
"       'Recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For any individual patient who suffers more than one episode of major depression, time to recovery and time to recurrence are inconsistent across multiple episodes. However, for groups of patients, course of illness remains the same for the cohort over time, including mean time to recovery from an episode of major depression, probability of recurrence, and amount of time ill with major depression. (See",
"      <a class=\"local\" href=\"#H856431\">",
"       'Course of illness over time'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depression is associated with poor psychosocial and physical functioning. (See",
"      <a class=\"local\" href=\"#H1384471\">",
"       'Functional outcomes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although most episodes of dysthymic disorder resolve, recurrences are common. Most patients with dysthymic disorder have exacerbations that meet criteria for a major depressive episode. (See",
"      <a class=\"local\" href=\"#H111698911\">",
"       'Dysthymic disorder'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depression is associated with coronary heart disease, diabetes mellitus, and stroke, and with worse outcomes in comorbid general medical illnesses. (See",
"      <a class=\"local\" href=\"#H1385537\">",
"       'Morbidity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Depression is associated with increased all-cause mortality and completed suicide. (See",
"      <a class=\"local\" href=\"#H1385544\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H855980\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Jeffrey M Lyness, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/2\">",
"      Donohue JM, Pincus HA. Reducing the societal burden of depression: a review of economic costs, quality of care and effects of treatment. Pharmacoeconomics 2007; 25:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/3\">",
"      Sobocki P, J&ouml;nsson B, Angst J, Rehnberg C. Cost of depression in Europe. J Ment Health Policy Econ 2006; 9:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/4\">",
"      Rush AJ, Kraemer HC, Sackeim HA, et al. Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006; 31:1841.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/5\">",
"      Eaton WW, Shao H, Nestadt G, et al. Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry 2008; 65:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/6\">",
"      Judd LL, Akiskal HS, Maser JD, et al. A prospective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders. Arch Gen Psychiatry 1998; 55:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/7\">",
"      Keitner GI, Posternak MA, Ryan CE. How many subjects with major depressive disorder meet eligibility requirements of an antidepressant efficacy trial? J Clin Psychiatry 2003; 64:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/8\">",
"      Zimmerman M, Chelminski I, Posternak MA. Generalizability of antidepressant efficacy trials: differences between depressed psychiatric outpatients who would or would not qualify for an efficacy trial. Am J Psychiatry 2005; 162:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/9\">",
"      Zimmerman M, Mattia JI, Posternak MA. Are subjects in pharmacological treatment trials of depression representative of patients in routine clinical practice? Am J Psychiatry 2002; 159:469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/10\">",
"      Gilbody S, Lightfoot T, Sheldon T. Is low folate a risk factor for depression? A meta-analysis and exploration of heterogeneity. J Epidemiol Community Health 2007; 61:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/11\">",
"      Chen L, Eaton WW, Gallo JJ, Nestadt G. Understanding the heterogeneity of depression through the triad of symptoms, course and risk factors: a longitudinal, population-based study. J Affect Disord 2000; 59:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/12\">",
"      Jabben N, Penninx BW, Beekman AT, et al. Co-occurring manic symptomatology as a dimension which may help explaining heterogeneity of depression. J Affect Disord 2011; 131:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/13\">",
"      Coryell W, Akiskal HS, Leon AC, et al. The time course of nonchronic major depressive disorder. Uniformity across episodes and samples. National Institute of Mental Health Collaborative Program on the Psychobiology of Depression--Clinical Studies. Arch Gen Psychiatry 1994; 51:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/14\">",
"      Solomon DA, Keller MB, Leon AC, et al. Recovery from major depression. A 10-year prospective follow-up across multiple episodes. Arch Gen Psychiatry 1997; 54:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/15\">",
"      Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA 2003; 289:3095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/16\">",
"      Fiedorowicz JG, Endicott J, Leon AC, et al. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry 2011; 168:40.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/17\">",
"      Clayton PJ, Guze SB, Cloninger CR, Martin RL. Unipolar depression: diagnostic inconsistency and its implications. J Affect Disord 1992; 26:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/18\">",
"      Kessing LV. Diagnostic stability in depressive disorder as according to ICD-10 in clinical practice. Psychopathology 2005; 38:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/19\">",
"      Schwartz JE, Fennig S, Tanenberg-Karant M, et al. Congruence of diagnoses 2 years after a first-admission diagnosis of psychosis. Arch Gen Psychiatry 2000; 57:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/20\">",
"      Tsuang MT, Woolson RF, Winokur G, Crowe RR. Stability of psychiatric diagnosis. Schizophrenia and affective disorders followed up over a 30- to 40-year period. Arch Gen Psychiatry 1981; 38:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/21\">",
"      Salvatore P, Baldessarini RJ, Tohen M, et al. McLean-Harvard International First-Episode Project: two-year stability of ICD-10 diagnoses in 500 first-episode psychotic disorder patients. J Clin Psychiatry 2011; 72:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/22\">",
"      Bromet EJ, Kotov R, Fochtmann LJ, et al. Diagnostic shifts during the decade following first admission for psychosis. Am J Psychiatry 2011; 168:1186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/23\">",
"      Khan A, Dager SR, Cohen S, et al. Chronicity of depressive episode in relation to antidepressant-placebo response. Neuropsychopharmacology 1991; 4:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/24\">",
"      Quitkin FM, Rabkin JG, Ross D, Stewart JW. Identification of true drug response to antidepressants. Use of pattern analysis. Arch Gen Psychiatry 1984; 41:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/25\">",
"      Holma KM, Holma IA, Melartin TK, et al. Long-term outcome of major depressive disorder in psychiatric patients is variable. J Clin Psychiatry 2008; 69:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/26\">",
"      Angst J, Preisig M. Course of a clinical cohort of unipolar, bipolar and schizoaffective patients. Results of a prospective study from 1959 to 1985. Schweiz Arch Neurol Psychiatr 1995; 146:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/27\">",
"      Keller MB, Klerman GL, Lavori PW, et al. Long-term outcome of episodes of major depression. Clinical and public health significance. JAMA 1984; 252:788.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/28\">",
"      Sz&aacute;d&oacute;czky E, R&oacute;zsa S, Z&aacute;mbori J, F&uuml;redi J. Predictors for 2-year outcome of major depressive episode. J Affect Disord 2004; 83:49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/29\">",
"      Swindle RW Jr, Cronkite RC, Moos RH. Risk factors for sustained nonremission of depressive symptoms: a 4-year follow-up. J Nerv Ment Dis 1998; 186:462.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/30\">",
"      Angst J. The course of affective disorders. Psychopathology 1986; 19 Suppl 2:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/31\">",
"      Coryell W, Leon A, Winokur G, et al. Importance of psychotic features to long-term course in major depressive disorder. Am J Psychiatry 1996; 153:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/32\">",
"      Goldberg JF, Harrow M. Consistency of remission and outcome in bipolar and unipolar mood disorders: a 10-year prospective follow-up. J Affect Disord 2004; 81:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/33\">",
"      Clayton PJ, Grove WM, Coryell W, et al. Follow-up and family study of anxious depression. Am J Psychiatry 1991; 148:1512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/34\">",
"      Coryell W, Endicott J, Winokur G. Anxiety syndromes as epiphenomena of primary major depression: outcome and familial psychopathology. Am J Psychiatry 1992; 149:100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/35\">",
"      Coryell W, Fiedorowicz JG, Solomon D, et al. Effects of anxiety on the long-term course of depressive disorders. Br J Psychiatry 2012; 200:210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/36\">",
"      Grilo CM, Stout RL, Markowitz JC, et al. Personality disorders predict relapse after remission from an episode of major depressive disorder: a 6-year prospective study. J Clin Psychiatry 2010; 71:1629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/37\">",
"      Skodol AE, Grilo CM, Keyes KM, et al. Relationship of personality disorders to the course of major depressive disorder in a nationally representative sample. Am J Psychiatry 2011; 168:257.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/38\">",
"      Scott J, Eccleston D, Boys R. Can we predict the persistence of depression? Br J Psychiatry 1992; 161:633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/39\">",
"      Hirschfeld RM, Klerman GL, Andreasen NC, et al. Psycho-social predictors of chronicity in depressed patients. Br J Psychiatry 1986; 148:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/40\">",
"      Steunenberg B, Beekman AT, Deeg DJ, Kerkhof AJ. Personality predicts recurrence of late-life depression. J Affect Disord 2010; 123:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/41\">",
"      Sherrington JM, Hawton K, Fagg J, et al. Outcome of women admitted to hospital for depressive illness: factors in the prognosis of severe depression. Psychol Med 2001; 31:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/42\">",
"      Solomon DA, Leon AC, Coryell W, et al. Predicting recovery from episodes of major depression. J Affect Disord 2008; 107:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/43\">",
"      Spijker J, de Graaf R, Bijl RV, et al. Determinants of persistence of major depressive episodes in the general population. Results from the Netherlands Mental Health Survey and Incidence Study (NEMESIS). J Affect Disord 2004; 81:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/44\">",
"      Nanni V, Uher R, Danese A. Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: a meta-analysis. Am J Psychiatry 2012; 169:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/45\">",
"      Coryell W, Endicott J, Keller M. Outcome of patients with chronic affective disorder: a five-year follow-up. Am J Psychiatry 1990; 147:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/46\">",
"      Pincus HA, Pettit AR. The societal costs of chronic major depression. J Clin Psychiatry 2001; 62 Suppl 6:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/47\">",
"      Mueller TI, Keller MB, Leon AC, et al. Recovery after 5 years of unremitting major depressive disorder. Arch Gen Psychiatry 1996; 53:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/48\">",
"      Keitner GI, Ryan CE, Solomon DA. Realistic expectations and a disease management model for depressed patients with persistent symptoms. J Clin Psychiatry 2006; 67:1412.",
"     </a>",
"    </li>",
"    <li>",
"     Practice Guideline for the Treatment of Patients with Major Depressive Disorder, Third Edition, 2010. file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on May 29, 2011).",
"    </li>",
"    <li>",
"     Depression: The Treatment and Management of Depression in Adults, National Clinical Practice Guideline 90, 2010 file://guidance.nice.org.uk/CG90 (Accessed on May 29, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/51\">",
"      Solomon DA, Keller MB, Leon AC, et al. Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/52\">",
"      Keller MB, Lavori PW, Lewis CE, Klerman GL. Predictors of relapse in major depressive disorder. JAMA 1983; 250:3299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/53\">",
"      Pintor L, Torres X, Navarro V, et al. Is the type of remission after a major depressive episode an important risk factor to relapses in a 4-year follow up? J Affect Disord 2004; 82:291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/54\">",
"      Giles DE, Jarrett RB, Biggs MM, et al. Clinical predictors of recurrence in depression. Am J Psychiatry 1989; 146:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/55\">",
"      Kessing LV. Severity of depressive episodes according to ICD-10: prediction of risk of relapse and suicide. Br J Psychiatry 2004; 184:153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/56\">",
"      Maj M, Veltro F, Pirozzi R, et al. Pattern of recurrence of illness after recovery from an episode of major depression: a prospective study. Am J Psychiatry 1992; 149:795.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/57\">",
"      Mueller TI, Leon AC, Keller MB, et al. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry 1999; 156:1000.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/58\">",
"      ten Doesschate MC, Bockting CL, Koeter MW, et al. Prediction of recurrence in recurrent depression: a 5.5-year prospective study. J Clin Psychiatry 2010; 71:984.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/59\">",
"      Karsten J, Hartman CA, Smit JH, et al. Psychiatric history and subthreshold symptoms as predictors of the occurrence of depressive or anxiety disorder within 2 years. Br J Psychiatry 2011; 198:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/60\">",
"      Colman I, Naicker K, Zeng Y, et al. Predictors of long-term prognosis of depression. CMAJ 2011; 183:1969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/61\">",
"      Hardeveld F, Spijker J, De Graaf R, et al. Recurrence of major depressive disorder and its predictors in the general population: results from The Netherlands Mental Health Survey and Incidence Study (NEMESIS). Psychol Med 2013; 43:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/62\">",
"      Nierenberg AA, Husain MM, Trivedi MH, et al. Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STAR*D report. Psychol Med 2010; 40:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/63\">",
"      Judd LL, Paulus MJ, Schettler PJ, et al. Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness? Am J Psychiatry 2000; 157:1501.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/64\">",
"      Judd LL, Akiskal HS, Maser JD, et al. Major depressive disorder: a prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse. J Affect Disord 1998; 50:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/65\">",
"      Coryell W, Endicott J, Keller MB. Predictors of relapse into major depressive disorder in a nonclinical population. Am J Psychiatry 1991; 148:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/66\">",
"      Eaton WW, Anthony JC, Gallo J, et al. Natural history of Diagnostic Interview Schedule/DSM-IV major depression. The Baltimore Epidemiologic Catchment Area follow-up. Arch Gen Psychiatry 1997; 54:993.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/67\">",
"      Zisook S, Lesser I, Stewart JW, et al. Effect of age at onset on the course of major depressive disorder. Am J Psychiatry 2007; 164:1539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/68\">",
"      de Jonge P, Conradi HJ, Kaptein KI, et al. Duration of subsequent episodes and periods of recovery in recurrent major depression. J Affect Disord 2010; 125:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/69\">",
"      Kennedy N, Abbott R, Paykel ES. Longitudinal syndromal and sub-syndromal symptoms after severe depression: 10-year follow-up study. Br J Psychiatry 2004; 184:330.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/70\">",
"      Angst J, Gamma A, Sellaro R, et al. Recurrence of bipolar disorders and major depression. A life-long perspective. Eur Arch Psychiatry Clin Neurosci 2003; 253:236.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/71\">",
"      Coryell W, Solomon D, Leon A, et al. Does major depressive disorder change with age? Psychol Med 2009; 39:1689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/72\">",
"      Coryell W, Endicott J, Winokur G, et al. Characteristics and significance of untreated major depressive disorder. Am J Psychiatry 1995; 152:1124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/73\">",
"      Judd LL, Akiskal HS, Zeller PJ, et al. Psychosocial disability during the long-term course of unipolar major depressive disorder. Arch Gen Psychiatry 2000; 57:375.",
"     </a>",
"    </li>",
"    <li>",
"     Kessler, RC, Mickelson, KD, Barber, CB, Wang, P. The association between chronic medical conditions and work impairment. In: Caring and doing for others: Social responsibility in the domains of family, work, and community, Rossi, AS (Ed), University of Chicago Press, Chicago 2001. p.403.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/75\">",
"      Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989; 262:914.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/76\">",
"      Adler DA, McLaughlin TJ, Rogers WH, et al. Job performance deficits due to depression. Am J Psychiatry 2006; 163:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/77\">",
"      Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3:e442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/78\">",
"      Leon AC, Solomon DA, Mueller TI, et al. The Range of Impaired Functioning Tool (LIFE-RIFT): a brief measure of functional impairment. Psychol Med 1999; 29:869.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/79\">",
"      Gonzales LR, Lewinsohn PM, Clarke GN. Longitudinal follow-up of unipolar depressives: an investigation of predictors of relapse. J Consult Clin Psychol 1985; 53:461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/80\">",
"      Klein DN, Shankman SA, Rose S. Ten-year prospective follow-up study of the naturalistic course of dysthymic disorder and double depression. Am J Psychiatry 2006; 163:872.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/81\">",
"      Klein DN, Taylor EB, Dickstein S, Harding K. Primary early-onset dysthymia: comparison with primary nonbipolar nonchronic major depression on demographic, clinical, familial, personality, and socioenvironmental characteristics and short-term outcome. J Abnorm Psychol 1988; 97:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/82\">",
"      Keller MB, Lavori PW, Endicott J, et al. \"Double depression\": two-year follow-up. Am J Psychiatry 1983; 140:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/83\">",
"      Keller MB, Klein DN, Hirschfeld RM, et al. Results of the DSM-IV mood disorders field trial. Am J Psychiatry 1995; 152:843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/84\">",
"      Klein DN, Schwartz JE, Rose S, Leader JB. Five-year course and outcome of dysthymic disorder: A prospective, naturalistic follow-up study. Am J Psychiatry 2000; 157:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/85\">",
"      McCullough JP Jr, Klein DN, Keller MB, et al. Comparison of DSM-III-R chronic major depression and major depression superimposed on dysthymia (double depression): validity of the distinction. J Abnorm Psychol 2000; 109:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/86\">",
"      McCullough JP Jr, Klein DN, Borian FE, et al. Group comparisons of DSM-IV subtypes of chronic depression: validity of the distinctions, part 2. J Abnorm Psychol 2003; 112:614.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/87\">",
"      Klein DN, Shankman SA, Lewinsohn PM, et al. Family study of chronic depression in a community sample of young adults. Am J Psychiatry 2004; 161:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/88\">",
"      Yang T, Dunner DL. Differential subtyping of depression. Depress Anxiety 2001; 13:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/89\">",
"      Hayden EP, Klein DN. Outcome of dysthymic disorder at 5-year follow-up: the effect of familial psychopathology, early adversity, personality, comorbidity, and chronic stress. Am J Psychiatry 2001; 158:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/90\">",
"      Klein DN, Shankman SA, Rose S. Dysthymic disorder and double depression: prediction of 10-year course trajectories and outcomes. J Psychiatr Res 2008; 42:408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/91\">",
"      Shankman SA, Klein DN. The impact of comorbid anxiety disorders on the course of dysthymic disorder: a 5-year prospective longitudinal study. J Affect Disord 2002; 70:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/92\">",
"      Chen LS, Eaton WW, Gallo JJ, et al. Empirical examination of current depression categories in a population-based study: symptoms, course, and risk factors. Am J Psychiatry 2000; 157:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/93\">",
"      Lyness JM, Heo M, Datto CJ, et al. Outcomes of minor and subsyndromal depression among elderly patients in primary care settings. Ann Intern Med 2006; 144:496.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/94\">",
"      Kessler RC, Zhao S, Blazer DG, Swartz M. Prevalence, correlates, and course of minor depression and major depression in the National Comorbidity Survey. J Affect Disord 1997; 45:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/95\">",
"      Skodol AE, Schwartz S, Dohrenwend BP, et al. Minor depression in a cohort of young adults in Israel. Arch Gen Psychiatry 1994; 51:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/96\">",
"      Evans DL, Charney DS, Lewis L, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005; 58:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/97\">",
"      Jackson JL, DeZee K, Berbano E. Can treating depression improve disease outcomes? Ann Intern Med 2004; 140:1054.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/98\">",
"      Krishnan KR. Depression as a contributing factor in cerebrovascular disease. Am Heart J 2000; 140:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/99\">",
"      Rudisch B, Nemeroff CB. Epidemiology of comorbid coronary artery disease and depression. Biol Psychiatry 2003; 54:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/100\">",
"      Musselman DL, Betan E, Larsen H, Phillips LS. Relationship of depression to diabetes types 1 and 2: epidemiology, biology, and treatment. Biol Psychiatry 2003; 54:317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/101\">",
"      Carnethon MR, Biggs ML, Barzilay JI, et al. Longitudinal association between depressive symptoms and incident type 2 diabetes mellitus in older adults: the cardiovascular health study. Arch Intern Med 2007; 167:802.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/102\">",
"      Golden SH, Lazo M, Carnethon M, et al. Examining a bidirectional association between depressive symptoms and diabetes. JAMA 2008; 299:2751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/103\">",
"      Cui X, Lyness JM, Tu X, et al. Does depression precede or follow executive dysfunction? Outcomes in older primary care patients. Am J Psychiatry 2007; 164:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/104\">",
"      Steffens DC, Otey E, Alexopoulos GS, et al. Perspectives on depression, mild cognitive impairment, and cognitive decline. Arch Gen Psychiatry 2006; 63:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/105\">",
"      Singh-Manoux A, Akbaraly TN, Marmot M, et al. Persistent depressive symptoms and cognitive function in late midlife: the Whitehall II study. J Clin Psychiatry 2010; 71:1379.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/106\">",
"      Gallo JJ, Bogner HR, Morales KH, et al. Depression, cardiovascular disease, diabetes, and two-year mortality among older, primary-care patients. Am J Geriatr Psychiatry 2005; 13:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/107\">",
"      Chang CK, Hayes RD, Perera G, et al. Life expectancy at birth for people with serious mental illness and other major disorders from a secondary mental health care case register in London. PLoS One 2011; 6:e19590.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/108\">",
"      Angst F, Stassen HH, Clayton PJ, Angst J. Mortality of patients with mood disorders: follow-up over 34-38 years. J Affect Disord 2002; 68:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/109\">",
"      Carney RM, Freedland KE, Jaffe AS, et al. Depression as a risk factor for post-MI mortality. J Am Coll Cardiol 2004; 44:472; author reply 473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/110\">",
"      Frasure-Smith N, Lesp&eacute;rance F, Talajic M. Depression following myocardial infarction. Impact on 6-month survival. JAMA 1993; 270:1819.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/111\">",
"      Mykletun A, Bjerkeset O, Overland S, et al. Levels of anxiety and depression as predictors of mortality: the HUNT study. Br J Psychiatry 2009; 195:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/112\">",
"      Satin JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 2009; 115:5349.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/113\">",
"      Pan A, Lucas M, Sun Q, et al. Increased mortality risk in women with depression and diabetes mellitus. Arch Gen Psychiatry 2011; 68:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/114\">",
"      Carney RM, Freedland KE, Steinmeyer B, et al. Depression and five year survival following acute myocardial infarction: a prospective study. J Affect Disord 2008; 109:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/115\">",
"      Hawton K, van Heeringen K. Suicide. Lancet 2009; 373:1372.",
"     </a>",
"    </li>",
"    <li>",
"     Stolberg, RA, Clark, DC, Bongar, B. Epidemiology, assessment, and management of suicide in depressed patients. In: Handbook of Depression, Gotlib, IH, Hammen, CL (Eds), Guilford Press, New York 2002. p.581.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38201/abstract/117\">",
"      Conwell Y, Duberstein PR, Caine ED. Risk factors for suicide in later life. Biol Psychiatry 2002; 52:193.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14693 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-122.72.76.133-94E968098A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38201=[""].join("\n");
var outline_f37_19_38201=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H854807\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15701673\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25596061\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1384350\">",
"      Setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H856410\">",
"      MAJOR DEPRESSIVE DISORDER",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H98355615\">",
"      Diagnostic stability",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H856417\">",
"      Recovery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H858471\">",
"      - Chronic major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H856424\">",
"      Recurrence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H856431\">",
"      Course of illness over time",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1384471\">",
"      Functional outcomes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H111698911\">",
"      DYSTHYMIC DISORDER",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15701729\">",
"      MINOR DEPRESSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1385537\">",
"      MORBIDITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1385544\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1385552\">",
"      All cause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1385559\">",
"      Suicide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H854807\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H855980\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14693\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14693|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?20/9/20638\" title=\"figure 1\">",
"      Time to recovery from first unipolar major depressive episode",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?18/52/19278\" title=\"figure 2\">",
"      Time to recovery in patients with unipolar major depression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/59/7103\" title=\"figure 3\">",
"      Depressive episodes over five-years by age group",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?19/11/19639?source=related_link\">",
"      Bipolar disorder in adults: Epidemiology and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/21/25944?source=related_link\">",
"      Depression in schizophrenia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/37/39514?source=related_link\">",
"      Diagnosis and management of late-life depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/8/40074?source=related_link\">",
"      Initial treatment of depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/33/27161?source=related_link\">",
"      Mild cognitive impairment: Epidemiology, pathology, and clinical assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/60/40906?source=related_link\">",
"      Secondary prevention of cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/61/27609?source=related_link\">",
"      Treatment of resistant depression in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/38/37481?source=related_link\">",
"      Unipolar depression in adults: Epidemiology, pathogenesis, and neurobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8055?source=related_link\">",
"      Unipolar major depression with psychotic features: Maintenance treatment and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_19_38202="Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy";
var content_f37_19_38202=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Infusion reactions to therapeutic monoclonal antibodies used for cancer therapy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/19/38202/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38202/contributors\">",
"     Ann S LaCasce, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38202/contributors\">",
"     Mariana C Castells, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38202/contributors\">",
"     Harold Burstein, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38202/contributors\">",
"     Jeffrey A Meyerhardt, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/19/38202/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38202/contributors\">",
"     Reed E Drews, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38202/contributors\">",
"     N Franklin Adkinson, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?37/19/38202/contributors\">",
"     Deputy Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38202/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?37/19/38202/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?37/19/38202/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 22, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Humanized monoclonal antibodies (MoAbs) represent a significant addition to therapeutic armamentarium for a variety of malignancies. Many of the agents that are used for cancer therapy share a risk for infusion reactions, most of which occur with the first dose. Although the majority of reactions are mild and not life threatening, serious reactions can occur and may be fatal if not managed appropriately.",
"   </p>",
"   <p>",
"    After an introductory section summarizing the characteristics of infusion reactions and the general principles underlying prevention and treatment of these reactions, this review will discuss the reactions that occur with individual MoAbs used for cancer treatment and the prevention and management of these reactions. A discussion of infusion reactions to conventional cytotoxic agents is presented separately, as is a more in depth discussion of cutaneous adverse effects associated with both cytotoxic agents and the therapeutic MoAbs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link\">",
"     \"Infusion reactions to systemic chemotherapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=see_link\">",
"     \"Cutaneous complications of conventional chemotherapy agents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CHARACTERISTICS OF REACTIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Timing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion reactions to MoAbs typically develop within 30 minutes to two hours after the initiation of drug infusion, although symptoms may be delayed for up to 24 hours. The majority of reactions occur after the first or second exposure to the agent, but between 10 and 30 percent occur during subsequent treatments [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/1\">",
"     1",
"    </a>",
"    ]. In general, the likelihood of an infusion reaction declines with each subsequent course of therapy.",
"   </p>",
"   <p>",
"    The incidence of an infusion reaction during the first drug administration varies among individual agents and is highest for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    (over 50 percent each),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    (up to 40 percent), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    (up to 20 percent, depending on the geographic area of residence).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Signs and symptoms of infusion reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion reactions may affect any organ system in the body. Most are mild in severity, although severe and even fatal reactions occur. The most common signs and symptoms of infusion reactions are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Fever",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      shaking chills",
"     </li>",
"     <li>",
"      Flushing",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      itching",
"     </li>",
"     <li>",
"      Alterations in heart rate and blood pressure",
"     </li>",
"     <li>",
"      Dyspnea or chest discomfort",
"     </li>",
"     <li>",
"      Back or abdominal pain",
"     </li>",
"     <li>",
"      Nausea, vomiting,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      diarrhea",
"     </li>",
"     <li>",
"      Various types of skin rashes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In this review, infusion reactions involving these symptoms will be referred to as \"standard infusion reactions\" or SIRs. These represent the majority of reactions to MoAbs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Mechanisms of SIRs",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact mechanism responsible for SIRs caused by any of the MoAbs is unclear. Most reactions appear to be the result of antibody-antigen interactions resulting in cytokine release. The most predictable reaction occurs with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    and is thought to be caused by the interaction of the drug with the target antigen (CD20) on circulating cells, followed by cytokine release from lymphocytes. Evidence for this mechanism includes the observation that severe and fatal reactions have typically occurred in patients with high numbers of circulating lymphocytes bearing the target antigen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism underlying infusion reactions with therapeutic MoAbs might also be related to their ability to elicit human antichimeric antibodies (HACAs), human antihuman (HAHAs), or human antimouse (HAMAs) antibodies. However, a correlation between infusion reactions and HACAs or HAHAs has not been convincingly demonstrated for any drug. Furthermore, the development of antibodies to most of these drugs is far less common (one percent in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/3\">",
"     3",
"    </a>",
"    ]) than the incidence of infusion reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Rituximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Signs and symptoms of anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis is a reaction that is rare with most MoAbs and best described with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    . Anaphylaxis caused by intravenously administered medications most often presents with the following signs and symptoms:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cutaneous symptoms: flushing, itching, urticaria,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      angioedema (usually of face, eyelids, or lips)",
"     </li>",
"     <li>",
"      Respiratory symptoms: repetitive cough, sudden nasal congestion, shortness of breath, chest tightness, wheeze, sensation of throat closure or choking, and or change in voice quality (due to laryngeal edema)",
"     </li>",
"     <li>",
"      Cardiovascular symptoms: faintness, tachycardia (or less often bradycardia), tunnel vision, chest pain, hypotension, sense of impending doom,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      loss of consciousness",
"     </li>",
"     <li>",
"      Gastrointestinal symptoms: such as nausea, vomiting, abdominal cramping, and diarrhea",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Anaphylaxis from all causes is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The signs and symptoms of anaphylaxis overlap with those of SIRs, and the two can be indistinguishable. However, there are certain signs and symptoms that are highly suggestive of anaphylaxis, and their presence should be specifically sought when evaluating a patient with an infusion reaction: urticaria, repetitive cough, wheeze, and throat",
"    <span class=\"nowrap\">",
"     tightness/change",
"    </span>",
"    in voice. These stereotypical signs and symptoms result from the release of mediators from mast cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    basophils. In contrast, fever and muscular pain are not features of anaphylaxis, and the presence of these suggests the reaction is a SIR.",
"   </p>",
"   <p>",
"    It is critical to undress the patient and examine the skin carefully during infusion reactions in order to detect urticaria. The neck, trunk, abdomen, and axillae are the sites at which urticaria often appear first.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Definition and mechanism of anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylaxis was traditionally defined as a constellation of signs and symptoms that arose from an IgE-mediated allergic reaction which resulted in explosive release of vasoactive mediators from mast cells and basophils throughout the body. However, the definition of anaphylaxis has been expanded in recent years to include any reaction that leads to widespread activation of mast cells",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    basophils [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/5\">",
"     5",
"    </a>",
"    ]. This more inclusive definition emphasizes the common endpoint of mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    activation and the severity of the reactions that can result and places less importance on the mechanism by which the cells are activated. Diagnostic criteria for anaphylaxis (from any cause) have been proposed by the American Academy of Allergy, Asthma, and Immunology (",
"    <a class=\"graphic graphic_table graphicRef72225 \" href=\"mobipreview.htm?22/43/23228\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/6\">",
"     6",
"    </a>",
"    ]. In addition, clinicians should not equate anaphylaxis with anaphylactic shock, as the latter represents the severe end of a spectrum. The goal should be early recognition and appropriate management of anaphylaxis in its milder forms. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    All reactions with features of anaphylaxis should be considered potentially severe because of the tendency of anaphylaxis to recur and worsen with reexposure to the causative agent. As an example, a patient who develops limited urticaria and mild wheezing after receiving a medication should be presumed to have anaphylaxis and should not be considered a candidate for premedication and drug readministration at a slower rate of infusion. Instead, referral to an allergist",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    use of a desensitization protocol should be pursued. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Agents that can cause anaphylaxis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In this topic review, as mentioned previously, anaphylaxis will be referred to as such, and all other infusion reactions will be grouped under the term standard infusion reactions (SIRs).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Evaluation of anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Evidence that a reaction was anaphylaxis can be obtained from blood tests collected at the time of the reaction and from skin testing, a technique employed by allergy specialists to identify drugs which are capable of causing mast cell activation, especially through IgE-mediated immune mechanisms. These two diagnostic tools are discussed in this section.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum tests that support the diagnosis of anaphylaxis &mdash; Mast cells and basophils contain various chemical mediators that are transiently released into the circulation during anaphylaxis. Some of these are unique to these cell types and, if elevated, can help confirm that the reaction was anaphylaxis. The finding of an elevated tryptase level suggests that the reaction was anaphylaxis, rather than a severe SIR.",
"      <br/>",
"      <br/>",
"      The laboratory test that is most useful in this setting is a serum total tryptase level. Tryptase levels usually peak within three hours of the onset of symptoms, so blood should be drawn shortly after the reaction occurs. Blood can be collected in a standard red top tube and serum should be frozen if it cannot be assayed promptly. Tryptase in frozen serum is stable for up to one year.",
"      <br/>",
"      <br/>",
"      The upper limit of normal for serum total tryptase is 11.4",
"      <span class=\"nowrap\">",
"       ng/ml,",
"      </span>",
"      depending on the assay system. Elevations in anaphylaxis can range from marginally elevated to greater than 100",
"      <span class=\"nowrap\">",
"       ng/mL.",
"      </span>",
"      Any elevation in serum tryptase is consistent with anaphylaxis, although a normal tryptase level does not exclude anaphylaxis because tryptase elevations are not seen in all anaphylactic reactions. The interpretation of tryptase levels in anaphylaxis is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=see_link\">",
"       \"Laboratory tests to support the clinical diagnosis of anaphylaxis\"",
"      </a>",
"      .)",
"      <br/>",
"      <br/>",
"      If a patient's reaction was suggestive of anaphylaxis but tryptase levels were not elevated, skin testing may still be informative.",
"     </li>",
"     <li>",
"      Skin testing to evaluate anaphylaxis &mdash; Skin testing is a technique used by allergy specialists to determine if a drug is capable of activating mast cells in the skin and therefore potentially able to cause anaphylaxis if administered systemically.",
"      <br/>",
"      <br/>",
"      Skin testing for drug allergy is generally performed by",
"      <span class=\"nowrap\">",
"       allergy/immunology",
"      </span>",
"      specialists, who have specific training in the technique, proper interpretation of results, and management of the rare allergic reactions that occur in response to the testing itself. Despite this, a few oncology centers perform this testing and have acquired some experience with testing for specific drugs, although this is not a widespread practice. The technique of skin testing is discussed in detail separately. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=see_link\">",
"       \"Overview of skin testing for allergic disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Agents that can cause anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some MoAbs (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    ) are believed to cause true IgE-mediated anaphylaxis. The best characterized is cetuximab, which has been associated with immediate and severe bronchospasm and hypotension requiring epinephrine and admission to the intensive care unit despite premedication with antihistamines with or without a glucocorticoid. These reactions are much more prevalent in some areas of the southeastern US, and investigations into the reasons for this has revealed that patients living in these areas are more likely to have preexisting IgE antibodies that are specific for galactose-alpha-1,3 galactose, which is present on the Fab portion of the cetuximab heavy chain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H48\">",
"     'Cetuximab'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    MoAbs with a high frequency of infusion reactions on first exposure (eg",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) have been presumed to be non-IgE dependent because of the lack of prior exposure and the low immunogenicity of humanized MoAbs. However, the demonstration of preexisting IgE anti-polysaccharide antibodies in patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    reactions (discussed above) raises questions about whether similar mechanisms may underlie other MoAb-associated infusion reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     CLASSIFICATION OF INFUSION REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most recent version of the NCI Terminology Criteria for Adverse Events (CTCAE) for grading adverse reactions during chemotherapy administration has a scale for grading the severity of infusion reactions (",
"    <a class=\"graphic graphic_table graphicRef57843 \" href=\"mobipreview.htm?28/31/29179\">",
"     table 2",
"    </a>",
"    ), as well as separate grading scales for allergic reactions and anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While use of these separate grading scales may be useful for classifying the nature of an infusion reaction for research purposes, they are less useful for clinical care, since it may not be obvious if the patient is having an infusion reaction or an allergic reaction.",
"    <span class=\"nowrap\">",
"     Allergists/immunologists",
"    </span>",
"    have a different approach to classifying infusion reactions, which divides them into reactions with features of mast cell or basophil activation (signifying potential progression to anaphylaxis) and those without such features (ie, SIRs). The severity of the reaction is considered separately. This approach is intended to identify patients at risk for anaphylaxis on re-exposure, regardless of the severity of the initial reaction.",
"   </p>",
"   <p>",
"    Patients with even mild symptoms of mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    activation (eg, urticaria and dyspnea) must be treated with caution, because reexposure to the causative agent could result in a fulminant and severe anaphylaxis. One of the authors (MC) is aware of unpublished cases in which failure to recognize anaphylaxis and manage it appropriately led to fatalities upon reexposure to the causative drug, despite the premedications and reduced infusion rates that would have adequately managed most SIRs.",
"   </p>",
"   <p>",
"    Another criticism of the NCI Common Toxicity Criteria is the inclusion of fever as a possible sign of an allergic reaction, since fever is not a manifestation of mast",
"    <span class=\"nowrap\">",
"     cell/basophil",
"    </span>",
"    activation and the prominence of fever during an infusion reaction is more indicative of an SIR.",
"   </p>",
"   <p>",
"    Thus, oncology specialists should be familiar with the characteristics of anaphylactic reactions and manage these rare reactions differently from SIRs. We recommend that patients with even mild signs or symptoms of anaphylaxis not be reexposed to the causative agent until they have been evaluated by an allergy specialist with experience in drug allergy and desensitization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/9\">",
"     9",
"    </a>",
"    ]. In particular, these patients should NOT be considered candidates for additional premedication and an attempt at drug readministration using a slower rate of infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     USE OF PREMEDICATION TO PREVENT INFUSION REACTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premedication can help prevent",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    reduce the severity of infusion reactions, particularly SIRs. In contrast, anaphylaxis is generally not prevented by premedication, although the severity of the reaction may be reduced in some cases. Attempts to identify patients who are likely to develop infusion reactions have met with limited success.",
"   </p>",
"   <p>",
"    Pharmacologic prophylaxis with antihistamines and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , with or without glucocorticoids, is recommended for certain drugs that are associated with a high incidence of infusion reactions (ie,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    [in patients who reside in certain geographic areas]). However, these regimens have been empirically derived rather than established through randomized trials. Furthermore, they are not completely protective, even for SIRs. Therefore, despite the use of premedication, patients must be monitored closely during and immediately following all infusions.",
"   </p>",
"   <p>",
"    Because infusion reactions are most common during the first or second exposures, many clinicians eliminate premedication after the first two courses if there has not been a reaction. However, as noted above, between 10 and 30 percent of infusion reactions with these agents occur after the first two courses of therapy. In some institutions,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    , a sedating antihistamine, is replaced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    , a nonsedating antihistamine, in patients who do not experience an infusion reaction during the first drug infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES OF TREATMENT AND RECHALLENGE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinicians should be prepared for a reaction to occur during each drug administration, and standing orders should be in place to allow immediate intervention if an infusion reaction occurs, without waiting for the clinician to arrive [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/2\">",
"     2",
"    </a>",
"    ]. Medical equipment and supplies needed for resuscitation (pharmacologic agents such as epinephrine, antihistamines, intravenous fluids, and aerosolized bronchodilators as well as oxygen, intubation and tracheostomy equipment, and a defibrillator) should be readily available in any area where chemotherapy is administered.",
"   </p>",
"   <p>",
"    Treatment of an infusion reaction and possible rechallenge depend upon the type and severity or the reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Treatment of mild to moderate SIRs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate SIRs (ie, infusion reactions that do not involve symptoms of anaphylaxis) are the most commonly-encountered reactions. These can usually be managed with temporary interruption of the infusion and symptom management. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Characteristics of reactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Rechallenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;After all symptoms have resolved, rechallenge with a reduced infusion rate and additional premedication is often successful.",
"   </p>",
"   <p>",
"    For patients who have recurrent SIRs despite premedication, desensitization protocols have allowed for continued use of the drug in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/10\">",
"     10",
"    </a>",
"    ]. Referral to an allergy specialist with experience in drug desensitization is an option for such patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Treatment of severe SIRs and anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe (grade 3 or 4, (",
"    <a class=\"graphic graphic_table graphicRef57843 \" href=\"mobipreview.htm?28/31/29179\">",
"     table 2",
"    </a>",
"    )) reactions and reactions with ANY features of anaphylaxis require discontinuation of the drug infusion, and immediate treatment with epinephrine and antihistamines.",
"   </p>",
"   <p>",
"    Prompt recognition and treatment are critical in anaphylaxis. In series of fatal anaphylaxis from all causes, death typically ensues within 30 minutes from exposure to the trigger. Detailed guidelines for the management of anaphylaxis are available from the Joint Council of Allergy, Asthma, and Immunology, which are summarized in a rapid overview table for adults (",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"     table 3",
"    </a>",
"    ) and children (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The initial management of anaphylaxis includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Stop the infusion of the suspect medication",
"     </li>",
"     <li>",
"      Intramuscular injection of epinephrine&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Call for help (summon a resuscitation team in the hospital setting, call 911 or an equivalent service in the community setting)",
"     </li>",
"     <li>",
"      Placement of the patient in the supine position (if tolerated) to maintain blood flow to vital organs",
"     </li>",
"     <li>",
"      Supplemental oxygen",
"     </li>",
"     <li>",
"      Volume resuscitation",
"     </li>",
"     <li>",
"      Intravenous antihistamines (",
"      <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"       table 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"       table 4",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Rechallenge after a severe SIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following a severe SIR, rechallenge is usually discouraged. However, the decision depends on whether the risk for a serious recurrent reaction is felt to be outweighed by mitigating clinical factors (ie, the potential clinical benefit of further treatment and no other reasonable alternatives). Examples at either end of the spectrum might include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The benefits of continued drug treatment probably outweigh the risks of rechallenge for a woman receiving adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"       trastuzumab",
"      </a>",
"      for a HER2-positive early breast cancer",
"     </li>",
"     <li>",
"      In contrast, drug substitution rather than rechallenge would be more appropriate for a patient who develops an SIR while receiving",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      as a second-line agent for metastatic colorectal cancer",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If a patient is felt to be a candidate for continuation of therapy because of the potential for clinical benefit and no other reasonable alternatives exist, then rechallenge may be pursued. In most cases, the mechanism of severe SIRs is not known, and so it is difficult to predict the best technique for preventing recurrence. However, we suggest the use of a \"desensitization\" protocol, in which the drug is readministered in a highly controlled manner, in sequential steps of gradually increasing dose. At the author's institution (MC), these reactions are managed in the same manner as anaphylaxis, with uniformly good outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h3\">",
"     Management after anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rechallenge should not be attempted for suspected anaphylaxis. Instead, we suggest referral to an allergy specialist or an oncology center with experience in drug desensitization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although this is NOT recommended, there may be instances in which a patient with an apparent episode of anaphylaxis was rechallenged shortly after the reaction (eg, 30 minutes after symptoms have resolved) and appeared to tolerate the reinfusion. This situation can be misinterpreted as evidence that the reaction was not anaphylaxis or as an indication that the patient can receive additional courses safely in the future using standard administration. However, we urge caution in this situation. Mast cells and basophils, the cells involved in anaphylaxis, can be temporarily desensitized immediately after a reaction and may be unable to be activated further. However, the patient is at high risk for a recurrence of anaphylaxis as soon as the cells have recovered their sensitivity, a process which takes days to weeks. This phenomenon has probably contributed to the confusion that currently exists in the medical literature about the safety of rechallenge following a severe infusion reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     Overview of desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization is indicated for allergic infusion reactions that have features of anaphylaxis. The technique can also be applied to severe SIRs that recur despite slower rates of infusion and premedications. Important points regarding this technique include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Desensitization is absolutely contraindicated in patients with a history of an exfoliative dermatitis, Stevens-Johnson syndrome, or toxic epidermal necrolysis to a MoAb or other biologic modifier. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H12#H12\">",
"       \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Other effects'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Desensitization has no role in the management of other idiosyncratic immunologic reactions such as serum sickness, hemolytic anemia, or drug fever.",
"     </li>",
"     <li>",
"      Desensitization should only be carried out under close medical supervision by experienced individuals who are comfortable with emergency management of anaphylaxis. At some institutions, all desensitization protocols are performed by allergists.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drug desensitization protocols are based upon administering increasing doses of medication in a stepwise manner, such that exposure is continuous, begins at very low doses, and increases gradually. The protocols presented herein have been performed successfully in published reports, although modifications may be needed in individual cases and experience with the technique is essential. Clinicians should avoid altering successful protocols to render them faster or significantly change the time interval between doses.",
"   </p>",
"   <p>",
"    Drug desensitization induces a state of temporary tolerance that is dependent on continuous drug exposure. Once the drug is cleared from the system, the state of tolerance is lost. Therefore, patients must be carefully counseled that they remain allergic to the drug and must be desensitized for each subsequent administration. At some institutions, initial desensitizations are carried out in the medical intensive care unit. If the procedure is well tolerated, subsequent desensitizations are performed on standard hospital floors or in hospital-associated infusion units.",
"   </p>",
"   <p>",
"    Successful desensitizations to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/11,12\">",
"     11,12",
"    </a>",
"    ],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/13\">",
"     13",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    have been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/10\">",
"     10",
"    </a>",
"    ]. In theory, any patient with an IgE-dependent drug reaction can be successfully desensitized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     RITUXIMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     Rituximab",
"    </a>",
"    is a",
"    <span class=\"nowrap\">",
"     mouse/human",
"    </span>",
"    chimeric MoAb targeting the CD20 antigen. Dose and schedule of administration vary according to the indication. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9865?source=see_link\">",
"     \"Initial treatment of limited stage (I/II) follicular lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30442?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of relapsed or refractory chronic lymphocytic leukemia\", section on 'Rituximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=see_link\">",
"     \"Overview of biologic agents in the rheumatic diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One of the most predictable side effects of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    is a constellation of",
"    <span class=\"nowrap\">",
"     symptoms/signs",
"    </span>",
"    that occurs within the initial 30 to 120 minutes of the first exposure in over 50 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. The most common are headache, fever, chills, sweats, skin rash, dyspnea, mild hypotension, nausea, rhinitis, urticaria, pruritus, asthenia, and a sensation of tongue and throat swelling (angioedema) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/3,14,15\">",
"     3,14,15",
"    </a>",
"    ]. Bronchospasm",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    severe hypotension are present in less than 10 percent of cases, and fewer than 5 percent of reactions are severe (grade 3 or 4) or suggestive of anaphylaxis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In most patients, the reaction complex is brief and resolves completely when drug infusion is withheld. In a review of the experience in almost 300 patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    for lymphoma, the mean duration of infusion-related symptoms was less than one hour for chills, angioedema, and nausea, 1.5 hours for headache and hypotension, and approximately three hours for fever [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Infusion reactions are markedly less common after the initial infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/4\">",
"     4",
"    </a>",
"    ]. The manufacturer reports a frequency of 77, 30, and 14 percent during the first, fourth, and eighth infusions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , respectively.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Mechanism",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of these infusion reactions are thought to be related to an antibody-antigen interaction between",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    (the antibody) and CD20 (the antigen) on lymphocytes, resulting in cytokine release from these cells [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/14\">",
"     14",
"    </a>",
"    ]. Severe symptoms (pulmonary infiltrates, acute respiratory distress syndrome, myocardial infarction, ventricular fibrillation, cardiogenic shock, and even death) have typically occurred in patients with high numbers of circulating cells bearing the target antigen (eg, as in CLL), and underlying comorbid conditions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. Reactions such as these can be minimized by fractionating the rituximab dose over several days. (See",
"    <a class=\"local\" href=\"#H23\">",
"     'Dose fractionation'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Prophylaxis of infusion reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because of the high incidence of infusion reactions, it is standard practice to premedicate patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (650 mg orally) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (50 mg orally) 30 minutes before the first and second infusions; at some institutions, routine premedication also includes an H2-receptor blocker (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    50 mg IV). Standard premedications can be eliminated during subsequent infusions if reactions are not evident.",
"   </p>",
"   <p>",
"    Premedication with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    attenuates but does not prevent infusion reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/2\">",
"     2",
"    </a>",
"    ]. The addition of a single pretreatment dose of a glucocorticoid (which is typically given for emesis prophylaxis just prior to chemotherapy in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ) does not appear to further reduce the rate of severe reactions; in one report grade 3 or 4 infusion reactions (",
"    <a class=\"graphic graphic_table graphicRef57843 \" href=\"mobipreview.htm?28/31/29179\">",
"     table 2",
"    </a>",
"    ) still occurred in 10 percent of patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/17\">",
"     17",
"    </a>",
"    ]. There are no reports evaluating the efficacy of a more extensive approach to prophylaxis, such as the addition of a glucocorticoid beginning &ge;12 hours prior to treatment, as is used for taxanes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/2\">",
"     2",
"    </a>",
"    ]. However, we have used this approach successfully in several patients with severe recurrent reactions. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=see_link&amp;anchor=H32#H32\">",
"     \"Infusion reactions to systemic chemotherapy\", section on 'Taxanes'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Infusion rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high incidence of infusion reactions has also led to the general practice of starting the first dose slowly and gradually increasing the speed of infusion. The first infusion is usually administered over approximately four hours, with later infusions over less time in the absence of a reaction.",
"   </p>",
"   <p>",
"    The first",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    infusion is typically initiated at a rate of 50",
"    <span class=\"nowrap\">",
"     mg/hour;",
"    </span>",
"    in the absence of an infusion reaction, it is increased by 50",
"    <span class=\"nowrap\">",
"     mg/hour",
"    </span>",
"    every 30 minutes to a maximum of 400",
"    <span class=\"nowrap\">",
"     mg/hour.",
"    </span>",
"    Subsequent infusions can be started at a rate of 100",
"    <span class=\"nowrap\">",
"     mg/hour",
"    </span>",
"    if the initial infusion was well tolerated and the rate increased by 100",
"    <span class=\"nowrap\">",
"     mg/hour",
"    </span>",
"    every 30 minutes to a maximum of 400",
"    <span class=\"nowrap\">",
"     mg/hour",
"    </span>",
"    if there is no evidence of an infusion reaction.",
"   </p>",
"   <p>",
"    For patients receiving a concurrent chemotherapy regimen for which glucocorticoids are included for emesis prophylaxis, an accelerated infusion schedule may be used after the first dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/18\">",
"     18",
"    </a>",
"    ]. The first treatment is given according to the standard schedule, beginning at 50",
"    <span class=\"nowrap\">",
"     mg/hour,",
"    </span>",
"    and gradually increasing thereafter. All subsequent cycles of rituximab can be administered over 90 minutes, with 20 percent of the dose given in the first 30 minutes, and the remainder over the next 60 minutes. The safety of this approach was shown in the phase III RATE trial, in which 363 previously untreated patients with non-Hodgkin lymphoma (NHL) who did not experience a grade 3 or 4 infusion-related reaction to rituximab (in combination with one of two different chemotherapy regimens, CHOP versus CVP) during cycle 1 all received a faster infusion in cycle 2, and if well-tolerated, all subsequent cycles [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/19\">",
"     19",
"    </a>",
"    ]. Twenty percent of the total dose was administered in the first 30 minutes, and if tolerated, the remainder was administered over 60 minutes. The incidence of grade 3 infusion-related reactions during cycle 2 was 1.1 percent (95% CI 0.3-2.8). Based upon these results, the FDA approved a 90-minute infusion for rituximab starting at cycle 2 for patients with NHL who did not experience a grade 3 or 4 infusion-related adverse reaction during cycle 1. Patients with clinically significant cardiovascular disease and high circulating lymphocyte counts",
"    <span class=\"nowrap\">",
"     (&gt;5000/microL)",
"    </span>",
"    are not recommended to receive the faster infusion, even in the absence of a severe infusion reaction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h3\">",
"     Dose fractionation",
"    </span>",
"    &nbsp;&mdash;&nbsp;As noted above, the likelihood of an infusion reaction is higher in patients who have a very elevated white blood cell (WBC) count. Many protocols fractionate the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    dose during cycle one in all patients in order to minimize the potential for a serious adverse reaction, particularly if the patient has chronic lymphocytic leukemia (CLL) and a high WBC count. A typical administration schedule is 50",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    on day 1, followed by the remainder of the dose (325",
"    <span class=\"nowrap\">",
"     mg/m2)",
"    </span>",
"    on day 3. For patients whose WBC count is",
"    <span class=\"nowrap\">",
"     &gt;100,000/microL,",
"    </span>",
"    rituximab may be withheld for the first cycle of therapy. (See",
"    <a class=\"local\" href=\"#H20\">",
"     'Mechanism'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Management of SIRs and rechallenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop a non-life-threatening mild to moderate SIR can usually be managed by temporary discontinuation of drug infusion alone. Once all symptoms have resolved, most patients will tolerate a slower infusion rate (one-half the rate at which the reaction occurred) with additional antihistamines plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . If the infusion reaction does not recur, the infusion rate may then be increased by 50",
"    <span class=\"nowrap\">",
"     mg/hour",
"    </span>",
"    to the maximum of 400",
"    <span class=\"nowrap\">",
"     mg/hour.",
"    </span>",
"   </p>",
"   <p>",
"    If",
"    the reaction is severe, additional treatment, such as saline infusion, bronchodilators, oxygen, epinephrine, and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/49/32528?source=see_link\">",
"     hydrocortisone",
"    </a>",
"    may be required. In these cases, rechallenge on the same day is generally discouraged. For severe SIRs that do NOT have features of anaphylaxis, subsequent rechallenge is usually successful with an intensified premedication regimen (a glucocorticoid such as hydrocortisone 100 mg or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    12 mg plus H1- and H2- receptor blockers the night before and one hour prior to rechallenge) and splitting of the dose, as is typically done for CLL (eg, 50",
"    <span class=\"nowrap\">",
"     mg/m2",
"    </span>",
"    on day 1 and the remainder of the dose on day 3).",
"   </p>",
"   <p>",
"    For patients who have recurrent infusion reactions despite premedication, referral to an allergist for desensitization may allow for continued use of the drug in some cases [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H60\">",
"     'Desensitization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Management of anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with signs or symptoms of possible anaphylaxis should be referred to an allergist or an oncology center with experience in drug desensitization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/9\">",
"     9",
"    </a>",
"    ]. Successful desensitization protocols for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    have been published (",
"    <a class=\"graphic graphic_table graphicRef80597 \" href=\"mobipreview.htm?30/54/31598\">",
"     table 5",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H60\">",
"     'Desensitization'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Other reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other less common infusion reactions associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    include mucocutaneous reactions (Stevens-Johnson syndrome, vesiculobullous dermatitis, and toxic epidermal necrolysis), which typically present 1 to 13 weeks after therapy. Patients who develop these exfoliative reactions should never be reexposed to the drug because of the risk of a fatal recurrence. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Serum sickness (a delayed type III allergic reaction, (",
"    <a class=\"graphic graphic_table graphicRef71375 \" href=\"mobipreview.htm?13/23/13692\">",
"     table 6",
"    </a>",
"    )) has been reported with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/20-22\">",
"     20-22",
"    </a>",
"    ]. Patients generally respond to pulse",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"     methylprednisolone",
"    </a>",
"    therapy with resolution of symptoms within 48 hours. In one case, antibodies to the mouse F(ab')(2) fragments of rituximab were identified. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=see_link\">",
"     \"Serum sickness and serum sickness-like reactions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over 50 percent of first infusions of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    are accompanied by an infusion reaction. Pretreatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    with or without glucocorticoids and an H2-receptor blocker attenuates but does not prevent these reactions. Severe reactions are most likely in patients with high circulating levels of tumor cells (particularly in CLL and mantle cell lymphoma); in these cases, fractionation of the rituximab dose is recommended in addition to premedication. For patients whose WBC count is",
"    <span class=\"nowrap\">",
"     &gt;100,000/microL,",
"    </span>",
"    rituximab may be withheld for the first cycle of therapy.",
"   </p>",
"   <p>",
"    Most reactions are mild to moderate in severity and consist of a constellation of flu-like symptoms (see",
"    <a class=\"local\" href=\"#H2\">",
"     'Characteristics of reactions'",
"    </a>",
"    above). Symptoms usually resolve with temporary withholding of the drug, and treatment can usually be resumed with additional premedication and a lower infusion rate. In the absence of a recurrent infusion reaction, premedication can be discontinued after the first two courses because the incidence of infusion reactions is lower in later cycles.",
"   </p>",
"   <p>",
"    More severe symptoms, as may be seen in patients with initially high peripheral WBC counts, necessitate more aggressive initial management. Once symptoms have resolved, rechallenge is usually possible with an intensified premedication regimen and fractionation of the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    dose over several days, as long as there are no signs or symptoms suggestive of anaphylaxis (ie, urticaria, angioedema, hypotension, or severe respiratory distress).",
"   </p>",
"   <p>",
"    Anaphylaxis is uncommon following",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    administration, although it has been reported. If anaphylaxis is suspected and there is no reasonable alternative agent, the patient should be referred to an allergy specialist with experience in drug desensitization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Other anti-CD20 monoclonal antibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;90-Yttrium-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/30/40422?source=see_link\">",
"     ibritumomab",
"    </a>",
"    tiuxetan (90Y-ibritumomab, Zevalin) and 131-Iodine-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/45/29398?source=see_link\">",
"     tositumomab",
"    </a>",
"    (131I-tositumomab, Bexxar) are radioimmunoconjugates in which a murine MoAb against CD20 is conjugated to a radioisotope. Both are used for the treatment of relapsed indolent lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7338?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of relapsed or refractory follicular lymphoma\", section on 'Radioimmunotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h3\">",
"     Ibritumomab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Potentially fatal infusion reactions with features of anaphylaxis (angioedema, bronchospasm, hypotension, hypoxia) have been reported with 90Y-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/30/40422?source=see_link\">",
"     ibritumomab",
"    </a>",
"    . Most of these occur during or within 30 to 120 minutes after the first infusion.",
"   </p>",
"   <p>",
"    The manufacturer recommends that patients be screened for human antimouse antibodies (HAMA) because they may be at increased risk of allergic or serious hypersensitivity reactions. However, the number of patients who develop HAMA after receiving an initial dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?39/30/40422?source=see_link\">",
"     ibritumomab",
"    </a>",
"    is low (2 percent in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/23\">",
"     23",
"    </a>",
"    ]), and there is no evidence that the presence of HAMA identifies patients at an increased risk for an infusion reaction. Known type I hypersensitivity or anaphylactic reactions to yttrium chloride, murine proteins, or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    are contraindications to treatment with ibritumomab. Patients should be referred to an allergist with experience in drug desensitization if the use of this agent is desired in a high-risk patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Treatment is generally given in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    , for which it is standard practice to premedicate patients with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (650 mg orally) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (50 mg orally) before the first and second infusions; at some institutions, routine premedication also includes an H2-receptor blocker (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    50 mg IV).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Tositumomab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion-related reactions are seen in 26 percent of patients treated with 131I-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/45/29398?source=see_link\">",
"     tositumomab",
"    </a>",
"    ; some are severe and fatalities are reported. Symptoms include chills, fever, hypotension, dyspnea, bronchospasm, nausea, and diaphoresis. The manufacturer suggests that patients should be screened for human antimouse antibodies (HAMA); if present, the individual may be at increased risk for serious infusion reactions.",
"   </p>",
"   <p>",
"    The manufacturer suggests routine premedication with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    prior to each dose. The rate of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/45/29398?source=see_link\">",
"     tositumomab",
"    </a>",
"    or 131I-tositumomab infusion should be decreased by 50 percent for mild-to-moderate infusion-related toxicities; once symptoms have resolved, infusion may be restarted at one-half the previous rate, with additional premedication.",
"   </p>",
"   <p>",
"    Treatment should be interrupted for severe SIRs or any symptoms of anaphylaxis. These patients should be referred to an allergist or an oncology center with experience in drug desensitization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h1\">",
"     TRASTUZUMAB AND OTHER HER2-TARGETED THERAPIES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H430532248\">",
"    <span class=\"h2\">",
"     Trastuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    is a humanized MoAb that binds to the extracellular domain of the human epidermal growth factor receptor 2 protein (HER2); it mediates antibody-dependent cellular cytotoxicity against cells that overexpress this protein. Trastuzumab is an important agent for the treatment of HER2-overexpressing metastatic breast cancer and for adjuvant treatment of high-risk HER2-overexpressing primary breast cancer. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=see_link\">",
"     \"Adjuvant medical therapy for HER2-positive breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11705?source=see_link\">",
"     \"Systemic treatment for metastatic breast cancer: Combination chemotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     Trastuzumab",
"    </a>",
"    treatment is usually initiated with a loading dose of 4",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    followed by 2",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    weekly, although some data support the safety and efficacy of every three week dosing (loading dose 8",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    followed by 6",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    IV every three weeks) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/24\">",
"     24",
"    </a>",
"    ]. The first dose is generally administered over 90 to 120 minutes, with subsequent infusions shortened to 30 to 45 minutes if no reactions occur.",
"   </p>",
"   <p>",
"    In general, infusion reactions are less frequent and less severe than with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    . Between 20 and 40 percent of women have an infusion reaction during the initial infusion. Somewhat higher rates (47 to 62 percent) are reported with combinations of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    and cytotoxic agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/25,26\">",
"     25,26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The most common symptoms are fever, chills, nausea, headache, abdominal pain, and dyspnea; less often vomiting, dizziness, rash, rhinitis, or hypotension. Most infusion reactions are mild and they begin shortly after the initiation of drug infusion [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Only a small percentage of reactions that develop during the first infusion are serious [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/26,29\">",
"     26,29",
"    </a>",
"    ]. In a summary of the postmarketing experience with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    in over 25,000 women with metastatic breast cancer, only 0.3 percent of patients had infusion reactions that were described as serious and had features of anaphylaxis (bronchospasm, hypotension, angioedema) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most clinicians do not routinely premedicate prior to the first",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    dose. However, patients may be instructed to self-administer",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    or a nonsteroidal antiinflammatory drug (NSAID) if flu-like symptoms develop in the first 24 hours after drug administration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Management and rechallenge",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h4\">",
"     Mild to moderate symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most mild to moderate SIRs are resolved by simply slowing the infusion rate. In some cases, temporary discontinuation of drug infusion with symptomatic treatment (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    ) is needed for persistent mild to moderate symptoms.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     Meperidine",
"    </a>",
"    is rarely indicated for",
"    <span class=\"nowrap\">",
"     chills/rigors.",
"    </span>",
"   </p>",
"   <p>",
"    Once",
"    symptoms resolve, retreatment is usually possible. Fever and chills generally do not recur with subsequent infusions; in one study, they were present in 40 and 3 percent of initial versus subsequent infusions, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/27\">",
"     27",
"    </a>",
"    ]. Despite the unclear benefit of pretreatment (and the markedly lower risk of an infusion reaction for the second and subsequent doses), many clinicians use",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    pretreatment as well as a slower infusion rate for the second infusion if there was a reaction to the first exposure, eliminating pretreatment for subsequent treatments if the drug is well tolerated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h4\">",
"     More severe reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The FDA-approved package labeling suggests interruption of the infusion for any patient who develops dyspnea, clinically significant hypotension. A severe SIR does not preclude rechallenge, provided there are no symptoms to suggest anaphylaxis. A rechallenge might be considered after complete resolution of symptoms if the risk for a serious recurrent reaction is felt to be outweighed by mitigating clinical factors (ie, the potential clinical benefit of further treatment and the lack of other reasonable alternatives). In such cases, premedication with both an H1 and H2 histamine receptor blocker (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"     ranitidine",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?0/45/728?source=see_link\">",
"     famotidine",
"    </a>",
"    ) and a glucocorticoid is generally recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H36\">",
"    <span class=\"h4\">",
"     Management of anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Drug infusion should be stopped immediately in patients who have signs of anaphylaxis such as urticaria, angioedema, hypotension, or severe respiratory distress. These patients should be treated for anaphylaxis.",
"   </p>",
"   <p>",
"    Rapid desensitization protocols have been developed for patients in whom continued",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    treatment is limited by recurrent infusion reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. However, experience with this regimen is limited to a small number of patients. Referral to an allergy specialist with experience in drug desensitization is recommended for patients with persistent reactions despite premedication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H351179237\">",
"    <span class=\"h2\">",
"     Trastuzumab emtansine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/16/11527?source=see_link\">",
"     Trastuzumab emtansine",
"    </a>",
"    (also known as T-DM1) is an antibody-drug conjugate composed of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , a thioether linker, and DM1, a derivative of the antimitotic agent, maytansine. It is approved for advanced breast cancer in patients previously exposed to trastuzumab and taxanes. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22202?source=see_link&amp;anchor=H720673240#H720673240\">",
"     \"Systemic treatment for metastatic breast cancer: Molecular targeted therapy\", section on 'Ado-trastuzumab emtansine'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In contrast to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , infusion-related adverse events occur rarely and are typically grade 1 or 2. Symptoms have included flushing, chills, fever, dyspnea, hypotension, wheezing, bronchospasm, and tachycardia; only one case of a serious",
"    <span class=\"nowrap\">",
"     allergic/anaphylactic-like",
"    </span>",
"    reaction has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine premedication is not indicated. The FDA-approved manufacturer&rsquo;s drug information suggests slowing or interrupting the infusion if an infusion reaction is suspected, and discontinuing therapy permanently for life-threatening infusion-related reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H430532295\">",
"    <span class=\"h2\">",
"     Pertuzumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/61/25557?source=see_link\">",
"     Pertuzumab",
"    </a>",
"    is a monoclonal antibody that binds a different epitope of the HER2 extracellular domain than",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , and prevents HER2 homo- and heterodimerization with other HER-family receptors. It is typically used in combination with trastuzumab.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?24/61/25557?source=see_link\">",
"     Pertuzumab",
"    </a>",
"    has been associated with infusion and hypersensitivity reactions. In a randomized trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/59/41913?source=see_link\">",
"     docetaxel",
"    </a>",
"    plus either pertuzumab or placebo conducted in 808 patients with HER2-positive breast cancer, the initial dose of pertuzumab or placebo was administered the day before trastuzumab and docetaxel to assess the frequency and severity of pertuzumab-associated infusion reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/31\">",
"     31",
"    </a>",
"    ]. The overall frequency of infusion reactions with pertuzumab was 13 percent (versus 9.8 percent with placebo); most reactions were mild, and fewer than 1 percent were grade 3 or 4. The most common symptoms were pyrexia, chills, fatigue, headache, asthenia, hypersensitivity, and vomiting. The overall frequency of",
"    <span class=\"nowrap\">",
"     infusion/hypersensitivity",
"    </span>",
"    reactions throughout the trial was 10.8 versus 9.1 percent in the pertuzumab and placebo groups, respectively, and four patients experienced anaphylaxis with pertuzumab (versus two in the placebo group). &nbsp;",
"   </p>",
"   <p>",
"    Routine premedication is not indicated. The US FDA-approved labeling information suggests that patients be observed closely for 60 minutes after the first infusion and for at least 30 minutes after subsequent infusions. If a significant infusion-associated reaction occurs, slow or interrupt the infusion and administer appropriate medical therapies. Consider permanent discontinuation in patients with severe infusion reactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H40\">",
"    <span class=\"h1\">",
"     ALEMTUZUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     Alemtuzumab",
"    </a>",
"    (Campath) is a recombinant humanized MoAb directed against the CD52 antigen, which is found on the surface of most T and B lymphocytes. It is used for treatment of CLL and some lymphomas and is increasingly being used in nonmalignant conditions such as rheumatologic disorders and solid organ transplants. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    Infusion reactions associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    are frequent because T lymphocytes are so rich in cytokines and normal CD52+ T cells are more numerous than normal B cells. Infusion-related symptoms occur in the majority of patients despite premedication, and include rigors, hypotension, fever, fatigue, dyspnea, rash, urticaria, and pruritus. Most of the data on infusion reactions are derived from a clinical trial of 93 patients with CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/32\">",
"     32",
"    </a>",
"    ]. All of these reactions were most common in the first week of therapy and declined with continued administration:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Rigors &mdash; 90 percent (41 percent grade 3)",
"     </li>",
"     <li>",
"      Fever &mdash; 85 percent (20 percent grade 3 or 4)",
"     </li>",
"     <li>",
"      Rash &mdash; 33 percent (all grade 1 or 2)",
"     </li>",
"     <li>",
"      Nausea &mdash; 54 percent",
"     </li>",
"     <li>",
"      Vomiting &mdash; 38 percent",
"     </li>",
"     <li>",
"      Dyspnea &mdash; 28 percent",
"     </li>",
"     <li>",
"      Hypotension &mdash; 17 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H41\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;Premedication with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    (50 mg orally) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (650 mg orally) 30 minutes prior to dosing is recommended by the manufacturer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H42\">",
"    <span class=\"h3\">",
"     IV infusion rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gradual escalation to the recommended maintenance dose, usually over three to seven days, is required at initiation and after interruption of therapy for &ge;7 days to minimize infusion-related reactions. In patients with CLL,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    is sometimes administered IV, with the initial dose (3 mg) given over two hours on the first day. Subsequent doses are increased to 10 mg daily then to the final maintenance dose of 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    three times per week every other day, as tolerated. Most clinicians administer the first three infusions over two hours until most of the B and T lymphocytes have been eliminated from the circulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H43\">",
"    <span class=\"h3\">",
"     Subcutaneous administration",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subcutaneous administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    is associated with a less frequent, milder initial systemic reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Because of sustained blood levels, infusion reactions do not recur with the same or higher intensity with subsequent doses, as often happens with the slow dose escalations from 3 to 30 mg during the first week of IV therapy. Another advantage is that the entire dose can be given safely from the outset of therapy, without the need for a gradual dose escalation.",
"   </p>",
"   <p>",
"    However, the subcutaneous route of administration is associated with a high frequency of local site reactions (pain and erythema) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/34\">",
"     34",
"    </a>",
"    ]. Cold packs applied to the injection sites help to reduce the inflammation.",
"   </p>",
"   <p>",
"    The best data on the incidence, type, and severity of both systemic and local infusion reactions with subcutaneous",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    come from a phase II trial in 20 patients with CLL [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/34\">",
"     34",
"    </a>",
"    ]. All patients received alemtuzumab 30 mg SC in one thigh and 3 mg SC in the contralateral thigh for dose 1, followed by a total dose 30 mg three times weekly SC as a single injection into the same thigh for up to 12 weeks. The first dose of 30 mg produced an injection site reaction in",
"    <span class=\"nowrap\">",
"     13/20",
"    </span>",
"    (65 percent); all were mild (grade 1 or 2). There was a mild local reaction in 10 patients after the second dose, in one patient after the third dose, and in none after the fifth dose. &nbsp;Mild flu-like symptoms (rigor, fever, urticarial rash, fatigue, headache) occurred during week one in 10 of 20 patients, the majority after the first day of treatment. None recurred after repeated dosing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H44\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who develop severe mild to moderate or severe SIRs can usually be retreated after premedication with glucocorticoids (which may be administered as a component of the antiemetic regimen) with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?11/44/11976?source=see_link\">",
"     meperidine",
"    </a>",
"    in addition to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    . Patients with reactions suggestive of anaphylaxis should not be rechallenged but instead referred to an allergist with experience in drug desensitization [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H45\">",
"    <span class=\"h1\">",
"     OFATUMUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/13/35029?source=see_link\">",
"     Ofatumumab",
"    </a>",
"    is a fully human anti-CD20 monoclonal antibody that is used for relapsed CLL. Treatment is administered weekly for seven weeks (initial dose 300 mg, and each subsequent dose 2000 mg), followed by a four week rest, then 2000 mg weekly for four weeks.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/13/35029?source=see_link\">",
"     Ofatumumab",
"    </a>",
"    is associated with a high frequency of infusion reactions during the first two weekly doses, despite premedication with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    and an antihistamine prior to each dose, and an intravenous glucocorticoid (equivalent to 50 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    ) 30 to 60 minutes before the first and second doses [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. In a summary of unpublished data from a phase II trial of 154 patients receiving ofatumumab for CLL, infusion reactions occurred in 44 percent on the day of the first infusion (300 mg), and in 29 percent of the day of the second infusion (2000 mg) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/36\">",
"     36",
"    </a>",
"    ]. Reactions were less frequent and less severe during subsequent cycles.",
"   </p>",
"   <p>",
"    The most common symptoms were transient rigors, pyrexia, fatigue, rash, and increased sweating. Reactions usually occurred within the first few hours after starting the infusion and were categorized as mild; only two patients had grade 3 or 4 (severe) pyrexia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/8\">",
"     8",
"    </a>",
"    ]. Other reported manifestations of an infusion reaction included bronchospasm, dyspnea, laryngeal and pulmonary edema, hypertension and hypotension, syncope, back pain, urticaria and angioedema [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H46\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;The manufacturer recommends premedication prior to each dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/13/35029?source=see_link\">",
"     ofatumumab",
"    </a>",
"    with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    1000 mg and an oral or intravenous antihistamine. They also recommend intravenous glucocorticoid (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/48/33536?source=see_link\">",
"     prednisolone",
"    </a>",
"    100 mg or its equivalent) for doses 1, 2, and 9, with a gradual reduction in the glucocorticoid dose for infusions 3 through 8 and 10 through 12 in the absence of a grade 3 or worse reaction during the prior infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H47\">",
"    <span class=\"h2\">",
"     Management",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients who develop a reaction during treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/13/35029?source=see_link\">",
"     ofatumumab",
"    </a>",
"    , the infusion should be interrupted. The following guidelines for resuming treatment are available from the manufacturer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/36\">",
"     36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade 4&nbsp;(",
"      <a class=\"graphic graphic_table graphicRef57843 \" href=\"mobipreview.htm?28/31/29179\">",
"       table 2",
"      </a>",
"      )&nbsp;reaction - Discontinue permanently",
"     </li>",
"     <li>",
"      Grade 1, 2, or 3 reaction - Resume if the reaction resolves or remains no worse than grade 2 with the following modifications based on the initial grade of the reaction:",
"     </li>",
"     <li>",
"      Grade 1 or 2 - Infuse at one-half the prior infusion rate",
"     </li>",
"     <li>",
"      Grade 3 - Infuse at a rate of 12",
"      <span class=\"nowrap\">",
"       mL/hour",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H48\">",
"    <span class=\"h1\">",
"     CETUXIMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     Cetuximab",
"    </a>",
"    is a",
"    <span class=\"nowrap\">",
"     human/mouse",
"    </span>",
"    chimeric antibody directed against the epidermal growth factor receptor (EGFR). It is composed of the Fc regions of a murine anti-EGFR antibody with human IgG1 heavy and kappa light chain constant regions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/37\">",
"     37",
"    </a>",
"    ]. Infusion reactions can occur in up to 25 percent of patients, but only 3 to 4 percent are severe.",
"   </p>",
"   <p>",
"    Grade 1 (transient flushing or rash, no fever) or 2 (flushing, urticaria, rash, and fever to &ge;100.4 degrees F) reactions occur in approximately 20 percent of patients, typically during the first exposure, although they can occur during subsequent doses. Severe reactions (grade 3 or 4) are characterized by the rapid onset of bronchospasm, stridor, hoarseness, nausea and vomiting, urticaria,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypotension. These symptoms are consistent with anaphylaxis. Ninety percent occur with the first dose, although some occur after several doses, underscoring the need to monitor patients for one hour after each drug infusion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H49\">",
"    <span class=\"h2\">",
"     Incidence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence of infusion reactions has been variable in different geographic areas. In Europe, rates of severe grade 3 or 4 infusion reactions in two trials of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    in patients with metastatic colorectal cancer were 2.5 and 3.5 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H56#H56\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Cetuximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Markedly higher rates have been reported in the middle southeastern region of the United States (North Carolina, Arkansas, Missouri, Virginia, Florida, and Tennessee), where the incidence of severe (grade 3 or 4) reactions with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    was over 20 percent (",
"    <a class=\"graphic graphic_table graphicRef57843 \" href=\"mobipreview.htm?28/31/29179\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/40\">",
"     40",
"    </a>",
"    ]. All of the observed reactions occurred during the first 30 minutes of the first dose of cetuximab. Patients with a history of allergic disorders (asthma, drug reactions, etc) were significantly more likely to experience a severe infusion reaction (29 versus 8 percent for those with no history of atopy).",
"   </p>",
"   <p>",
"    There is evidence that a significant proportion of these severe infusion reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , although probably not all [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/41,42\">",
"     41,42",
"    </a>",
"    ], are caused by IgE-mediated anaphylaxis. In a series of patients living in the southeast US who experienced severe reactions to cetuximab,",
"    <span class=\"nowrap\">",
"     17/25",
"    </span>",
"    were found to have IgE antibodies in pre-treatment serum that were specific for galactose-alpha-1,3 galactose, an oligosaccharide present on the Fab portion of the cetuximab heavy chain [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/7\">",
"     7",
"    </a>",
"    ]. In contrast, only 1 of 51 patients who tolerated cetuximab had these antibodies. Tests for IgE specific to this allergen are commercially available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/43,44\">",
"     43,44",
"    </a>",
"    ]. There is some evidence to suggest that patients develop IgE antibodies to galactose-alpha-1,3 galactose as a result of tick bites, as the distribution of patients with cetuximab reactions is similar to that of the Lone Star species of tick found in the southeastern US, and many patients have reported reactions following a series of tick bites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/45\">",
"     45",
"    </a>",
"    ]. The same allergen is also found in meats, and some patients with cetuximab reactions report allergic reactions to meat ingestion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36072?source=see_link&amp;anchor=H8#H8\">",
"     \"Allergy to meats\", section on 'Meats and monoclonal antibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Not all anti-EGFR MoAbs contain galactose-alpha-1,3 galactose. The presence of this oligosaccharide is related to the production of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    in a murine cell line.",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     Panitumumab",
"    </a>",
"    , a fully humanized monoclonal antibody against EGFR, is produced using different cell culture techniques and does not contain galactose-alpha-1,3 galactose, a fact that may explain the lack of cross reactivity between these two agents and the lower rate of severe infusion reactions with panitumumab. (See",
"    <a class=\"local\" href=\"#H52\">",
"     'Panitumumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H50\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is currently no reliable method of detecting patients at risk for IgE-mediated allergic reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    . Skin testing patients with cetuximab before initial administration has not been demonstrated to reliably identify patients who will have a severe reaction [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/46\">",
"     46",
"    </a>",
"    ]. An immunoassay for the presence of IgE antibodies to cetuximab has been developed, but it is available from only a small number of commercial laboratories [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/47\">",
"     47",
"    </a>",
"    ] and had a positive predictive value of only about 30 percent for identifying patients with moderate to severe reactions cetuximab in one study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One option for patients in high-risk areas is to begin the drug infusion at a lower rate initially (eg, 2.5 to 3",
"    <span class=\"nowrap\">",
"     mL/minute)",
"    </span>",
"    under close observation by an advanced practitioner (clinician, clinician assistant, nurse practitioner) familiar with the immediate management of anaphylaxis and physically present during at least the first 30 minutes of the initial infusion. In addition, the patient could be questioned in advance about characteristics that have been identified as possible risk factors for reactions to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    . These are:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A history of other allergic disorders (medication or food allergies, venom allergy, asthma, atopic dermatitis, or allergic rhinitis) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/40\">",
"       40",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Allergic reactions within a few hours of eating beef, pork, or lamb [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/7\">",
"       7",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Local reactions to tick bites lasting for weeks or longer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/45\">",
"       45",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    We would suggest that patients with any of these possible risk factors be observed especially closely during their first exposure to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , particularly in high-risk areas. Although these approaches may not eliminate reactions in highly sensitized patients who react to low doses of the drug, close observation will ensure that the infusion is stopped at the earliest sign of allergic symptoms. In the absence of a reaction during the initial 30 minutes, the rate of infusion could be increased and the remainder of the dose administered over 90 minutes.",
"   </p>",
"   <p>",
"    The US FDA-approved manufacturer&rsquo;s package insert recommends premedication with an H1 antagonist 30 to 60 minutes prior to the first dose. The benefit of glucocorticoid premedication, in addition to an antihistamine, was suggested by the MABEL (Monoclonal Antibody Erbitux in A European Pre-Licensure) registry database of over 1000 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    for metastatic colorectal cancer [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/49\">",
"     49",
"    </a>",
"    ]. Cetuximab-related infusion reactions were recorded in 16 percent of the population. Rates of any infusion reaction were significantly lower among those pretreated with an antihistamine plus a glucocorticoid as compared to an antihistamine alone (9.6 versus 26 percent) and for grade 3 or 4 reactions (1 versus 4.7 percent).",
"   </p>",
"   <p>",
"    An important point is that premedication would not be expected to prevent true IgE-mediated anaphylaxis, so clinicians must remain vigilant for signs of this type of reaction. (See",
"    <a class=\"local\" href=\"#H6\">",
"     'Signs and symptoms of anaphylaxis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In practice, most patients receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    are also receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    , for which premedication with both a glucocorticoid and antihistamine is recommended. For patients receiving cetuximab alone, pretreatment with an antihistamine alone is acceptable, although the addition of a glucocorticoid (with or without a H2 receptor antagonist) is reasonable for those living in high-incidence areas. (See",
"    <a class=\"local\" href=\"#H49\">",
"     'Incidence'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Patients should be monitored for at least one hour following completion of infusion or longer if a reaction occurs.",
"   </p>",
"   <p>",
"    Following the initial dose, premedication with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    is optional and should be based on clinical judgment. In some institutions, diphenhydramine is replaced by",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/39/7799?source=see_link\">",
"     loratadine",
"    </a>",
"    , a nonsedating antihistamine, if there is no reaction during the first infusion of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As an alternative to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    , patients in high-risk areas have been preferentially treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    rather than cetuximab. Both MoAbs appear to be therapeutically interchangeable. There are data supporting the use of panitumumab in combination chemotherapy regimens, but no data directly comparing panitumumab versus cetuximab in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H38#H38\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Are cetuximab and panitumumab interchangeable?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H51\">",
"    <span class=\"h2\">",
"     Management and rechallenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mild to moderate infusion reactions without features of anaphylaxis may be managed by temporarily halting the drug infusion and additional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    . Most patients will tolerate readministration using a slower infusion rate (2.5",
"    <span class=\"nowrap\">",
"     mL/minute)",
"    </span>",
"    with additional premedication after all symptoms have resolved. Patients should be observed for one hour after the end of each infusion.",
"   </p>",
"   <p>",
"    In the case of a severe SIRs or anaphylaxis, drug infusion should be discontinued immediately. Appropriate medical therapy during the reaction includes epinephrine, IV fluids, IV antihistamines, glucocorticoids, and if needed, bronchodilators and oxygen&nbsp;(",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"     table 3",
"    </a>",
"    ). Patients should be carefully observed until the resolution of all symptoms and signs.",
"   </p>",
"   <p>",
"    The manufacturer recommends that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    be permanently discontinued if there is a severe infusion reaction. Although the addition of steroids may not block the anaphylactic reaction, at least three case reports note successful retreatment with glucocorticoid premedication and close monitoring in an intensive care unit setting [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. In addition, successful desensitization to cetuximab has been reported and a protocol is available [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/52\">",
"     52",
"    </a>",
"    ]. Therefore, management of a patient with suspected cetuximab anaphylaxis depends upon the expertise and resources available to the supervising clinician.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     Panitumumab",
"    </a>",
"    , another MoAb directed against the EGFR, has comparable antitumor efficacy and a lack of cross-reactivity with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    . Patients with a severe infusion reaction or anaphylaxis to cetuximab can be safely be switched to panitumumab. There are data supporting the use of panitumumab in combination chemotherapy regimens, but no data directly comparing panitumumab versus cetuximab in this setting. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=see_link&amp;anchor=H38#H38\">",
"     \"Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations\", section on 'Are cetuximab and panitumumab interchangeable?'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H52\">",
"    <span class=\"h1\">",
"     PANITUMUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     Panitumumab",
"    </a>",
"    is a MoAb directed against the EGFR that is produced using a different cell culture technique than that for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    . It is a fully human IgG2 MoAb. Since it contains no murine component, it was predicted to cause fewer infusion reactions. As noted above, the significantly lower incidence of infusion reactions with panitumumab compared to cetuximab may also be related to the absence of galactose 1,3-alpha galactose on the Fab fragment. (See",
"    <a class=\"local\" href=\"#H48\">",
"     'Cetuximab'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    In single agent treatment trials and during postmarketing surveillance, the rate of any infusion reaction was 4 percent, and 1 percent were severe (anaphylaxis, bronchospasm, fever, chills, hypotension, some fatal) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/53-55\">",
"     53-55",
"    </a>",
"    ]. However, in light of this low rate of infusion reactions, routine premedication is not recommended prior to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    infusion. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=see_link&amp;anchor=H62#H62\">",
"     \"Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials\", section on 'Panitumumab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients who develop a grade 1 or 2 infusion reaction without symptoms of anaphylaxis should have the drug temporarily withheld, and after symptoms have resolved, restarted at 50 percent of the infusion rate. Permanent discontinuation of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    is recommended in the setting of anaphylaxis or a grade 3 or 4 reaction. Due to the rarity of such reactions, there are no data on rechallenge or desensitization. However, successful treatment with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    has been reported [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is one unpublished report of delayed-onset angioedema occurring several days after a third",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"     panitumumab",
"    </a>",
"    dose, which was initially attributed to an antibiotic [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/57\">",
"     57",
"    </a>",
"    ]. However, a subsequent panitumumab dose caused recurrent angioedema and respiratory arrest.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H53\">",
"    <span class=\"h1\">",
"     BEVACIZUMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion reactions are much less common with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    than with the MoAbs discussed above. Bevacizumab is a partially humanized MoAb that binds vascular endothelial growth factor (VEGF). It contains less than 10 percent murine protein. Infusion reactions of any grade are reported in &lt;3 percent of cases, most of which are mild to moderate in severity.",
"   </p>",
"   <p>",
"    The approved administration schedule uses a 90 minute infusion with the first dose, 60 minutes with the second dose, and 30 minutes with subsequent doses. However, some institutions use a 10-minute infusion (0.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per minute) for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    dosed at 5",
"    <span class=\"nowrap\">",
"     mg/kg,",
"    </span>",
"    and a more rapid rate of infusion does not appear to increase the incidence of reactions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/58\">",
"     58",
"    </a>",
"    ]. In a series of over 2300 courses of therapy in 370 patients, the incidence of mild infusion reactions was 1.6 percent, and no serious reactions were observed.",
"   </p>",
"   <p>",
"    There is no standard premedication regimen for prevention or prophylaxis of infusion reactions. There is also no information on rechallenge.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H582577\">",
"    <span class=\"h1\">",
"     BRENTUXIMAB",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?16/6/16486?source=see_link\">",
"     Brentuximab vedotin",
"    </a>",
"    is a CD30-directed antibody-drug conjugate that is used for treatment of certain CD30-positive lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27785?source=see_link&amp;anchor=H4185630#H4185630\">",
"     \"Treatment of relapsed or refractory peripheral T cell lymphoma\", section on 'Brentuximab'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38009?source=see_link&amp;anchor=H15846182#H15846182\">",
"     \"Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma\", section on 'Brentuximab vedotin'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a phase I study of 45 patients with refractory or relapsed CD30-positive hematologic malignancies, brentuximab was administered intravenously once every three weeks. One patient developed an infusion-related reaction, which resolved after symptomatic treatment and did not recur with restarting the infusion, and a second patient developed anaphylaxis during administration of the second dose three weeks after the first dose [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Routine premedication is not recommended in the FDA-approved manufacturer&rsquo;s labeling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/60\">",
"     60",
"    </a>",
"    ]. In contrast, patients who have experienced a prior infusion-related event should be premedicated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    , an antihistamine, and a corticosteroid prior to subsequent infusions. Anaphylaxis should prompt immediate and permanent discontinuation, unless a desensitization procedure is carried out under the supervision of an allergy expert.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H54\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all of the therapeutic monoclonal antibodies (MoAbs) used for cancer treatment have the potential to cause infusion reactions, but certain drugs (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    [in patients who reside in high-risk geographic areas],",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"     alemtuzumab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?34/13/35029?source=see_link\">",
"     ofatumumab",
"    </a>",
"    ) are associated with a high enough risk to warrant special precautions. (See",
"    <a class=\"local\" href=\"#H1\">",
"     'Introduction'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    There is a wide spectrum of severity, ranging from mild fever and chills to life-threatening anaphylaxis with bronchospasm, and hypotension. Infusion reactions are most likely during the first or second infusion; however, between 10 and 30 percent of reactions occur during subsequent courses of therapy, so the clinician must remain vigilant for these reactions with every administration. (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Characteristics of reactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The mechanism underlying MoAb-related infusion reactions is unclear, but most are thought to be related to antigen-antibody interactions precipitating cytokine release. Anaphylaxis is uncommon, but has been reported primarily with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"     cetuximab",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H2\">",
"     'Characteristics of reactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The allergists' approach to classifying infusion reactions emphasizes the differentiation of anaphylaxis from all other types of infusion reactions (termed standard infusion reactions, or SIRs), regardless of severity. Characteristic symptoms of anaphylaxis include urticaria, wheezing, hypotension, and gastrointestinal symptoms but not fever. The distinction between anaphylaxis and other reactions is emphasized because anaphylaxis is likely to recur despite premedication and typically becomes more severe upon reexposure. For these reasons, patients with symptoms of anaphylaxis (even if mild) should not be reexposed to the drug until they have been evaluated by an allergist or oncologist with experience in drug allergy. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Classification of infusion reactions'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H55\">",
"    <span class=\"h2\">",
"     Prevention",
"    </span>",
"    &nbsp;&mdash;&nbsp;For certain agents, specific prophylactic maneuvers can be helpful:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Pharmacologic prophylaxis with antihistamines and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      with or without a glucocorticoid is suggested for high-risk agents (ie,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , first infusion of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      in a patient who resides in a high-risk area, intravenous",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      ). Since infusion reactions are most likely during the first or second infusion, many clinicians eliminate routine premedication after the first two exposures if there has not been a reaction. However, as noted above, reactions can also occur with later courses of therapy. Specific premedication regimens for individual agents are addressed in the sections that discuss these agents above.",
"     </li>",
"     <li>",
"      With",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , more severe infusion reactions should be anticipated if there are high levels of circulating malignant cells, as with chronic lymphocytic leukemia (CLL) or mantle cell lymphoma. In such cases, fractionation of the rituximab dose (ie, 50",
"      <span class=\"nowrap\">",
"       mg/m2",
"      </span>",
"      on day 1, and the remainder of the dose administered on day 3) with premedication is advisable. For patients whose WBC count is",
"      <span class=\"nowrap\">",
"       &gt;100,000/microL,",
"      </span>",
"      rituximab may be withheld for the first cycle of therapy. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Rituximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      With",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?25/25/26008?source=see_link\">",
"       alemtuzumab",
"      </a>",
"      , administration by the subcutaneous rather than IV route is associated with a lower incidence and severity of infusion reactions, and is preferred where possible. (See",
"      <a class=\"local\" href=\"#H40\">",
"       'Alemtuzumab'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite premedication, clinicians must be prepared for an infusion reaction to occur during each drug administration. Standing orders should be in place to allow immediate intervention without waiting for the physician to arrive. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'General principles of treatment and rechallenge'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H56\">",
"    <span class=\"h2\">",
"     Immediate treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immediate management of infusion reactions is tailored to the clinical situation. The following represent general guidelines for management of a patient who is suspected of having an infusion reaction during therapy with a therapeutic MoAb.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57\">",
"    <span class=\"h3\">",
"     Mild to moderate SIRs",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the reaction is limited to mild or moderate symptoms of SIR (grades 1 or 2), without features suggestive of anaphylaxis, drug infusion should be temporarily stopped and assessment of airway, breathing, circulation, and mentation accomplished rapidly. IV administration of 50 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"     diphenhydramine",
"    </a>",
"    and 650 mg of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    may provide symptomatic relief. Once symptoms have resolved, resumption of the drug infusion at a slowed rate may permit treatment continuation with close monitoring. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Treatment of mild to moderate SIRs'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58\">",
"    <span class=\"h3\">",
"     Severe SIRs or anaphylaxis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Severe SIRs (grades 3 or 4) or reactions of any severity with any features of anaphylaxis (eg, generalized urticaria, wheezing, hypotension, and angioedema) require prompt recognition and treatment. In fatal anaphylaxis, death typically ensues within 30 minutes from exposure to the trigger. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Treatment of severe SIRs and anaphylaxis'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Detailed guidelines for the management of anaphylaxis are available from the Joint Council of Allergy, Asthma, and Immunology, and are summarized in a rapid overview table for adults (",
"    <a class=\"graphic graphic_table graphicRef58346 \" href=\"mobipreview.htm?16/26/16813\">",
"     table 3",
"    </a>",
"    ) and children (",
"    <a class=\"graphic graphic_table graphicRef74242 \" href=\"mobipreview.htm?17/50/18221\">",
"     table 4",
"    </a>",
"    ). These guidelines should be available to all practitioners who administer agents with the potential for an infusion reaction. They include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Immediately discontinue drug infusion",
"     </li>",
"     <li>",
"      Assess airway, breathing, circulation, and adequacy of mentation",
"     </li>",
"     <li>",
"      Call for help (summon a resuscitation team in the hospital setting, call 911 or an equivalent service in the community setting)",
"     </li>",
"     <li>",
"      Place the patient in the supine position with legs elevated (if tolerated)",
"     </li>",
"     <li>",
"      Administer intramuscular epinephrine into the anterolateral thigh (0.3 to 0.5 mg aqueous epinephrine, 1",
"      <span class=\"nowrap\">",
"       mg/mL",
"      </span>",
"      preparation)",
"     </li>",
"     <li>",
"      Establish IV access with two 14 to 16 gauge catheters",
"     </li>",
"     <li>",
"      Administer both an H1- (eg, 50 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/2/33824?source=see_link\">",
"       diphenhydramine",
"      </a>",
"      ) and an H2- (eg, 50 mg of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?41/56/42888?source=see_link\">",
"       ranitidine",
"      </a>",
"      ) histamine receptor blocker IV",
"     </li>",
"     <li>",
"      Systemic administration of a glucocorticoid (eg, 125 mg",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?30/25/31129?source=see_link\">",
"       methylprednisolone",
"      </a>",
"      IV) may not help acutely, although it may prevent a prolonged or recurrent reaction",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The treatment of anaphylaxis is covered in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=see_link\">",
"     \"Anaphylaxis: Rapid recognition and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H59\">",
"    <span class=\"h2\">",
"     Rechallenge",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the acute event has subsided, the issue of rechallenge must be addressed. The decision to attempt retreatment depends upon the drug, the severity of the reaction, the cancer being treated, and whether there are reasonable treatment alternatives. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'General principles of treatment and rechallenge'",
"    </a>",
"    above.):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the reaction was mild to moderate and did not involve symptoms of anaphylaxis, rechallenge is usually possible with premedication (corticosteroids, antihistamines) and a slower rate of infusion after the symptoms have cleared.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      In the case of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"       rituximab",
"      </a>",
"      , fractionation of the dose over three days is recommended. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Management of SIRs and rechallenge'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In the case of a patient with a severe reaction to the initial infusion of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/58/10151?source=see_link\">",
"       cetuximab",
"      </a>",
"      , switching to the non-cross reacting alternative agent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/48/6918?source=see_link\">",
"       panitumumab",
"      </a>",
"      is a reasonable alternative to rechallenge with cetuximab. (See",
"      <a class=\"local\" href=\"#H48\">",
"       'Cetuximab'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      If the reaction was severe or involved any symptoms of anaphylaxis, the patient should either be changed to an alternative drug (if one is available) or, if there are no reasonable alternatives and use of the drug is clinically necessary, referred for evaluation to an allergist or oncologist with experience in drug desensitization.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H60\">",
"    <span class=\"h2\">",
"     Desensitization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Desensitization protocols have allowed for continued use of the drug in some patients with severe SIRs and anaphylaxis; however, experience with desensitization to MoAbs is relatively limited. At some institutions, these are only performed by allergy specialists. Successful desensitization protocols have been published for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/12/41161?source=see_link\">",
"     rituximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?37/19/38202/abstract/13\">",
"     13",
"    </a>",
"    ], and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/39/6776?source=see_link\">",
"     trastuzumab",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H18\">",
"     'Overview of desensitization'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H19\">",
"     'Rituximab'",
"    </a>",
"    above and",
"    <a class=\"local\" href=\"#H31\">",
"     'Trastuzumab and other HER2-targeted therapies'",
"    </a>",
"    above.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/1\">",
"      Lenz HJ. Management and preparedness for infusion and hypersensitivity reactions. Oncologist 2007; 12:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/2\">",
"      Dillman RO, Hendrix CS. Unique aspects of supportive care using monoclonal antibodies in cancer treatment. Support Cancer Ther 2003; 1:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/3\">",
"      Grillo-L&oacute;pez AJ, White CA, Varns C, et al. Overview of the clinical development of rituximab: first monoclonal antibody approved for the treatment of lymphoma. Semin Oncol 1999; 26:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/4\">",
"      McLaughlin P, Grillo-L&oacute;pez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16:2825.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/5\">",
"      Johansson SG, Bieber T, Dahl R, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/6\">",
"      Sampson HA, Mu&ntilde;oz-Furlong A, Campbell RL, et al. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol 2006; 117:391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/7\">",
"      Chung CH, Mirakhur B, Chan E, et al. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358:1109.",
"     </a>",
"    </li>",
"    <li>",
"     National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) available online at file://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf (Accessed on April 27, 2011).",
"    </li>",
"    <li>",
"     Academic centers in the United States and Europe with departments of Allergy and Immunology are likely to have such experience. In the United States, these centers include Brigham and Women's Hospital, John's Hopkins, the Mayo Clinic, Massachusetts General Hospital, National Institutes of Health, University of California and Los Angeles, Scripps Clinic, and University of Texas (Southwestern Medical Center).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/10\">",
"      Castells MC, Tennant NM, Sloane DE, et al. Hypersensitivity reactions to chemotherapy: outcomes and safety of rapid desensitization in 413 cases. J Allergy Clin Immunol 2008; 122:574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/11\">",
"      Lee CW, Matulonis UA, Castells MC. Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses. Gynecol Oncol 2005; 99:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/12\">",
"      Melamed J, Stahlman JE. Rapid desensitization and rush immunotherapy to trastuzumab (Herceptin). J Allergy Clin Immunol 2002; 110:813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/13\">",
"      Brennan PJ, Rodriguez Bouza T, Hsu FI, et al. Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment. J Allergy Clin Immunol 2009; 124:1259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/14\">",
"      Dillman RO. Infusion reactions associated with the therapeutic use of monoclonal antibodies in the treatment of malignancy. Cancer Metastasis Rev 1999; 18:465.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/15\">",
"      Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999; 58:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/16\">",
"      Plosker GL, Figgitt DP. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs 2003; 63:803.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/17\">",
"      Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/18\">",
"      Sehn LH, Donaldson J, Filewich A, et al. Rapid infusion rituximab in combination with corticosteroid-containing chemotherapy or as maintenance therapy is well tolerated and can safely be delivered in the community setting. Blood 2007; 109:4171.",
"     </a>",
"    </li>",
"    <li>",
"     Revised prescribing information available online at file://www.accessdata.fda.gov/drugsatfda_docs/label/2012/103705s5367s5388lbl.pdf (Accessed on October 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/20\">",
"      Herishanu Y. Rituximab-induced serum sickness. Am J Hematol 2002; 70:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/21\">",
"      D'Arcy CA, Mannik M. Serum sickness secondary to treatment with the murine-human chimeric antibody IDEC-C2B8 (rituximab). Arthritis Rheum 2001; 44:1717.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/22\">",
"      Disperati P, Hicks LK, Buckstein R. Rituximab-induced serum sickness in a patient with follicular lymphoma. Leuk Lymphoma 2007; 48:1633.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/23\">",
"      Bouabdallah R, Mounier N, Guettier C, et al. T-cell/histiocyte-rich large B-cell lymphomas and classical diffuse large B-cell lymphomas have similar outcome after chemotherapy: a matched-control analysis. J Clin Oncol 2003; 21:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/24\">",
"      Leyland-Jones B, Gelmon K, Ayoub JP, et al. Pharmacokinetics, safety, and efficacy of trastuzumab administered every three weeks in combination with paclitaxel. J Clin Oncol 2003; 21:3965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/25\">",
"      Fountzilas G, Tsavdaridis D, Kalogera-Fountzila A, et al. Weekly paclitaxel as first-line chemotherapy and trastuzumab in patients with advanced breast cancer. A Hellenic Cooperative Oncology Group phase II study. Ann Oncol 2001; 12:1545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/26\">",
"      Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/27\">",
"      Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/28\">",
"      Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002; 20:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/29\">",
"      Cook-Bruns N. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 2001; 61 Suppl 2:58.",
"     </a>",
"    </li>",
"    <li>",
"     FDA-approved prescribing information abailable online at file://www.accessdata.fda.gov/drugsatfda_docs/label/2013/125427lbl.pdf?et_cid=31141095&amp;et_rid=463638624&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2013%2f125427lbl.pdf (Accessed on February 25, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/31\">",
"      Baselga J, Cort&eacute;s J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366:109.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/32\">",
"      Keating MJ, Flinn I, Jain V, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99:3554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/33\">",
"      Lundin J, Kimby E, Bj&ouml;rkholm M, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100:768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/34\">",
"      Karlsson C, Lundin J, Kimby E, et al. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced-stage, relapsed chronic lymphocytic leukaemia. Br J Haematol 2009; 144:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/35\">",
"      Coiffier B, Lepretre S, Pedersen LM, et al. Safety and efficacy of ofatumumab, a fully human monoclonal anti-CD20 antibody, in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: a phase 1-2 study. Blood 2008; 111:1094.",
"     </a>",
"    </li>",
"    <li>",
"     US Food and Drug Prescribing information for ofatumumab available online at www.accessdata.fda.gov/drugsatfda_docs/label/2009/125326lbl.pdf (Accessed on April 28, 2011).",
"    </li>",
"    <li>",
"     Cetuximab package insert, ImClone, Inc, February, 2004.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/38\">",
"      Van Cutsem E, K&ouml;hne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009; 360:1408.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/39\">",
"      Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004; 351:337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/40\">",
"      O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007; 25:3644.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/41\">",
"      Pointreau Y, Commins SP, Calais G, et al. Fatal infusion reactions to cetuximab: role of immunoglobulin e-mediated anaphylaxis. J Clin Oncol 2012; 30:334; author reply 335.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/42\">",
"      Tronconi MC, Sclafani F, Rimassa L, et al. Fatal infusion reaction to cetuximab: the need for predictive risk factors and safer patient selection. J Clin Oncol 2011; 29:e680.",
"     </a>",
"    </li>",
"    <li>",
"     Available from ViracorIBT Laboratories. Search test menu on \"Alpha-Gal IgE\" www.viracoribt.com (Accessed on March 01, 2013).",
"    </li>",
"    <li>",
"     University of Virginia Medical Laboratories performs testing for IgE to alpha gal. Information is available at: file://www.healthsystem.virginia.edu/alive/medlabs/LabTestSearch/LabTests.cfm?searchType=detail&amp;LabTest_ID=19520 (Accessed on March 01, 2013).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/45\">",
"      Commins SP, James HR, Kelly LA, et al. The relevance of tick bites to the production of IgE antibodies to the mammalian oligosaccharide galactose-&alpha;-1,3-galactose. J Allergy Clin Immunol 2011; 127:1286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/46\">",
"      Arnold DF, Misbah SA. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. N Engl J Med 2008; 358:2735; author reply 2735.",
"     </a>",
"    </li>",
"    <li>",
"     Available from Viracor-IBT Laboratories. Search test menu on \"Alpha-Gal IgE\" www.viracoribt.com (Accessed on January 26, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/48\">",
"      Mariotte D, Dupont B, Gervais R, et al. Anti-cetuximab IgE ELISA for identification of patients at a high risk of cetuximab-induced anaphylaxis. MAbs 2011; 3:396.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/49\">",
"      Siena S, Glynne-Jones R, Adenis A, et al. Reduced incidence of infusion-related reactions in metastatic colorectal cancer during treatment with cetuximab plus irinotecan with combined corticosteroid and antihistamine premedication. Cancer 2010; 116:1827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/50\">",
"      Melichar B, Cerman J Jr, Mal&iacute;rov&aacute; E. Successful management of infusion reaction accompanying the start of cetuximab therapy. Support Care Cancer 2007; 15:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/51\">",
"      Nielsen DL, Pfeiffer P, Jensen BV. Re-treatment with cetuximab in patients with severe hypersensitivity reactions to cetuximab. Two case reports. Acta Oncol 2006; 45:1137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/52\">",
"      Jerath MR, Kwan M, Kannarkat M, et al. A desensitization protocol for the mAb cetuximab. J Allergy Clin Immunol 2009; 123:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/53\">",
"      Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007; 110:980.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/54\">",
"      Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658.",
"     </a>",
"    </li>",
"    <li>",
"     Letter to Healthcare providers, Amgen, June 25, 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/56\">",
"      Saif MW, Syrigos KI, Hotchkiss S, et al. Successful desensitization with cetuximab after an infusion reaction to panitumumab in patients with metastatic colorectal cancer. Cancer Chemother Pharmacol 2009; 65:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/57\">",
"      Gleich G, Leiferman KM. Anaphylaxis: Implications of Monoclonal Antibody Use in Oncology. Oncology 2009; 23:S7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/58\">",
"      Reidy DL, Chung KY, Timoney JP, et al. Bevacizumab 5 mg/kg can be infused safely over 10 minutes. J Clin Oncol 2007; 25:2691.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?37/19/38202/abstract/59\">",
"      Younes A, Bartlett NL, Leonard JP, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med 2010; 363:1812.",
"     </a>",
"    </li>",
"    <li>",
"     Prescribig information for brentuximab vedotin available online at file://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=50872&amp;CFID=11456208&amp;CFTOKEN=1f74eda9f81e615f-6771DE68-92AA-956A-3738E4B0F5A05DA7&amp;jsessionid=ca302b29638075417258 (Accessed on September 13, 2011).",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2811 Version 17.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-9318902EC1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38202=[""].join("\n");
var outline_f37_19_38202=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H54\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CHARACTERISTICS OF REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Timing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Signs and symptoms of infusion reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Mechanisms of SIRs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Signs and symptoms of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Definition and mechanism of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Evaluation of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Agents that can cause anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      CLASSIFICATION OF INFUSION REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      USE OF PREMEDICATION TO PREVENT INFUSION REACTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      GENERAL PRINCIPLES OF TREATMENT AND RECHALLENGE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Treatment of mild to moderate SIRs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Rechallenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Treatment of severe SIRs and anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Rechallenge after a severe SIR",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      - Management after anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - Overview of desensitization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      RITUXIMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Mechanism",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Prophylaxis of infusion reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Infusion rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      - Dose fractionation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Management of SIRs and rechallenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Management of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Other reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Other anti-CD20 monoclonal antibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      - Ibritumomab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Tositumomab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      TRASTUZUMAB AND OTHER HER2-TARGETED THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H430532248\">",
"      Trastuzumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Management and rechallenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      Mild to moderate symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      More severe reactions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H36\">",
"      Management of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H351179237\">",
"      Trastuzumab emtansine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H430532295\">",
"      Pertuzumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H40\">",
"      ALEMTUZUMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H41\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H42\">",
"      - IV infusion rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H43\">",
"      - Subcutaneous administration",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H44\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H45\">",
"      OFATUMUMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H46\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H47\">",
"      Management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H48\">",
"      CETUXIMAB",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H49\">",
"      Incidence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H50\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H51\">",
"      Management and rechallenge",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H52\">",
"      PANITUMUMAB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H53\">",
"      BEVACIZUMAB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H582577\">",
"      BRENTUXIMAB",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H54\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H55\">",
"      Prevention",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H56\">",
"      Immediate treatment",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H57\">",
"      - Mild to moderate SIRs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H58\">",
"      - Severe SIRs or anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H59\">",
"      Rechallenge",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H60\">",
"      Desensitization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2811\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2811|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?22/43/23228\" title=\"table 1\">",
"      Anaphylaxis diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?28/31/29179\" title=\"table 2\">",
"      Grade of infusion related reactions NCI CTCAE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/26/16813\" title=\"table 3\">",
"      Emergent management of anaphylaxis in adults",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/50/18221\" title=\"table 4\">",
"      Rapid overview for pediatric anaphylaxis treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?30/54/31598\" title=\"table 5\">",
"      Rituximab desens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?13/23/13692\" title=\"table 6\">",
"      Types of allergic reactions",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11384?source=related_link\">",
"      Adjuvant medical therapy for HER2-positive breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/14/36072?source=related_link\">",
"      Allergy to meats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/29/35290?source=related_link\">",
"      Anaphylaxis: Rapid recognition and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/7/36986?source=related_link\">",
"      Cutaneous complications of conventional chemotherapy agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/57/43930?source=related_link\">",
"      Infusion reactions to systemic chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?9/40/9865?source=related_link\">",
"      Initial treatment of limited stage (I/II) follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/54/40809?source=related_link\">",
"      Laboratory tests to support the clinical diagnosis of anaphylaxis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/19/3384?source=related_link\">",
"      Overview of biologic agents in the rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32633?source=related_link\">",
"      Overview of skin testing for allergic disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/7/38009?source=related_link\">",
"      Second and third line chemotherapy regimens and biologic therapy for relapsing or resistant classical Hodgkin lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/40/8842?source=related_link\">",
"      Serum sickness and serum sickness-like reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44554?source=related_link\">",
"      Systemic chemotherapy for metastatic colorectal cancer: Completed clinical trials",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/1/44058?source=related_link\">",
"      Systemic chemotherapy for nonoperable metastatic colorectal cancer: Treatment recommendations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/27/11705?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Combination chemotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?21/43/22202?source=related_link\">",
"      Systemic treatment for metastatic breast cancer: Molecular targeted therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/46/30442?source=related_link\">",
"      Treatment of relapsed or refractory chronic lymphocytic leukemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/10/7338?source=related_link\">",
"      Treatment of relapsed or refractory follicular lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?27/8/27785?source=related_link\">",
"      Treatment of relapsed or refractory peripheral T cell lymphoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f37_19_38203="Agonists for platelet activation and their receptors";
var content_f37_19_38203=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F76852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F76852&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=5\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Physiologic agonists for platelet activation and their respective receptors on the platelet surface",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Agonist",
"       </td>",
"       <td class=\"subtitle1\">",
"        Source",
"       </td>",
"       <td class=\"subtitle1\">",
"        Receptor(s)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        Thrombin",
"       </td>",
"       <td colspan=\"1\" rowspan=\"2\">",
"        End product of coagulation cascade",
"       </td>",
"       <td colspan=\"1\">",
"        7 transmembrane domain",
"receptor&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GPIb-alpha",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Adenosine dephosphate",
"       </td>",
"       <td>",
"        Platelet dense body",
"       </td>",
"       <td>",
"        Aggregin",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Collagen",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Subendothelium component",
"       </td>",
"       <td>",
"        GPIa/IIa&nbsp;&nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GPIIb/IIIa",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        GPIV",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Serotonin",
"       </td>",
"       <td>",
"        Platelet dense body",
"       </td>",
"       <td colspan=\"1\">",
"        5HT2 receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thromboxane A2",
"       </td>",
"       <td>",
"        Produced by platelets after initial stimulation",
"       </td>",
"       <td colspan=\"1\">",
"        PGH2/TxA2 receptor",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Platelet activating factor",
"       </td>",
"       <td>",
"        Lipid mediator produced by other cells",
"       </td>",
"       <td colspan=\"1\">",
"        PAF receptor",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     GP: glycoprotein; HT: hydroxytryptamine, serotonin; PG: prostaglandin; Tx: thromboxane",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38203=[""].join("\n");
var outline_f37_19_38203=null;
var title_f37_19_38204="Etravirine susceptibility";
var content_f37_19_38204=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F55515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F55515&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    New weighted scores for etravirine susceptibility",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Monogram",
"       </td>",
"       <td class=\"subtitle1\" colspan=\"2\">",
"        Janssen Therapeutics (Tibotec)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2\">",
"        Weight",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mutations",
"       </td>",
"       <td class=\"subtitle2\">",
"        Weight",
"       </td>",
"       <td class=\"subtitle2\">",
"        Mutations",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        4",
"       </td>",
"       <td>",
"        100I, 101P, 181C/I",
"       </td>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        181I/V",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        3",
"       </td>",
"       <td>",
"        138A/G, 179E, 190Q, 230L, 238N",
"       </td>",
"       <td class=\"indent1\">",
"        2.5",
"       </td>",
"       <td>",
"        101P, 100I, 181C, 230L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        2",
"       </td>",
"       <td>",
"        101E, 106A, 138K, 179L, 188L",
"       </td>",
"       <td class=\"indent1\">",
"        1.5",
"       </td>",
"       <td>",
"        138A, 106I, 190S, 179F",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        <p>",
"         90I, 101H, 106M, 138Q, 179D/F/M, 181F,",
"        </p>",
"        <p>",
"         190E/T, 221Y, 225H, 238T",
"        </p>",
"       </td>",
"       <td class=\"indent1\">",
"        1",
"       </td>",
"       <td>",
"        90I, 179D, 101E, 101H, 98G, 179T, 190A",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Total score*:",
"       </td>",
"       <td class=\"subtitle2_left\" colspan=\"2\">",
"        Total score",
"        <span class=\"small\">",
"         &bull;",
"        </span>",
"        :",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\" rowspan=\"3\">",
"        &ge;4 = reduced susceptibility",
"       </td>",
"       <td class=\"indent1\" colspan=\"2\">",
"        0-2: Susceptible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        2.5-3.5: Intermediate",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"2\">",
"        &ge;4: Resistant",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Weighted scoring systems for determining etravirine susceptibility based on genotype analysis. The score is determined by adding the weights for each mutation present.",
"    <div class=\"footnotes\">",
"     * The Monogram system (left) predicts phenotypic susceptibility.",
"     <br>",
"      <font class=\"bullet\">",
"       &bull;",
"      </font>",
"      The Janssen Therapeutics (Tibotec) system (right) predicts virologic response in the DUET trials:",
"      <br>",
"       - 0-2 = 74 percent response",
"       <br>",
"        - 2.5-3.5 = 52 percent response",
"        <br>",
"         - &ge;4 = 38 percent response.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br>",
"      <ol>",
"       <li>",
"        Tibotec system: Vingerhoets, J, Peeters, M, Azijn, H, et al. An update of the list of NNRTI mutations associated with decreased virologic response to etravirine (ETR): multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data. Program and abstracts of the XVII International HIV Drug Resistance Workshop; Sitges, Spain; June 10-14, 2008; Vol. Abstract 24.",
"       </li>",
"       <li>",
"        Monogram system: Benhamida, J, Chappey, C, Coakley, E, Parkin, NT. HIV-1 genotype algorithms for prediction of etravirine susceptibility: novel mutations and weighting factors identified through correlations to phenotype. Program and abstracts of the XVII International HIV Drug Resistance Workshop; Sitges, Spain; June 10-14, 2008; Vol. Abstract 130.",
"       </li>",
"      </ol>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38204=[""].join("\n");
var outline_f37_19_38204=null;
var title_f37_19_38205="Muscle innervation part B";
var content_f37_19_38205=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F50878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F50878&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Function and peripheral and segmental innervation of muscles: part B",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Function",
"       </td>",
"       <td class=\"subtitle1\">",
"        Muscle",
"       </td>",
"       <td class=\"subtitle1\">",
"        Nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"3\" rowspan=\"1\">",
"        Plexus brachialis: C5-T1 (cont'd)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abduction of metacarpal I",
"       </td>",
"       <td>",
"        Abductor pollicis brevis",
"       </td>",
"       <td>",
"        C7-T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion of proximal phalanx of thumb",
"       </td>",
"       <td>",
"        Flexor pollicis brevis",
"       </td>",
"       <td>",
"        C7-T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Opposition of metacarpal I",
"       </td>",
"       <td>",
"        Opponens pollicis brevis",
"       </td>",
"       <td>",
"        C6-C7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Median nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion of proximal phalanges and extension of other joints",
"       </td>",
"       <td>",
"        Lumbricales: Index and middle fingers",
"       </td>",
"       <td class=\"\">",
"        C8-T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Ulnar nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"1\">",
"        Flexion of proximal phalanges and extension of other joints",
"       </td>",
"       <td>",
"        Lumbricales: Fourth and little fingers",
"       </td>",
"       <td>",
"        C8-T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Ulnar nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion and ulnar bending of hand",
"       </td>",
"       <td>",
"        Flexor carpi ulnaris",
"       </td>",
"       <td>",
"        C7-T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion of proximal phalanges of fourth and little fingers",
"       </td>",
"       <td>",
"        Flexor digitorum profundus (ulnar portion)",
"       </td>",
"       <td>",
"        C7-T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Adduction of metacarpal I",
"       </td>",
"       <td>",
"        Adductor pollicis",
"       </td>",
"       <td>",
"        C8-T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abduction of middle finger",
"       </td>",
"       <td>",
"        Abductor digiti V",
"       </td>",
"       <td>",
"        C8-T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Opposition of little finger",
"       </td>",
"       <td>",
"        Opponens digiti V",
"       </td>",
"       <td>",
"        C7-T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;&nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Ulnar nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion of little finger in metacarpo- phalangeal joint",
"       </td>",
"       <td>",
"        Flexor digiti brevis V",
"       </td>",
"       <td>",
"        C7-T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Bending of proximal phalanges; stretching of fingers III, IV,",
"and V in middle and distal joints as well as spreading and closing of",
"these fingers",
"       </td>",
"       <td>",
"        <p>",
"         Interossei palmares and dorsales",
"        </p>",
"        <p>",
"         Lumbricales 3 and 4",
"        </p>",
"       </td>",
"       <td>",
"        C8-T1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Radial nerve",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extension of elbow",
"       </td>",
"       <td>",
"        Triceps brachii and M. anconeus",
"       </td>",
"       <td>",
"        C6-C8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Flexion of elbow",
"       </td>",
"       <td>",
"        Brachioradialis",
"       </td>",
"       <td>",
"        C5-C6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extension and radial abduction of hand",
"       </td>",
"       <td>",
"        Extensor carpi radialis",
"       </td>",
"       <td>",
"        C6-C8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Extension of proximal phalanges II-V",
"        </p>",
"        <p>",
"         Extension and dorsoflexion of hand; stretching and spreading of fingers",
"        </p>",
"       </td>",
"       <td>",
"        Extensor digitorum",
"       </td>",
"       <td>",
"        C6-C8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extension of proximal phalanx of little finger",
"       </td>",
"       <td>",
"        Extensor digiti V",
"       </td>",
"       <td>",
"        C6-C8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extension and ulnar deviation of hand",
"       </td>",
"       <td>",
"        Extensor carpi ulnaris",
"       </td>",
"       <td>",
"        C6-C8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Supination of forearm",
"       </td>",
"       <td>",
"        Supinator",
"       </td>",
"       <td>",
"        C5-C7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Abduction of metacarpal I; radial extension of hand",
"       </td>",
"       <td>",
"        Abductor pollicis longus",
"       </td>",
"       <td>",
"        C6-C7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extension of thumb in proximal phalanx",
"       </td>",
"       <td>",
"        Extensor pollicis brevis",
"       </td>",
"       <td>",
"        C7-C8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extension of distal phalanges of thumb",
"       </td>",
"       <td>",
"        Extensor pollicis longus",
"       </td>",
"       <td>",
"        C7-C8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Extension of proximal phalanx of index finger",
"       </td>",
"       <td>",
"        Extensor indicis proprius",
"       </td>",
"       <td>",
"        C6-C8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"2\" rowspan=\"1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle2_left\">",
"        Thoracic nerves",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Elevation of ribs; expiration; abdominal compression; anteroflexion and lateroflexion of trunk",
"       </td>",
"       <td>",
"        Thoracis and abdominalis",
"       </td>",
"       <td>",
"        T1-L1",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Duus, P. Topical Diagnosis in Neurology, 2nd ed. Thieme Medical Publishers, New York, 1989.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38205=[""].join("\n");
var outline_f37_19_38205=null;
var title_f37_19_38206="Mandibular advance splint I";
var content_f37_19_38206=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F52099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F52099&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mandibular advancement splint",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 324px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This mandibular advancement splint is manufactured in a laboratory from dental impressions (Klearway appliance, Great Lakes Orthodontics, Inc, Tonawanda, NY). Special features stressed by the manufacturer are the full dental coverage, the low profile of the appliance, and adjustability of mandibular position by means of a screw.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38206=[""].join("\n");
var outline_f37_19_38206=null;
var title_f37_19_38207="Premature puberty in Cushings syndrome";
var content_f37_19_38207=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F55622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F55622&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Premature puberty in Cushing's syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 540px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A 2.5 year-old boy with an adrenocortical carcinoma that secreted excess cortisol and androgens. He presented with signs of Cushing's syndrome (moon face, obesity) and premature puberty (Tanner III pubic hair and penis enlargement, with prepubertal testicular volume).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with kind permission from Springer Science + Business Media B.V.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f37_19_38207=[""].join("\n");
var outline_f37_19_38207=null;
